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In birds, prolactin secretion is stimulated by a hypothalamic prolactin releasing
hormone, vasoactive intestinal polypeptide (VIP). Active immunization against VIP
suppresses both prolactin and LH secretion. Since VIP in physiological doses, does not
stimulate LH release, it is suggested that it might act to regulate the function of LH-
producing cells in a paracrine manner. The aim of this thesis is to provide biochemical,
molecular and anatomical evidence to support this hypothesis.
Vasoactive intestinal polypeptide was shown to be present in the chicken anterior
pituitary gland using high performance liquid chromatography (HPLC),
radioimmunoassay (RIA) and immunocytochemistry. The VIP antibodies used for both
RIA and immunocytochemistry showed no cross reaction with any known VIP-like
peptides, including pituitary adenylate cyclase activating polypeptide (PACAP). VIP
mRNA was also shown to be present in anterior pituitary gland, using reverse-
transcription polymerase chain reaction (RT-PCR) and primers designed from the chicken
VIP cDNA sequence, and by solution hybridization RNAse protection assay.
Two VIP-immunoreactive cell (VIP-ir) types were found throughout the cephalic and
caudal lobes of the anterior pituitary gland. The morphological features of the VIP-ir cell
types were similar to that of the folliculo-stellate cell type (FS-cell). One VIP-cell type
contained the Ca 2+ binding protein S-100 protein, a specific marker of FS-cells, while
the S-100 protein was not detected in the second VIP-cell type. The VIP-cells were
closely associated with gonadotrophs, lactotrophs and unidentified cell types, but VIP-ir
was not colocalised with LH or PRL. The VIP-cell characteristically enveloped several
adjacent gonadotrophs with cytoplasmic projections, which suggests that intra-pituitary
VIP may regulate the gonadotroph in a paracrine manner.
VIP receptors were localised immunocytochemically, in the anterior pituitary gland
and hypothalamus, using antibodies raised the peptide sequence of the human subtype-I
(VIP-RI) and the subtype-II VIP receptors (VIP-RII). The VIP-RI was not present in
PRL-, LH- or GH-cells, but was found exclusively in ACTH-cells. The VIP-RII was
diffusely distributed through both lobes of the chicken anterior pituitary gland, but the cell
type containing VIP-RII immunoreactivity was not identified.
The effects of VIP and PACAP on pituitary hormone secretion were determined in
vitro using cultured hemi-pituitaries. VIP and PACAP stimulated PRL secretion in a dose
dependent manner. High concentrations of VIP and PACAP stimulated GH and LH
secretion but did not affect ACTH secretion.
In conclusion, VIP is produced in the anterior pituitary gland and occurs in a FS-cell
type which is closely associated with gonadotrophs. These observations are consistent
with the view that intra-pituitary VIP may act in a paracrine manner to regulate the
function of gonadotrophs.
Chapter 1: INTRODUCTION
1.1 Vasoactive intestinal polypeptide in the peripheral nervous system
Vasoactive intestinal polypeptide (VIP) is a 28 amino acid polypeptide originally
isolated from the porcine duodenum (Said and Mutt, 1970; 1972), and the chicken
intestine (Nilsson, 1974). The biological activity of VIP was first determined using
a bioassay initially established for secretin, a closely related gastrointestinal peptide
extracted from the same source. The assay involved the measurement in the turkey,
of the bicarbonate and protein composition and rate of flow of pancreatic secretions
(Heatley et al., 1965; Dockray, 1973). The regulation of pancreatic secretion by
secretin in birds is essentially the same as that observed in mammals. However, in
birds VIP is 30 times more potent than secretin in stimulating flow of pancreatic
juices (Dockray, 1973).
1.1.1 Distribution of VIP in the peripheral nervous system
VIP-like immunoreactivity is widely distributed in the peripheral nervous system
occurring in the sympathetic ganglia (Hokfelt et al., 1977), in the vagus,
splanchnic and sciatic nerves (Lundberg et al., 1978; 1979) and in nerves
supplying the gastrointestinal (Fuxe et al., 1977; Polak et al., 1974) and genito¬
urinary tracts (Aim et al., 1977; Larsson et al., 1977; Hokfelt et al., 1978). It also
occurs in the nerves supplying the connective tissue, alveoli, lactiferous ducts in
the nipple and parenchyma tissue of the human and rat mammary gland (Erikkson
et al., 1996), and within ganglion-like structures around airways, and pulmonary
vessels of the mammalian lung (Dey et al., 1981; Eriksson et al., 1996).
VIP-like immunoreactivity (VIP-ir) has been localised in the chicken and quail
embryo by immunocytochemistry, where it is distributed throughout the peripheral
nervous system. VIP-ir nerve fibres are abundant along the entire digestive tract of
the chicken (Fontaine-Perus, 1984), in the submucosal and myenteric plexus and
are also prominent in the oesophagus and pancreas (Nilsson, 1974; 1975, Sundler
et al., 1979, Vaillant et al., 1980). VIP nerve fibres occur in the pancreas of the
chicken in the exocrine portion, the adventia artery and in the connective tissue of
the ductal wall. VIP nerve fibres are also found in the intrapulmonary ganglia of the
12-day-old chick embryo, and in the lamina propria of the primary and secondary
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bronchi, and in the pulmonary septa of the lung of the chick at hatch (Salvi and
Renda, 1992). In the adult chicken, VIP immunoreactive nerve fibres are observed
throughout the primary bronchus wall in the lung septa (Salvi and Renda,
1992).VIP immunoreactivity is also present in postganglionic secretory nerves of
the glandular parenchyma of the salt gland in the duck (Gertsberger, 1988).
1.1.2 Biological action of VIP
The widespread distribution of VIP in the peripheral nervous system reflects its
biological functions. VIP stimulates bronchodilation (Said and Mutt, 1970; 1988)
smooth muscle relaxation (Piper et ai, 1970) and secretory processes in the
gastrointestinal tract (Said, 1982; Barbezat and Grossman, 1971; Makhlouf et al.,
1978). Systemic administration of VIP stimulates hypotension by inducing
peripheral vasodilation in the guinea-pig and cat, and inhibits vagally induced
respiratory insufflation pressure (Lundberg et al., 1984).
In the reproductive system, VIP is a modulator of vascular activity for penile
erection (Ottesen et al., 1984; Dixson et al., 1984) and also increases cervical
(Allen et al., 1988) and vaginal (Fahrenkrug et al., 1988) blood flow. In the
mammary gland VIP released by oxytocin, may stimulate vasodilation in the skin
overlying the mammary gland, which is observed in association with milk ejection
(Eriksson et al., 1996).
In birds, VIP stimulates the secretion of bicarbonate-rich pancreatic juices in the
turkey, possibly in a neuroendocrine manner (Dockray, 1973, Vaillant et al.,
1980). VIP also stimulates the secretion of highly concentrated saline from the
supraorbital salt gland of the duck acting on both the arteriolar network and the
secretory tubules (Gertsberger, 1988).
1.2 Related peptides in the VIP gene family
The structural similarity between VIP and other peptide hormones isolated from the
gastrointestinal tract, shows that it is a member of the secretin-glucagon family
(Figure 1.1). This family of peptides includes, secretin, glucagon, growth
hormone releasing hormone (GHRH), peptide histidine isoleucine/methionine
(PHI/M), and the recently isolated pituitary adenylate cyclase activating polypeptide
(PACAP; Section 1.8) (Said and Mutt, 1970; 1988; Said 1986; Bloom et al., 1983;
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Gozes and Brenneman, 1989). The structural similarity between these peptides, is
also reflected in the similarity between the genes encoding for the VIP gene family,
and suggests they may have evolved from a common ancestral gene (Gozes and
Brenneman, 1989). Distinct regulatory mechanisms controlling the expression of
specific peptides in the VIP gene family have also evolved, which may regulate
tissue and cell specific expression.
cVIP
HIS SER ASP ALA VAL PHE THR ASP ASN TYR SER ARG PHE ARG LYS GLN MET
ALA VAL LYS LYS TYR LEU ASN SER VAL LEU THR
mVIP
HIS SER ASP ALA VAL PHE THR ASP ASN TYR THR ARG LEU ARG LYS GLN MET
ALA VAL LYS LYS TYR LEU ASN SER ILE LEU ASN
PHI
HIS KLA ASP GLY VAL PHE THR SER ASP PHE SER ARG LEU LSI GLY GLN LEU
SER ALA LYS LYS TYR LEU GLU SER LEU ILE
cPACAP
HIS ILE ASP GLY ILE PHE THR ASP SER TYR SER ARG TYR ARG LYS GLN MET
ALA VAL LYS LYS TYR LEU ALA VAL LEU GLY LYS ARG TYR TYR LYS GLN ARG
VAL LYS ASN LYS
SECRETIN
HIS SER ASP GLY THR PHE THR SER GLU LEU SER ARG LEU ARG ASP SER ALA
ARG LEU GLN ARG LEU LEU GLN GLY LEU VAL
GHRH
TYR ALA ASP ALA ILE PHE THR ASN SER TYR ARG LYS VAL LEU GLY GLN LEU
SER ALA ARG LYS LEU LEU GLN ASP ILE MET SER
GLUCAGON
HIS SER GLN GLY THR PHE THR SER ASP TYR SER LYS TYR LEU ASP SER ARG
ARG ALA GLN ASP PHE VAL GLN TRP LEU MET ASN
Figure 1.1 A comparison of the amino acid sequence of chicken VIP (cVIP) and
peptides in the VIP gene family. The differences in amino acids are underlined.
Mammalian VIP (mVIP) sequence is found in human, porcine, bovine and rat.
peptide histidine isoleucine (PHI) is the porcine sequence; pituitary adenylate
cyclase activating polypeptide (PACAP) is chicken. Secretin is the porcine and
bovine sequence; growth hormone releasing hormone (GHRH) is the human
sequence; glucagon is the porcine and human sequence (Adapted from Said, 1986)
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1.2.1 Molecular biology of VIP
Vasoactive intestinal polypeptide cDNAs encoding the prepro VIP were first
isolated in man (Itoh et al., 1983), and subsequently rat (Giladi et al., 1990),
chicken and turkey. The mammalian and avian VIP genes too are made up of seven
exons with each exon encoding a distinct functional domain (Figure 1.2). It can be
predicted from the cDNA sequence that transcription of the gene results in the
production of a mRNA encoding VIP itself and a second peptide containing 27
amino acids. This second peptide is termed peptide histidine isoleucine (PHI) in
rats and the pig, and peptide histidine methionine (PHM) in humans (Itoh et al.,
1983; Giladi et al., 1990). VIP and PHI/M are encoded by exon 5 and exon 4
respectively of the VIP gene, and the two peptides are synthesised as part of the
same protein.
Mammalian VIP and PHI/M are produced by the fully processed VIP mRNA, and
there is evidence that they are not always produced in the same tissue, since a
differential distribution has been demonstrated in the brain of the rat (Beinfeld et
al., 1984; Christofides et al., 1984). Although, there is no evidence for alternative
splicing of the mammalian VIP gene (Linder et al., 1987).
Genomic VIP DNA
Figure 1.2 Transcription of the mammalian VIP gene.
1.2.2 Comparison between mammalian and avian VIP
The cDNA encoding the avian prepro VIP gene is highly homologous with cDNAs
encoding mammalian VIP pre-pro polypeptides (Talbot et al., 1995; McFarlin et
al., 1995; You et al., 1995). The chicken genomic DNA sequence was analysed by
PCR, and identified exons encoding both VIP and PHI, but analysis of several
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clones from a hypothalamic cDNA library failed to confirm the presence of the
exon encoding PHI. In fact, the largest VIP clone contained a complete open-
reading frame coding for a 165 amino acid pre-pro VIP, which did not contain a
sequence encoding PHI (Talbot et ai, 1995). It was confirmed by RT-PCR,
solution hybridisation, and RNase protection assay that the chicken VIP gene
transcript is alternatively spliced (Figure 1.3); and that two forms of the VIP
mRNA are expressed in unequal amounts in different tissues, with the form
containing PHI being the least abundant (Talbot et al., 1995).
Genomic VIP DNA
Figure 1.3 Transcription of the avian VIP gene.
1.3 Localisation of VIP in the central nervous system
The chemical characterisation of VIP extracted from various brain tissues showed
that it is identical to VIP extracted from the gut (Marley and Emson, 1982). Studies
using immunocytochemistry and autoradiography demonstrated that the distribution
and biological action of VIP is widespread in the mammalian brain, being present
in the cerebral cortex, amygdala, hippocampus, and hypothalamus (Said 1982;
1986; Rostene, 1984; Gozes and Brenneman, 1989).
VIP-positive bipolar neurones occur in all the cortical regions, with dendritic
branching in layers I and deep cortical layers, (Morrison and Magistretti, 1983;
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Morrison et al., 1984). In the rat, approximately 1% of all cortical neurones are
VIP-positive, distributed uniformly in all cortical areas (Morrison et al., 1984). In
the forebrain many nuclei including the lateral and basolateral nuclei of the
amygdala contain VIP cell bodies (Roberts et al., 1982). VIP is also found in the
retina (Loren et al., 1980; Fukuda et al., 1981) caudally in the brainstem and in the
dorsal horn of the spinal cord (Loren et al., 1979; Eiden et al., 1982; Honda et al.,
1983).
In birds, topographical studies of the distribution of VIP in the CNS have been
described for the pigeon (Hof et al., 1991) chicken (Eposito et al., 1994; Kuenzel
and Blasher, 1994) and quail (Aste et al., 1995). The VIP-immunoreactivity occurs
in several extrahypothalamic regions including the hippocampus, the organum septi
laterale (LSO), and the lobus paraolfactorius (LPO) (Eposito et al., 1994; Aste et
al., 1995). VIP-ir perikarya are also found in the lateral septum (SL), nucleus striae
terninalis (nST), posterior hypothalamus and tuberal hypothalamus (see Section
1.3.2), which are associated with control of reproductive function (Aste et al.,
1995). The distribution of VIP in the quail CNS is shown in Fig. 1.4.
Abbreviations for Figure 1.4, (next page) AA, archistratium anterius; AM, nucleus
anterior medialis hypothalami; Ap, archistratium posterius; AVT, area ventralis (Tsai); CP,
commissura posterior; DMN, nucleus dorsomedialis hypothalamii; DSV, decussatio supraoptica
ventralis; EW, nucleus of Edinger-Westphal; GCt, substantia grisea centralis; Hb, habenula, ICo,
nucleus intercollicularis, IP, nucleus interpeduncularis; LA, nucleus lateralis anterior thalami;
LFS, lamina fontalis superior; LH, lamina hyperstriatica; LHy, regio lateralis hypothalami;
LMD, lamina medullaris dorsalis; LPO, lobus paraolfactorius; LSO, organum septi laterale; MLd.
nucleus mesnephalicus lateralis, pars dorsalis; NC, neostriatum caudale; nST, nucleus striae
terminalis; OM, nucleus nervi oculomotori; PA, paleostriatum augmentatum; POM, nucleus
preopticus medialis; PVN, nucleus paraventricular^ magnocellularis, PVT, paleostriatum
ventrale; QF, Tratus quintofrontalis, SGFS, stratum griseum et fibrosum superficial; SGP,
srtatum griseum periventriculare; SL, nucleus septalis lateralis, TO, tuberculum olfactorium, Tn,
nucleus taeniae, Va, vallecula telecephali.
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Figure 1.4 Schematic drawings of frontal sections of quail brain illustrating the
distribution of VlP-immunoreactivity. Immunopositive cell bodies and fibres are
indicated by large dots and small dots respectively. (Aste et ai, 1995). For a list of
abbreviations see previous page.
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1.3.1 VIP in the mammalian hypothalamus
Vasoactive intestinal polypeptide containing cell bodies and nerve terminals are
found in the rat anterior hypothalamus, are concentrated in the suprachiasmatic
nucleus (SCN) (Besson et al., 1979a, b; Loren et al., 1979; Card et al, 1988).
Other more diffusely distributed VIP cell bodies are found elsewhere in the
hypothalamus. In the rat, VIP occurs in the hypophyseal portal vasculature at a
concentration 10 times greater than that in the peripheral plasma (Said and Porter,
1979; Shimatsu et al., 1981). This suggests that VIP is released from the median
eminence, and does not originate from peripheral regions, such as the gut. This
view is supported by the observation that VIP concentrations in the portal
vasculature are not affected by the removal of the gut (Brar et al., 1985).
Since lesions centred on the VIP cell bodies in the SCN do not depress
concentrations of VIP in the portal vasculature, it seems that VIP cell bodies other
than those in the SCN, project to the median eminence (Rostene et al., 1982).
Retrograde tracing and immunocytochemistry studies in the rat, show that VIP cell
bodies in the parvocellular and periventricular parts of the paraventricular nucleus
(PVN) project to the median eminence (Dalcik and Phelps, 1993).
1.3.2 VIP in the avian hypothalamus
Vasoactive intestinal polypeptide-immunoreactivity occurs in the septal and preoptic
regions of the quail and chicken (Yamada et al., 1982; Macnamee et al., 1986).
This corresponds to the distribution of luteinising hormone releasing hormone
(LHRH) cell bodies and fibres (Sterling and Sharp, 1982; Panzica et al., 1992),
and suggests that VIP may influence LHRH secretion in birds. VIP-like
immunoreactivity also occurs in cell bodies and terminals throughout the
hypothalamus of the Japanese quail (Yamada et al., 1982), ring dove (Silver et al.,
1988) turkey (Mauro et al., 1989) and bantam hen (Macname et al., 1986).
A subset of VIP-ir neurons occur adjacent to the ventral lateral ventricles, which are
proposed to be encephalic photoreceptors because they also contain opsin-like
immunoreactivity (Silver et al., 1988). Cell bodies containing VIP-like material in
the mediobasal hypothalamus (MBH) project to the external layer of the median
eminence (ME) (Silver et al., 1988; Sharp et al., 1989). The distribution of VIP in
the medial basal hypothalamus and median eminence is consistent with the view
that VIP is an avian hypothalamic releasing hormone (Section 1.3.1).
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1.4 Central action and neuroendocrine role of VIP in mammals
1.4.1 Biological effects of VIP in the CNS
Vasoactive intestinal polypeptide acts as a neurotransmitter and neuromodulator in
the rat CNS, and stimulates adenylate cyclase activity in the retina, olfactory bulb,
hippocampus, cerebral cortex, thalamus and hypothalamus, in the presence of
calcium (Quik et al., 1978) (see Section 1.8.1). The application of VIP to
corticospinal cells induces an excitatory response (Phillis et al., 1978; Phillis and
Kirkpatrick, 1980), while depolarisation is induced after the administration of VIP
to motor and inter-neurones in the dorsal horn of the toad spinal cord (Phillis and
Kirkpatrick, 1980) and pyramidal neurones of the CA1 subfield of the rat
hippocampus (Dodd et al., 1979; Dingeldine et al., 1980).
The immunocytochemical demonstration of VIP in nerves innervating blood
vessels in the CNS, suggests that VIP may regulate cerebral blood flow (Larsen et
al,. 1981). The anterior arteries receive a greater VIP-ergic innervation than the
caudal arteries (Edvinsson et al., 1980), and a role for VIP in the regulation of
central blood flow is established in several species (Heistad et al., 1980; Larsen et
al., 1981; Wei et al., 1980). Although it is not certain whether this effect is a direct
or an indirect effect through the regulation of neurotransmitters, particularly
acetylcholine or norepinephrine.
Vasoactive intestinal polypeptide increases cAMP levels and tyrosine hydroxylase
(TH) gene expression (or stability), in cultured avian sympathetic neurons (Zurn et
al., 1993). This observation suggests that VIP may play a long term
neuromodulatory role in the nervous system via the regulation of TH gene
expression, which is an enzyme involved in the biosynthesis of catecholamines
(Zurn et al., 1993).
1.4.2 Neurotrophic action ofVIP
The amount of VIP in several brain areas changes markedly during embryogenesis,
development and growth of the nervous system (Said, 1982; 1984; Gozes and
Brenneman, 1989; 1993; Waschek, 1995) and these changes have been shown to
reflect a neurotrophic role for VIP in neural tissue. A 30-fold increase in VIP
mRNA occurs in the rat cerebral cortex between birth and 30 day of age, after
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which VIP mRNA levels decrease to about 60% of the peak levels. This decrease is
associated with an increase in the SCN (Gozes et al., 1987; Gozes, 1988), which
demonstrates that different factors may operate at different stages of development,
to regulate VIP gene expression in specific regions of the brain.
1.4.2.1 Electrical activity and the regulation of VIP
Changes in electrical activity may influence the neurotrophic action of VIP, by
regulating VIP gene expression in specific regions of the CNS. This view is
supported by the observation that the addition of tetrodotoxin to spinal cord
cultures, which blocks synaptic and electrical activity, also accelerates cell death
(Brenneman et al., 1985a), and inhibits the secretion and synthesis of endogenous
VIP (Brenneman et al., 1985a; Foster et al., 1989; Agoston et al., 1991).
Furthermore, the addition of VIP to spinal-cord dorsal root ganglion neurons
incubated with tetrodotoxin, prevents neuronal cell death (Kasper and Fipton,
1990). VIP-like immunoreactivity is also found in spinal cord cultures, and
incubation with VIP antisera results in significant neuronal cell death (Brenneman
and Eiden, 1986; Brenneman and Foster, 1987). These observations suggest that
the electrical activity of neurons may modulate cell survival by regulating the
expression and secretion of VIP.
1.4.2.2 Trophic action of VIP in the CNS
Many neurotrophic neuropeptides which affect development and or differentiation
act directly on the target cell, but the neurotrophic actions of VIP may involve
indirect cellular mechanisms (Gozes and Brenneman, 1989; Gozes and
Brenneman, 1993). VIP released by neurons may diffuse to adjoining cells and
promote neuronal survival, by stimulating high affinity receptors on astroglia
(Banker, 1980; Brenneman et al., 1987; 1990; Gozes and Brenneman, 1989;
1993). Glia are thought to have a supportive role for developing neurons by
providing directional cues (Wessells et al., 1980; Silver et al., 1982; Noble et al.,
1984) and growth promoting substances (Banker, 1980; Muller et al., 1984;
Eagleson et al., 1985). The neuronal survival factors released by glial cells in
response to VIP are not fully characterised, but one candidate is interleukin-l-like
substance (Brenneman et al., 1992), which stimulates glial proliferation (Giulian et
al., 1988).
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1.4.2.3 Effects of VIP on cell proliferation and differentiation
At micromolar concentrations VIP acts as a mitogenic factor and stimulates cAMP
formation and DNA synthesis in embryonic neurons in the superior cervical
ganglion (Pincus et al., 1990; 1991). Low concentrations of VIP significantly
increase the rate of mitosis in neural and non-neural tissue over a 4 hour period in
whole embryos (mouse) (Gressens et al., 1993). VIP may also act as an autocrine
regulator of neurogenesis (Wollman et al., 1993). For example, Northern analysis
demonstrates that VIP mRNA occurs in a neuroblastoma cell line (Wollman et al.,
1993), and VIP is reported to stimulate cell differentiation (O'Dorisio et al., 1992;
Pence and Shorter, 1993) and mitosis in some neuroblastoma cell lines (Wollman
et al., 1993).
The importance of VIP in the development of the brain is demonstrated in the
following studies. The administration of a VIP antagonist, during the development
of the CNS in neonatal rats, results in the impairment of neuronal development,
acquisition of reflexes, and learning and memory mechanisms, but these effects are
reversed by coadministration of VIP (Gozes et al., 1990; Panlilo et al 1990; Hill et
al., 1991). It appears that changes in VIP gene expression and VIP secretion from
neurons, coupled with changes in the production of neurotrophic factors by glial
cells, may mediate the development and growth of the central nervous system.
1.4.3 Effect of VIP on energy metabolism in the CNS
VIP may locally regulate glycogenolysis in several regions of the cortex, an effect
which may be mediated by cAMP production (Magistretti et al., 1981). A
quantitative autoradiographic 14C-deoxyglucose study demonstrated increased
glucose utilisation in caudate nucleus, cingulate cortex and several other regions, in
response to VIP administration (McCulloch et al., 1983; McCulloch and Kelly,
1983). In addition, VIP stimulates an increase in glycogenolysis and changes in
morphology in astroglia cells acting through specific VIP receptors (see Section
1.5.5) (Magistretti, 1988).
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1.4.4 Effect of VIP on pituitary hormone production
1.4.4.1 Prolactin releasing factor in mammals
The release of PRL in mammals is controlled primarily by the inhibitory action of
hypothalamic dopamine (Ben-Jonathan et al., 1989; Gala, 1990), although
releasing factors do influence PRL secretion to a lesser extent. VIP for example,
stimulates PRL secretion in man and rats (Said and Mutt, 1970; Ruberg et al.,
1978; Malarkey et al., 1981; Nagy et al., 1988) and passive immunization against
VIP in ovariectomized rats, reduces peripheral PRL levels (Lasaga et al., 1989;
Murai et al., 1989) and PRL secretion in vitro (Hagen et al., 1986; Nagy et al.,
1988). VIP stimulates PRL release at plasma concentrations similar to those found
in the hypophyseal portal vasculature of lactating rats (Gozes and Shani, 1986;
Gozes and Brenneman, 1989; Lam, 1991). This suggests that hypothalamic VIP
plays a major role in the release of prolactin during lactation. In support of this
view, VIP concentration in the rostral anterior hypothalamus (rAHN) and
paraventricular nuclei (PVN) of lactating rats, is higher than in virgin diestrous rats
(Chiocchio et al., 1991). Quantitative autoradiography using [I125]-VIP
demonstrates that the number of VIP binding sites increase in the striatum,
thalamus, anterior portion of the anterior paraventricular hypothalamus and anterior
pituitary gland of the female rat during lactation, when PRL levels are significantly
elevated (Viau et al., 1992). This observation is consistent with the view that VIP
produced by the PVN plays a key role in the suckling-induced release of PRL in
rats (Kiss et al., 1986).
1.4.4.2 Growth hormone
VIP is reported to stimulate GH release in mammals (Rotsztejn et al., 1980a;
Westendorf et al., 1983) by a direct action on the anterior pituitary gland
(Dorflinger and Schonbrunn, 1983). GH release is stimulated by VIP from GH
tumor cells in vitro (Matsushita et al., 1981) and from superfused rat anterior
pituitary cells in vitro, provided the cells are treated with dexamethasone (Denef et
al., 1985). Intracerebroventricular infusion of VIP in the rat induces GH secretion
(Vijayan et al., 1979), and VIP antagonises the action of the GH-inhibiting factor
somatostatin in vitro (Enjalbert et al., 1982).
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1.4.4.3 Adrenocorticotrophic hormone
VIP stimulates ACTH release from primary cultures of rat anterior pituitary cells,
but only at high concentrations (l-3|xM) which may not be physiologically
significant (Westendorf et al., 1983). VIP also induces the release of
adrenocorticotrophic hormone in vitro (ACTH) from a mouse pituitary
corticotroph-like AtT20 cell line (Reisine et al., 1982) and from a human
ACTH-secreting pituitary adenoma (Oliva et al., 1982), by stimulating cAMP
production. The ability of VIP to stimulate ACTH release from human
corticotropinoma cells is additive with arginine vasopressin (AVP), and is
modulated by hydrocortisone (White et al., 1982). It seems that VIP may regulate
ACTH secretion in certain physiological states by a direct action on the pituitary
(Westendorf et al., 1983).
Vasoactive intestinal polypeptide infused into the aorta or cerebral ventricle of the
rat stimulates the release of oxytocin, AVP (Bardrum et al., 1987; 1988) and
ACTH (Itoh et al., 1982) into the systemic circulation. Similarly infusion of VIP,
into the PVN the site of AVP and CRF cell bodies, also increases plasma ACTH
and corticosterone (CORT) levels in the rat (Alexander and Sander, 1994). This
stimulatory action of VIP is reduced when CRF or AVP antagonists are co¬
administered (Alexander and Sander, 1995).
Feeding has been shown to influence the activity of the hypothalamic-pituitary-
adrenal (HPA) axis (Ishizuka et al., 1983; Al-Dumluji et al., 1987). Central
infusion of a VIP antagonist into the PVN, reduces the increase in plasma ACTH
and CORT levels associated with feeding (Alexander et al., 1995). The
imunocytochemical observation that synaptic connections occur between VIP-
containing nerve terminals and AVP neuronal perikarya, supports the view that
hypothalamic VIP may play a key role in the release of ACTH releasing factors and
ACTH secretion (Ibata et al., 1993). In conclusion, hypothalamic VIP may
stimulate ACTH release directly from the corticotroph, but it is more likely to
stimulate the release of corticotrophin releasing factors such as CRF or AVP from
the PVN (Alexander and Sander, 1995; Alexander et al., 1995).
1.4.4.4 Luteinising hormone
In rats and man VIP may stimulate or inhibit LH secretion acting at the level of the
hypothalamus. Vijayan et al. (1979) found that the infusion of VIP into the third
cerebral ventricle (ICV) of ovariectomised (OVX) rats, increases luteinising
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hormone release, presumably by inducing GnRH release. Similarly, studies in
vitro show that VIP stimulates gonadotrophin hormone releasing hormone (GnRH)
from the rat medio-basal hypothalamus (Ohtsuka et al., 1988) and median
eminence synaptosomes in vitro (Samson et al., 1981).
There is also evidence that VIP inhibits LH secretion at the level of the
hypothalamus. Akema et al. (1988) found that infusion of VIP into the rat preoptic
hypothalamus or third cerebral ventricle in OVX rats significantly reduces LH
secretion. This finding has been confirmed in OVX rats treated with oestrogen and
progesterone (Alexander et al., 1985; Weick and Stobie, 1992).
The inhibitory action of VIP on GnRH release from the hypothalamus may be
mediated through the suprachiasmatic nucleus (SCN) or the PVN. The destruction
of the SCN in the rat, by electrolytic lesion abolishes LH pulses, and renders the
rat hyper-responsive to the inhibitory action of VIP, on LH release (Stobie and
Weick, 1990). However, lesions in the PVN block the inhibitory influence of VIP
on LH secretion (Stobie and Weick, 1990). In conclusion, it seems that VIP
originating from the SCN, acts directly on the VIP receptors in the PVN (Shaffer
and Moody, 1986) to inhibit LH secretion, via a non-VIPergic connection between
the PVN and the GnRH pulse generator (Figure 1.5) (Stobie and Weick, 1990;
Weick et al., 1992; Weick and Stobie, 1995).
Figure 1.5 A hypothetical model of the SCN-PVN VIPergic pathway that
mediates the inhibitory effect of exogenous VIP on pulsatile LH secretion in the rat





VIP may also act at the level of the anterior pituitary gland to modulate the action of
GnRH. In man, an infusion of VIP into the peripheral circulation, followed by an
infusion of GnRH 30 min later, significantly augments the release of LH but not
FSH (Hammond et al., 1993). This demonstrates that VIP may act directly at the
level of the anterior pituitary to potentiate GnRH-stimulated LH release. However,
the LH releasing activity of GnRH in rat anterior pituitary cultures (Culler and
Paschall, 1991) or in vivo (Alexander et al., 1985; Stobie and Weick, 1989) is not
potentiated by pre-treatment with VIP. These observations suggest, that the ability
of VIP to augment the LH releasing activity of GnRH is species dependent, and
occurs in man, but not the rat.
1.5 The neuroendocrine role of VIP in control of incubation behaviour
in birds
Incubation behaviour is characterised by continuous sitting on eggs, aggressive
nest protection and warning vocalisations. Riddle et al. (1935) was first to
demonstrate that PRL plays a major role in broodiness, and this was confirmed by
the observation that PRL increases in the pituitary gland and plasma at the onset of
incubation behaviour (Sharp et al., 1979; Lea et al., 1981). The main endocrine
features associated with incubation are an increase in the concentration of plasma
prolactin (PRL), (Burke and Dennison, 1980; Proudman and Opel, 1981; Etches
and Cheng, 1982), and a decline in plasma luteinising hormone (LH) and ovarian
steroids (Cogger et al., 1979; Sharp et al., 1979). VIP is the avian prolactin
releasing hormone and plays a major role in the neuroendocrine control of
incubation behaviour in birds (Sharp, 1989, El Halawani et al., 1990) (Section
1.5.3).
1.5.1 Ovarian steroids and the induction ofbroodiness
In laying hens, rapidly growing ovarian follicles secrete oestrogen which stimulates
sexual responsiveness, and induces in concert with progesterone, nesting
behaviour (Sharp, 1980). The pre-ovulatory ovarian follicles release large amounts
of progesterone during the final stages of maturation (Sharp, 1980). Nesting
behaviour associated with oviposition of the resulting ovulated ovum, occurs 24-32
hours after the preovulatory release of progesterone. Bantam and turkey hens lay
large clutches of eggs and nesting behaviour is associated with the laying of each
egg. After several eggs have been laid, the bird starts to sit on the nest at night,
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thereby transforming nesting behaviour gradually into full incubation behaviour
(Lea et al., 1981).
1.5.2 Prolactin and the induction ofbroodiness.
Increased plasma PRL is associated with the expression of incubation behaviour in
poultry (Sharp et al., 1979; El Halawani et al., 1986; Sharp et al., 1988) and doves
(Goldsmith et al., 1981). The administration of PRL to oestrogen-progesterone
primed ovariectomised turkeys, but not to ovariectomised turkeys increases the
persistency of nesting behaviour, and transforms it to incubation behaviour. The
transformation of oestrogen-progesterone primed dependent nesting behaviour into
full incubation behaviour in poultry therefore depends on increased prolactin
secretion (El Halawani et al., 1986; Sharp et al., 1988).
Plasma PRL concentration falls when the nest and eggs are removed from the
incubating turkey or bantam, but readiness to incubate appears to persist for 2-3
days (El Halawani et al., 1980; Sharp et al., 1988). Active immunization against
PRL in the bantam hen blocks the action of PRL and inhibits the development of
incubation behaviour (March et al., 1994). This illustrates the importance of
circulating prolactin in the induction of incubation in the turkey and chicken.
Prolactin may induce incubation behaviour by acting directly on the brain, because
intracranial infusion of PRL induces full incubation behaviour in the laying turkey
(Youngren et al., 1991).
In the dove, PRL appears to play a less important role in the maintenance of
incubation behaviour, than in the turkey or bantam. Peripheral administration of
PRL to doves deprived of their nest, maintains their readiness to incubate (Janik
and Buntin, 1985), and prolongs the time doves will normally incubate by 5 days
(Leaetal., 1986). However, nest deprivation and return studies have also shown
that there is no concomitant increase in prolactin secretion in the dove (Lea and
Sharp, 1989). Recent studies also suggest that peripheral PRL is not required for
the maintenance of incubation behaviour in doves (Lea et al., 1991). These authors
showed that passive immunisation against VIP, the major PRL releasing factor in
birds, prevents the development of the prolactin-dependent crop sac in incubating
doves but does not inhibit the expression of incubation behaviour (Lea et al.,
1991). These studies demonstrate that there is difference in the physiological
requirement for peripheral prolactin in the dove compared to that of the bantam and
turkey.
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1.5.3 VIP as the avian prolactin releasingfactor
Increased plasma PRL levels associated with the development of incubation
behaviour are related to increased amounts of VIP, VIP-cell number, area and
immunoreactive density in the mediobasal hypothalamus in bantams, turkeys and
doves (Sharp et ai, 1989; Mauro et al., 1988; 1989; Cloues et al., 1990; You et
al., 1995). Hypothalamic extracts containing VIP stimulate PRL secretion from
turkey anterior pituitary cells in culture, while VIP immunoneutralization depresses
PRL secretion (El Halawani et al., 1990). The dismption of incubation behaviour
by nest deprivation results in a parallel decline in plasma PRL levels and number of
VIP neurons in the medio-basal hypothalamus (Mauro et al., 1989). However, VIP
neurones found elsewhere in the hypothalamus do not show morphological
changes associated with the development of incubation behaviour in the dove
(Cloues et al., 1990).
The importance of VIP in the regulation of PRL is demonstrated by the finding that
active immunization against VIP in the turkey (El Halawani et al., 1995), or
passive immunization against VIP in the chicken (Sharp et al., 1989), suppresses
incubation behaviour, and depresses plasma PRL secretion. The release of a
prolactin releasing factor and PRL secretion by electrical stimulation of the
hypothalamus, is blocked in turkeys which are actively immunized against VIP
(Youngren et al., 1994).
VIP increases PRL mRNA in the anterior pituitary gland when injected into laying
bantam hens, and PRL mRNA in the pituitary is reduced by passive immunization
against VIP in the incubating chicken (Talbot et al., 1991) and turkey (Youngren et
al., 1994). The direct action of VIP is mediated in the turkey pituitary gland by
specific VIP binding sites (see Section 1.7.3). The number of VIP binding sites in
the anterior pituitary gland increase in incubating hens, which correlates with an
increase in plasma PRL concentration (Rozenboim and El Halawani, 1993). In
conclusion, radioimmunoassay, immunocytochemical, and passive and active
immunization studies support the hypothesis that hypothalamic VIP is the main
PRL releasing factor in birds.
17
1.5.4 Active immunization against VIP in the chicken
Active immunization against prolactin in the bantam chicken blocks the biological
actions of prolactin, preventing broodiness without disrupting egg production
(March et al., 1994). It was predicted that active immunization against VIP would
have a similar effect. However, plasma PRL and plasma LH were suppressed in
immunized birds, after they were transferred from short to long days
(photostimulated) (Fig. 1.6) (Sharp et al., 1993). Photostimulation (week 10) of
the control birds stimulated a resumption of egg laying in association with an
increase in plasma LH and PRL (Fig. 1.6). The immunized birds began to come
back into lay, after all the control birds were laying and plasma PRL was
suppressed throughout the experiment. In the immunised birds the plasma LH
concentration increased transiently compared to that of the controls, and remained
moderately low for a 8-10 week period after photostimulation. The results of this
study suggest that in addition to controlling PRL secretion, VIP may also facilitate
the function of gonadotrophs and modulate LH secretion.
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1.6 Discovery of VIP in the anterior pituitary gland
The observation that basal PRL release from rat dispersed anterior pituitary cells is
suppressed in the presence of VIP antibodies, suggests that PRL secretion may be
regulated by VIP which is synthesised by the anterior pituitary (Hagen et al.,
1986). This was confirmed by the observation that anterior pituitary fragments
incorporated [3H]-labelled leucine into immunoreactive intra-pituitary VIP in vitro
(Arnaout et al., 1986), and immunoreactive VIP was immunoprecipitated by a
specific anti-VIP antiserum (Lam et al., 1989).
Early immunocytochemical studies demonstrated that a VIP-cell type is not easily
detected in the pituitary gland of normal rats, but is observed following
thyroidectomy or chronic administration of oestrogen (Lam et al., 1989; Steel et
al., 1989; Koves et al., 1990a). Immunocytochemical studies showed that VIP is
present in cells in the anterior pituitary gland, but there are still doubts concerning
the cell type synthesising VIP. While some authors have reported that intra-
pituitary VIP in the rat is synthesised and colocalised in lactotrophs (Morel et al.,
1982; Nagy et al., 1988), others have evidence that this is not the case (Lam et al.,
1989; Segerson et al., 1989; Carrillo and Phelps, 1992). The latter authors reported
that the pituitary VIP immunoreactive cell type is distinct from lactotrophs and
thyrotrophs (Lam et al., 1989; Segerson et al., 1989; Carrillo and Phelps, 1992).
Therefore it appears that VIP synthesis occurs in the rat anterior pituitary gland, but
there is doubt whether the lactotroph or a different cell type cell, contains VIP
immunoreactivity.
1.6.1 The influence ofsteroids on intra-pituitary VIP
Intra-pituitary VIP content is manipulated by a several endocrine factors. VIP gene
expression is reduced after ovariectomy in rats (O'Halloran et al., 1990), and
increases after treatment with oestrogen (Lam, 1991; Kasper et al., 1992).
Oestrogen administration in the female rat also increases the number of VIP-ir cells
(Steel et al., 1989). However, the effect of oestrogen on VIP pituitary content and
gene expression, may only be of pathological significance. The high doses of
oestrogen (70|lg) (Carrillo et al., 1991) required to induce changes in VIP content,
induced an abnormal hyperprolactinemia (Maletti et al., 1982; Montagne et al.,
1995). Low doses of oestrogen (7|ig) stimulate a significant increase in pituitary
PRL content, without changing plasma PRL levels or VIP content (Carrillo et al.,
1991). The increases in pituitary VIP and PRL content following oestrogen
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treatment support the view that VIP may play a role in the development of
oestrogen-induced hyperprolactinaemia in the rat (Carrillo et al., 1991; Montagne et
al., 1995).
1.6.2 Effect of thyroidectomy on intra-pituitary VIP
Thyroidectomy results in an increase in VIP content and mRNA in the pituitary,
which is reversed following thyroxine (T4) replacement, but these effects are not
observed in the hypothalamus (Lam et al., 1989; Lam and Srivastava, 1990; Jones
et al., 1994). This evidence suggests that the response of the anterior pituitary to
hypothyroidism is tissue specific, but the factor or factors which influence VIP
expression in the anterior pituitary are not known.
1.6.3 Effect ofadrenalectomy on in tra-pituitary VIP
There is evidence that VIP levels in the brain are controlled by corticosteroids.
Adrenalectomy reduces the concentration of VIP in the hippocampus (Rotsztejn et
al., 1980b) and of VIP mRNA in the SCN and anterior pituitary gland. The
depressive effect of adrenalectomy on VIP mRNA in the juvenile rat anterior
pituitary but not in the hypothalamus, is reversed by treatment with dexamethasone
(Lam et al., 1992). In contrast, adrenalectomy in the adult rat reduces VIP mRNA
in the SCN of the hypothalamus, but this effect is not reversed by corticosterone
replacement (Gozes et al., 1994). These observations suggest that adrenal steroids
regulate VIP in the pituitary gland, but indirect mechanisms influenced by the
adrenal gland regulate VIP in the SCN.
1.6.4 The influence of the hypothalamic factors on intra-pituitary VIP
Anterior pituitary VIP content is significantly reduced in the rat, after removing the
hypothalamic input to the anterior pituitary. This was achieved by transplanting the
anterior pituitary under the kidney capsule, (Prysor-Jones et al., 1987) or by
colchicine administration which blocks the release of hypothalamic factors, which
act on the anterior pituitary gland (Carretero et al., 1992). These studies support the
view that hypothalamic factor(s) may modulate intra-pituitary VIP.
Lesions of hypothalamic nuclei, also block the release of hypothalamic factors
which may influence intra-pituitary VIP content. For example, the ablation of the
hypothalamic arcuate-median eminence, results in a reduction of concentration of
VIP in the anterior pituitary gland (Carrillo and Dluzen, 1993). Furthermore, the
increase in pituitary VIP concentration, which is induced by hypothyroidism, is
21
significantly reduced by anterolateral deafferentation of the hypothalamus
(Mickalkiewicz and Suzuki, 1994). This observation shows that the biosynthesis
of VIP in the pituitary is not due solely to the withdrawal of thyroid hormones (see
Section 1.6.2), but is mediated by a factor released by the hypothalamus in
response to hypothyroidism.
In rats it has been suggested that serotonin may be released from the hypothalamus
to stimulate PRL secretion (Ben-Jonathan, et al., 1989), and by inference VIP
secretion. Serotonin may stimulate intra-pituitary VIP mRNA, which in turn,
stimulates PRL release. This view is supported by the observation that the
tryptophan hydroxylase inhibitor, para-chlorophenylalanine methyl ester (pCPA)
an inhibitor of serotonin biosynthesis, depletes the stores of serotonin in the medial
basal hypothalamus, and reduces VIP mRNA in the rat anterior pituitary gland
(Signs et al., 1993). The administration of 5-hydroxytryptophan a
precursor for serotonin, supplements the loss of serotonin in pCPA treated rats,
and partially restores intra-pituitary VIP mRNA (Signs et al., 1993). The use of
specific 5-HT receptor antagonists also significantly reduces VIP mRNA levels in
the anterior pituitary, and supports the hypothesis that hypothalamic serotonin may
play a major role in the expression of VIP mRNA in the rat anterior pituitary gland
(Signs et al., 1993; 1994).
1.6.5 A paracrine or autocrine role for VIP in the regulation of lactotroph function
Pituitary VIP may play an autocrine role in the regulation of PRL secretion. Nagy
et al., (1988) used ahaemolytic plaque assay to study PRL release from individual
lactotrophs and demonstrated that VIP antiserum suppressed PRL secretion.
Therefore, it appears that VIP may stimulate PRL secretion from the lactotroph in
an autocrine manner. This view is supported by the observation that VIP was
localised in a small population of lactotrophs (Morel et al., 1982; Steel et al., 1989;
Koves et al., 1990a), although these immunocytochemical observations have not
been confirmed by other authors (see Section 1.6).
The influence of VIP on PRL secretion in rats has been studied by implanting the
anterior pituitary gland under the kidney capsule, and to induce
hyperprolactinaemia or by implanting GH3 (PRL cell line) tumors. Under these
conditions hyperprolactinaemia suppresses intrapituitary VIP content, an effect
which is reversed by oestrogen treatment (Prysor-Jones et al., 1988; Montagne et
al., 1995). Therefore, it seems likely that intra-pituitary VIP mediates the action of
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oestrogen in the rat anterior pituitary and possibly induces hyperprolactinaemia in
certain physiological situations (Montagne et al., 1995), but it is still not clear
whether this is in an autocrine/paracrine manner.
1.7 The VIP receptor
1.7.1 Characterisation of the VIP binding site
The VIP-binding protein has been characterised using a covalent cross-linking
technique, in several tissues (Laburthe et al., 1984: Laburthe and Couvineau, 1988;
Luis et al., 1988). The apparent molecular weights of the VIP-binding protein,
vary according to species and tissue, ranging from 45kDa to 73kDa. Structural
differences in the protein core or post-translational glycosylation of the VIP binding
site, may account for the differences in molecular weight. The cloning of the rat
VIP receptor has confirmed the presence of glycosylation sites (see Section 1.8.3)
(Ishihara et al., 1992), and differences in the composition of the oligosaccharide
chains attached to the VIP receptor may be responsible for its heterogeneity (Fabre
etal., 1993).
1.7.2 Signal transduction pathways linked to the VIP receptor
The VIP receptor is coupled to guanosine tri-phosphate (GTP)-binding proteins,
(G-protein) which are heterotrimers, consisting of a, 13 and y subunits (see Figure
1.6). The G-proteins bind to guanine nucleotides, providing a bridge between the
receptor and the signal transduction pathway (Fig. 1.7). When guanosine
diphosphate (GDP) is bound (a subunit) to the heterotrimer, the receptor complex
is inactivated. However, when VIP interacts with the membrane receptor protein,
the 6 and y subunits bind to the receptor-ligand complex and dissociate from the a
subunit which has GTPase activity, and exchanges GDP for GTP. The a subunit
undergoes a transformation and interacts with adenylate cyclase, which has the
ability to catalyse the dephosphorylation of adenosine triphosphate (ATP) to cyclic
adenosine monophosphate (cAMP). The cAMP molecule acts as a second
messenger, responsible for the induction of downstream events, including the
stimulation of protein kinase A (PKA), and Ca2+ influx, which may also lead to a









Figure 1.7 Schematic representation of the proposed second messenger pathway
for VIP. Abbreviations: AC adenylate cyclase; ATP adenosine triphosphate; Ca2+
calcium; cAMP cyclic adenosine monophosphate; GDP guanosine diphosphate:
GTP guanosine triphosphate: PKA protein kinase A (Adapted from Bennett and
Whitehead, 1983).
1.7.3 The avian VIP receptor
The avian VIP receptor has not been cloned but has been characterised by covalent
cross linking radiolabeled VIP to chicken pineal gland membranes (Meunier et al.,
1991). Two high affinity binding sites were observed with apparent molecular
weights of 57kDa and 70kDa (Meunier et al., 1991). The distribution of VIP
binding sites has been mapped in the brain of a pigeon, using autoradiography
(Hof et al., 1994; Kuenzel et al., 1996). Intense labelling occurs in the
periventricular area and moderate to low binding occurs in the nucleus
posteromedialis hypothalami and lateral hypothalami (Hof et al., 1994). These
areas contain VIP immunoreactive fibres as reported in the quail (Yamada et al.,
1982) and the chicken (Macnamee et al., 1986; Aste et al., 1995).
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The turkey anterior pituitary contains high- and low-affinity binding sites for VIP
(Rozenboim and El Halawani, 1993). This is consistent with observations in the rat
anterior pituitary (Wanke andRorstad, 1990b) uterus (Huang and Rorstad, 1990),
pineal (Kaku et al., 1983) and blood vessels (Huang and Rorstad, 1987). The
number of VIP-binding sites in the anterior pituitary increases in the incubating
turkey hen (Rozenboim and El Halawani, 1993), in association with the increase in
concentration of pituitary PRL content and plasma PRL (Mauro et al., 1989; Sharp
et al., 1989).
A VIP receptor has been characterised in the chicken anterior pituitary gland,
hypothalamus, and median eminence, and shown to be represented by a single
class high affinity binding site (Gonzales et al., 1994b). The specific binding of the
VIP receptor in the cephalic lobe of the anterior pituitary gland is greater than in the
caudal lobe of the anterior pituitary, but increases in both lobes after progesterone
treatment (Gonzales et al., 1994a). The specific binding of the VIP receptor is also
greater in the cephalic lobe of the incubating hen compared to the cephalic lobe of
the laying hen (Gonzales et al., 1994c). This evidence supports the view that avian
VIP, as in the rat, stimulates PRL secretion directly from the lactotroph, or a cell
type which occurs predominantly in the cephalic lobe.
1.7.4 Molecular biology of the mammalian subtype-I VIP receptor
The subtype-I VIP receptor has been cloned from man (Sreedharan et al., 1993)
and rat (Ishihara et al., 1992), and was shown to be structurally related to the
secretin (Ishihara et al., 1991), calcitonin (Lin et al., 1991) and parathyroid
hormone (Juppner et al., 1991) receptors. These receptors all have seven
transmembrane domains, are linked to G-protein and are part of a signal
transduction pathway involving adenylate cyclase (see Section 1.8.2).
The human VIP receptor (hVIP-RI) cDNA was isolated from Nairn 6 leukaemia
pre-B cells and HT-29 human colon adrenocarcinoma cells (Sreedharan et al.,
1993), which are two cell lines which possess specific receptors for VIP
(O'Dorisio et al., 1989; Sambrook et al., 1989). The potential membrane
topography of the seven hydrophobic segments is shown in Fig. 1. 8
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Figure 1.8 A diagram illustrating the potential membrane topography of the
human subtype-I VIP receptor. The seven hydrophobic transmembrane segments
are shaded black. The extracellular amino terminus is designated ET, and three
extracellular loops are designated ECL-I, -II, and -III, respectively. The
intracellular carboxyl terminus is labelled CT, and the three intracellular loops are
labelled ICL-I, -II, and-III respectively (Sreedharan et al., 1993).
The rat VIP-R (rVIP-RI) cDNA was isolated by generating a cDNA library from
the human colon adrenocarcinoma WiDr cell line (derivative of human HT-29), and
screened using a rat secretin receptor cDNA (Ishihara et al., 1991) as a probe
(Ishihara et al., 1992). An intact cDNA clone was isolated after Northern analysis
of rat lung mRNA, using the human WiDr cell line as a probe (Ishihara et al.,
1992). The specificity of the VIP-RI cDNA isolated from both man and the rat,
was confirmed by transfection into a cell line (human- COS-7; rat-COP), which
does not express the VIP receptor. When the clones were expressed in these cell
lines, VIP stimulated adenylate cyclase and cAMP production (Sreedharan et al.,
1993; Ishihara et al., 1992). The VIP-RI mRNAs are detected in tissues which
contain specific VIP-binding sites, including the liver, lung, small intestine and
brain (Sreedharan et al., 1993; Ishihara et al., 1992).
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Following the discovery of the subtype-II VIP receptor (see Section 1.7.5) the
original rat and human VIP-RI described in this section, were designated the
subtype-I VIP-receptor (VIP-RI).
1.7.5 Molecular biology of the subtype-II VIP-receptor
VIP-binding proteins occur in the brain and periphery with a range of molecular
weights (see Section 1.8) and it was originally suggested that there are several VIP
receptors (Laburthe et al., 1989; Robberecht et al., 1990). Similarly, studies using
peptide analogues have demonstrated the existence of more than one
pharmacologically distinct class of VIP receptor (Robberecht et al., 1986; Gozes et
al., 1991a, b; Blum et al., 1992). Two subtypes of the VIP receptor are known
which differ in their sensitivity to GTP analogues (Hill et al., 1992). These two
receptor subtypes, in the mouse embryo, can be differentially regulated by the
treatment with a VIP antagonist (Gressens et al., 1993).
Although, mRNA for the hVIP-RI is abundant in the lung and small intestine, there
are several tissues which have specific VIP binding sites, such as the spleen,
pancreas and adrenal, which do not express subtype-I VIP-R mRNA (Sreedharan
et al., 1993). A second VIP receptor cDNA clone was isolated by PCR, from a rat
pituitary cDNA library. Degenerate oligonucleotide primers corresponding to the
third and seventh transmembrane domains of the G-protein linked receptor family
were used to isolate a full-length cDNA clone from a rat olfactory bulb cDNA
library (Lutz et al., 1993). When the clone is expressed in COS-7 cells, VIP
stimulates cAMP production. The distribution of this VIP receptor mRNA is also
consistent with that of VIP-binding sites (Lutz et al., 1993), but differs from that of
the human and rat subtype-I VIPR mRNA (Sreedharan et al., 1993; Ishihara et al.,
1992). This second VIP-R has a different sequence and distribution from the first
human and rat VIP receptors. The second VIP-R is designated the subtype-II VIP-
receptor (VIP-RII) by Lutz et al. (1993), and the first VIP receptor cloned by
Sreedharan et al (1993) and Ishihara et al (1992), has been designated the subtype-I
VIP-receptor (VIP-RI).
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1.7.6 Differential distribution of the type-1 and type-II VIP receptor
The distribution of the VIP-RI and VIP-RII, has been described in the central and
peripheral nervous systems of the rat, using PCR, Northern analysis and in situ
hybridization (Usdin et al., 1994). The study revealed that the two receptors are
pharmacologically similar, but are differentially expressed in most tissues (Table
1.1) (Usdin et al., 1994).
TABLE 1.1 The distribution of mRNA for the VIP-RI and VIP-RII in several
regions of the rat brain. Abreviations: anteroventral nucleus (AVN);
suprachiasmatic nucleus (SCN), organum vasculosum lamina terminalis (OVLT);
paraventricular nucleus (PVN); supraoptic nucleus (SON); accessory magnocellular
















Throughout the thalamic nuclei
except the AVN
Also expressed
Medial & lateral preoptic nuclei;
OVLT; periventricular portion &
ventral subdivision of the SCN;
Magnocellular cells of the PVN,
SON & AMN; DMN, posterior
hypothalamic nucleus &
mammillary nuclei.
Highly expressed in many cells
In conclusion, the VIP-RI mRNA is found in peripheral tissues where VIP acts
through specific VIP-binding sites, but not in the testes and stomach. In these
tissues the action of VIP may be mediated by a second VIP receptor subtype, and
this is supported by the observation that VIP-RII mRNA, and not VIP-RI is
expressed in the testes and stomach (Usdin et al., 1994). In addition, the VIP-RII
mRNA is also found in a number of regions in the central nervous system
associated with neuroendocrine function, including several hypothalamic nuclei and
the pituitary gland (Usdin et al., 1994).
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1.7.7 VIP binding sites in the anterior pituitary gland
VIP-binding sites have been demonstrated in anterior pituitary tissue, in a
corticotroph-like (AtT20) cell line, and in two prolactin secreting GH cell lines. In
the anterior pituitary, the high affinity VIP binding sites are the same as those that
are found in other VIP responsive tissues (Rosselin, 1986; Wanke and Rorstad,
1990b). A specific VIP-binding site is also found on lactotrophs (Wanke and
Rorstad, 1990a).
A second low affinity VIP binding site also occurs in the pituitary gland (Wanke
and Rorstad, 1990b), but its significance is not known. It is possible that VIP may
also bind to VIP-like receptors present in the anterior pituitary which have a lower
affinity for VIP, than the specific VIP receptor (Magistretti et al. 1986). Several
peptide receptors in the peripheral and central nervous system share a structural
homology with the VIP receptor (secretin-glucagon receptor family), and these
VIP-like receptors can bind VIP and other VIP-like peptides to a varying degree.
For example, VIP may bind to the subtype-I PACAP receptor (PACAP-RI) which
is highly expressed in the anterior pituitary gland. The PACAP-RI has a high
affinity for PACAP, but a lower affinity for VIP (see Section 1.8.4). Low affinity
VIP binding sites also occur in a GH3 cell line (Wood et al., 1985), whereas low
and high affinity binding sites occur in the GH4C1 cell line (Bjoro et al. 1987).
Steroids affect VIP-binding sites in the pituitary gland. In male castrated rats the
number of VIP binding sites increase in the rat anterior pituitary gland, an effect
which is reversed by a prior injection of testosterone. In contrast, VIP-binding sites
in the liver, prostate or brain are not affected by steroids (Wanke et al., 1990). This
suggests that testosterone may play a role in the regulation of VIP receptor function
in the male anterior pituitary gland.
1.7.8 VIP receptor mRNA in the anterior pituitary gland
The mRNA for the VIP-RII occurs in the rat anterior pituitary gland (Lutz et al.,
1993; Rawlings et al., 1995) and VIR-RII mRNA is greater in the pituitary of a
pregnant rat compared to that of a nonpregnant rat (Usdin et al., 1994). The VIP-
RII also occurs in the somatotroph-like GH4C1 cell line (Rawlings et al., 1995),
consistent with reports of VIP-binding sites in normal somatotrophs and clonal
GH3 cells (Rawlings et al., 1993; Coleman and Bancroft, 1993; Deutsch and Sun,
1992). VIP-RII mRNA is also found in a gonadotroph-like aT3-l cell line, and
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analysis of PRL and GH enriched cell populations with PCR primers, suggests that
type-II VIP receptor mRNA is the principal VIP-R in these cell types (Vertongen et
al, 1995a).
Little or no mRNA for the VIP-RI is found in the pituitary (Usdin et al., 1994;
Rawlings et al., 1995). VIP does stimulate differentiation in the corticotroph-like
AtT20 cell line (Braas et al., 1994) and the mRNA encoding the VIP-RI and VIP-
RII is present in this cell line (Journot and Rawlings, unpublished data). The VIP-
RI mRNA has not been demonstrated in normal corticotroph cells, but its presence
would explain the low level of VIP-RI mRNA detected in the rat anterior pituitary
gland (Usdin et al., 1994; Rawlings et al., 1995).
1.8 Pituitary adenylate cyclase activating polypeptide
A hypothalamic peptide similar to VIP originally isolated from the ovine
hypothalamus, stimulates adenylate cyclase, and cAMP production in anterior
pituitary gland cells. It is known as pituitary adenylate cyclase activating
polypeptide (PACAP) (Miyata et al., 1989) and occurs as a 38 amino acid, C-
terminally amidated peptide (PACAP38) and a 27 amino acid form (PACAP27)
(Miyata et al., 1989: 1990).
PACAP cDNA has been isolated from several species (Kimura et al., 1990; Ogi et
al., 1990; 1993), and the deduced amino acid sequences are identical. The chicken
form of PACAP38 is identical to mammalian PACAP, except at position 2 where
lie replaces Ser (Yasuhara et al., 1993) (see Section 1.2.2). The first 28 amino
acids of mammalian PACAP38 share a 68% homology with porcine VIP (Miyata et
al., 1989), and is also a member of the VIP/Secretin gene family. It is possible that
many biological effects of VIP could be mediated by PACAP or vice versa, since
there is a high degree of structural similarity between these neuropeptides.
1.8.1 Distribution ofPACAP
Like VIP, PACAP is widely distributed in the mammalian peripheral and central
nervous systems (see reviews Arimura, 1992; Christophe, 1993), but there are a
number of cases where the distribution of PACAP is different from that of VIP.
PACAP-immunoreactivity occurs in nerve fibres in the gut wall of the rat, human,
sheep and chicken (Sundler et al., 1992). PACAP-ir also occurs in endocrine cells
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of the proventriculus, and is colocalised with VIP in nerve cell bodies and nerve
fibres in the chicken gut (Sundler et al., 1992). This observation suggests that
PACAP like VIP, is involved in the regulation of motor and secretory activities of
the gastrointestinal tract.
The distribution of PACAP immunoreactive neurons has been studied in the brain
of the rat, human and sheep (Koves et al., 1990b: 1991; Vigh et al., 1991).
PACAP cell bodies are present in the supraoptic and paraventricular nuclei, of the
rat and ovine hypothalamus, and immunopositive fibres are also found in the
external and internal zones of the median eminence (Koves et al., 1990b: 1991;
Vigh et al., 1991). These observations support the view that PACAP like VIP, may
also act as a hypothalamic releasing factor to regulate anterior pituitary function or
secretion. PACAP immunoreactivity also occurs in the chicken brain (Yasuhara et
al., 1992), but there are no published reports describing its distribution. Based on
the observations in mammalian species, it is likely that PACAP would have a
similar distribution and role in the chicken.
1.8.2 Multiple receptors for PACAP and VIP
Binding studies show that PACAP and VIP bind to two major groups of receptor.
PACAP is 1000 times more potent than VIP, in stimulating cAMP production in
the rat anterior pituitary gland (Miyata et al., 1989), and specific receptors have
been identified in the pituitary (Vigh et al., 1993) which have a greater affinity for
PACAP than VIP (Gottschall et al., 1990). The PACAP receptor which binds
PACAP38 and PACAP27 with a greater affinity than VIP is referred to as the
PACAP Type I receptor (PACAP-I-R or PVR1), and its encoding gene has been
cloned by several groups (Rawlings, 1994; Harmar and Lutz, 1994; Arimura and
Shioda, 1995). The PACAP-I-R gene is expressed in several regions of the rat
CNS, and pituitary, adrenal, and testis, but there is little or no expression in other
peripheral tissues (Spengler et al., 1993; Hashimoto et al., 1993; Ogi et al., 1993).
The second receptor subtype which binds PACAP38, PACAP27 and VIP with
approximately the same affinity, is the classic VIP receptor (VIP-RI/II) (Section
1.7.4 and 1.7.5), which is also known as the PACAP Type II receptor (PACAP-
II-R or PVR2/PVR3). Both type I and type II PACAP receptors are linked to G-
proteins and are part of the VIP/secretin family of receptors (Christophe, 1993;
Rawlings, 1994).
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1.8.3 Effect ofPACAP on pituitary hormone cells
PACAP stimulates ACTH, GH, LH and PRL secretion from superfused rat
pituitary cells, but has no effect on static cultures despite an increase in cAMP
production (Miyata et al., 1989). PACAP also stimulates a change in intracellular
Ca2+ ([Ca2+i]) in several pituitary cell types, notably somatotrophs, gonadotrophs
and follicular stellate cells (Canny et al., 1992; Yada et al., 1993). In gonadotrophs
PACAP stimulates a 'Ca2+ spike' response which is independent of extracellular
Ca2+, and is believed to involve the release of Ca2+ from an intracellular store
(Canny et al., 1992) through a 1,4,5-inositol triphosphate [Ins(l,4,5)P3]-
dependent mechanism (Fig. 1.9) (Rawlings et al., 1993; 1994).
In addition, PACAP stimulates an extracellular Ca2+ dependent 'Ca2+ plateau'
response in gonadotrophs and somatotrophs (Canny et al., 1992) , which is likely
to result from the stimulation of adenylate cyclase and cAMP production through
the PACAP-II-R (VIP-R). There are cases where it appears that the PACAP-I-R is
coupled to both the adenylate cyclase and inositol phosphate turnover (PI)
signalling pathways, through different G-proteins (Christophe, 1993). This view is
supported by the observation in the T3-1 (LH-like) cell line, that PACAP stimulates
a Ca2+ store-dependent Ca2+ spike, through a inositol phosphate pathway and
Ca2+ influx. In contrast, VIP only stimulates Ca2+ influx, and with a lower
potency than that of PACAP. (Rawlings et al., 1995). These observations suggest
that PACAP-I-R is more abundant than the VIP-RII in the aT3-l cell line.
Alternatively, the PACAP-I-R may be more efficiently coupled to adenylate cyclase
than the VIP-RII, or may compete more effectively for available G-proteins
(Rawlings et al., 1995).
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[Ca2+]
Figure 1.9 Schematic representation of the inositol phosphate (PI) signal
transduction pathway triggered by the Type-I PACAP receptor in gonadotrophs.
Abbreviations'. Ca2+ Calcium; Ca2+i intracellular Calcium; DG diacylglycerol; IP3
inositol 1,4,5-triphosphate, R VIP receptor; PIP2 phosphatidylinositol 4,5,-
biphosphate; PKC Protein kinase C; PLC Phospholipase C.
1.8.4 VIP-PACAP receptors in the anterior pituitary
Observations on VIP-PACAP receptors in the anterior pituitary gland and pituitary
derived cell lines suggest that differential expression might result in a complex
regulation of pituitary cell function by VIP and PACAP. This point is illustrated in
Table 1.2 which shows the relationship between VIP/PACAP receptors and their
signal transduction pathways in various cell types.
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TABLE 1.2 . Expression of VIP-PACAP receptors in pituitary derived cell lines
and pituitary tissue, and the signal transduction mechanisms linked to each receptor
subtype. Abbreviations: A.C. adenylate cyclase; aT3-l gonadotroph-like cell line;
AtT-20 corticotroph-like cell line; GH4C1 somatotroph/lactotroph-like cell line;
PKA Protein kinase A; PKC protein kinase C; PLC phospholipase C; PVR1
PACAP receptor subtype I; PVR2 PACAP receptor subtype II & VIP receptor
subtype I; PVR3 PACAP receptor subtype III & VIP receptor subtype II; (+)




aT3-l + - +
GH4C1 - - +
AtT-20 - +
Pituitary + + +
Signal transduction
pathway
A.C. & PKA + + +
PLC & PKC +
1.9 Paracrine control of anterior pituitary function
In an endocrine tissue such as the anterior pituitary gland, hormones are released
from cells into the peripheral circulation to reach distant specific target cells (Denef,
1986). Hormones can also be released locally to influence neighbouring cells to act
in a paracrine manner. When the secretory cell regulates its own function, through
receptors on its surface for its own secretory product, the cell is regulated in an
autocrine manner (Le Roith et al., 1983, Denef, 1986; Schwartz and Cherny,
1992).
A number of features of the anterior pituitary cells are consistent with a role for
paracrine control mechanisms within the gland. These include the topographical
arrangement of different pituitary cells, the presence of neuropeptides, growth
factors and biogenic amines which effect pituitary hormone release in vitro and the
local action of pituitary hormones within the gland (Denef, 1986).
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1.9.1 Folliculo-stellate cell
The folliculo-stellate cell (FS-cell) is of particular interest to researchers studying
paracrine and autocrine mechanisms within the anterior pituitary gland. The FS-
cells were first described in the rat and human pituitary gland by Farquhar (1957),
and are distinct from normal hormone secreting pituitary cell types (Vila-Porcile,
1972; Perryman, 1983). The FS-cell is also present in the avian anterior pituitary
gland (Harrisson et al., 1982a, b; Fernandez et al, 1986). Morphological features
used to identify the FS-cell include: 1) stellate appearance, 2) a lack of secretory
granules, 3) junctional complexes linking similar cells, 4) cilia and microvilli
projecting into the follicular lumen and 5) a limited number of organelles and
ribosomes (Harrison et al 1982b) (Figure 1.10)
Figure 1.10 A diagrammatic representation of the FS-cell in the anterior pituitary
of the rat. The FS-cell (dark background) surround various follicular cavities (fl).
Their processes extend between granulated cells (GC) (clear background), and abut
onto the parenchymal basal lamina (pbl). Some fenestrated capillaries (c) are also
shown. (Allaerts et al., 1990).
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1.9.2 Localisation ofS-100 protein in FS-cells
Folliculo-stellate cells are characterised by the presence of a soluble membrane
bound protein called S-100 (Cocchia and Miani, 1980; Nakajima et al., 1980;
Shirasawa et al., 1983). S-100 protein was first isolated from the central nervous
system, where it has unique Ca2+ binding properties (Moore, 1965; Calissano et
al., 1969). In mammals, S-100 protein is found in glial cells in the CNS, and in
several cell types (Boyes et al., 1986; Donato, 1986; Vanstapel et al., 1986;
Haimoto et al., 1987). Although the precise function of S-100 protein remains
uncertain, S-100 immunocytochemistry (Kahn et al., 1983; Takahashi et al., 1984)
has provided a useful tool in identifying FS-cells in the mammalian (Cocchia and
Miani, 1980; Nakajima et al., 1980; Shirasawa et al., 1983) and avian (Atoji et al.,
1990) anterior pituitary gland.
1.9.3 Origin ofFS-cells
Folliculo-stellate cells may be related to glial cells, and therefore be of
neuroectodermal origin, although this is not consistent with the classical view that
the anterior pituitary is ectodermal in origin (Cocchia and Miani, 1980). The glial
cell and FS-cell share common features, such as cell membrane ATPase activity
(Semoff and Hadley, 1978), similar structural features (Barberini and Correr,
1984; Stokeef et al., 1986) and a common supportive role (Dingemans and
Feltkamp, 1972).
The cytoskeletal intermediate filament proteins vimentin and glial fibrillary acidic
protein (GFAP) also occur in glial cells (Gown and Gabbiani, 1984). The
distribution of GFAP-immunoreactive glial cells has also been mapped out in the
central nervous system of several species including the rat (Hajos and Gallatz,
1987) and quail (Cameron-Curry et al., 1991). The use of antisera to specific glial
cell markers such as, S-100 protein (Cocchia and Miani, 1980), GFAP (Calvo et
al., 1988) and vimentin (Marin et al., 1989) demonstrates that FS-cells in anterior
pituitary are glial-like, supporting the view that FS-cells share a common origin
with glial cells.
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The FS-cells represent about 5-10% of the anterior pituitary cell population and are
dispersed throughout the gland (Allaerts et al., 1990). The FS-cells may associate
in groups and form follicles, or be closely associated with hormone secreting cells,
with long cytoplasmic extensions between neighbouring cells (Allaerts et al.,
1990).
1.9.4 Function ofFS-cells in the anterior pituitary
The function of the FS-cell in the mammalian pituitary gland is suggested by its
morphological structure and its association with the granulated hormone-secreting
pituitary cells. The FS-cells may play a role in the transfer of waste material from
degenerating cells into the lumen of follicular cavities (Fernandez, et al 1986), and
the phagocytosis of cells during endocrine dysfunction (Perryman et al., 1980;
Vila-Porcile, 1972). In female rats primed with oestrogen for several weeks,
lysosomes and autophagic vacuoles occur in the FS-cells, after the withdrawal of
the oestrogen treatment (Stokeef et al., 1986). The FS-cells may also provide
mechanical support in the pituitary (Blanco et al., 1978), in addition to providing
trophic support for the hormone secreting cells (Vila-Porcile, 1972).
1.9.5 Growth factors, cytokines and FS-cells
Growth factors and cytokines produced and localised within FS-cells together with
their effects on pituitary hormone secretion are listed in Table 1.3
Table 1.3 The effect of substances known to be expressed by FS-cells, on
pituitary hormone secretion. Abbreviations'. (+) stimulatory action (-) inhibitory
action ACTH adrenocorticotroph ; bFGF basic fibroblast growth factor; GH
somatotroph; IGF-I Insulin-like growth factor-I; IL-6 interleukin-6; LH
gonadotroph; ne indicates no effect.; PRL prolactin; S-100 S-100 protein; TSH
Thyrotroph; (Allaerts et al., 1990, Houben and Denef, 1994).
Pituitary cell type














The development of a method to culture FS-cells in vitro has facilitated a direct
experimental approach to the study of the functional properties of FS-cells, and the
identification of paracrine factors they produce (Ferrara et al., 1986; Allaerts and
Denef, 1989). FS-cells contain and release S-100 protein, which stimulates PRL
secretion from cultured clonal PRL cells (Ishikawa et al., 1983), and is implicated
in cell division and growth (Fan, 1982; Kligman and Hilt, 1988).
Basic fibroblast growth factor (bFGF) is secreted by FS-cells, which enhances the
responsiveness of lactotrophs and thyrotrophs to TRH (Baird et al., 1985). A
novel vascular endothelial growth factor (VEGF) also occurs in FS-cells (Ferrara
and Henzel, 1989; Gospodarowicz and Lau, 1989) and may regulate the
microvasculature of the anterior pituitary gland. The cytokine interleukin-6 (IL-6)
occurs in S-100(+) FS-cells (Vankelecom et al., 1993), which stimulates PRL, GH
(Spangelo et al., 1989) LH (Yamaguchi et al., 1990) secretion in vitro and ACTH
secretion in vivo (Bateman et al., 1989) and in vitro (Woloski et al., 1985).
A number of studies have demonstrated that the FS-cell attenuates the secretory
activity of most pituitary cell types by reducing their response to stimulatory (Baes
et al., 1987) as well as inhibitory hypothalamic releasing factors (Allaerts and
Denef, 1989). Follistatin inhibits follicle stimulating hormone (FSH) secretion, and
is released by FS-cells in monolayer cultures, and therefore may act directly on the
gonadotroph and regulate FSH secretion in the pituitary (Gospodarowicz and Lau,
1989). This observation is consistent with a paracrine role of the FS-cell in
modulating pituitary hormone secretion. It is therefore interesting to note, that after
gonadectomy in the rat, FS-cells closely surround gonadotrophs but not
thyrotrophs (Shirasawa et al., 1983), which further supports the view that FS-cells
may modulate the function of pituitary hormone cells.
In conclusion, FS-cells in the anterior pituitary gland are involved in a number of
physiological responses to changes in the endocrine environment. The production
and secretion of paracrine factors by FS-cells, and their relationship with pituitary
hormone secreting cells, suggests that this cell type plays an important role in cell-
to-cell communication and regulation of pituitary function.
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1.10 Research objectives
The preceding literature shows that one of the functions of VIP in the central
nervous system is to regulate the secretion of hormones from the anterior pituitary
gland. In birds, VIP is the major hypothalamic prolactin releasing factor, with no
apparent LH-releasing activity. However, a recent study showed that active
immunization against VIP in the bantam hen results in the expected depression in
PRL secretion, and an unexpected depression of LH secretion (Sharp et al., 1993).
On the basis of this observation it was suggested that VIP may also facilitate the
function of gonadotrophs.
Vasoactive intestinal polypeptide immunoreactivity (Lam et al., 1989; Steel et al.,
1989; Carrillo and Phelps, 1992) and VIP mRNA (Lam et al., 1989; O'Halloran et
al., 1989) occurs in the rat anterior pituitary gland. A VIP-cell type demonstrated
immunocytochemically appears to be distinct from that of the lactotroph (Lam et
al., 1989; Sergeson et al., 1989; Carrillo and Phelps, 1992), and may secrete VIP
to affect pituitary hormone function. It is suggested that VIP might also be
produced in the chicken anterior pituitary gland, and act in a similar fashion. The
depression of plasma LH secretion in the chicken, after actively immunizing against
VIP, may be due to the suppression of intra-pituitary VIP, which has a trophic
action on the gonadotroph and thereby modulates LH secretion.
The objectives of this thesis were:-
• To determine whether VIP-immunoreactivity occurs in the chicken anterior
pituitary gland.
• To localise cells containing VIP in the anterior pituitary and determine their
relationship with other cell types.
• To establish whether the VIP mRNA occurs in the anterior pituitary, and if so
which cell type expresses the VIP gene.
• To identify VIP binding sites on pituitary cell types by immunocytochemistry.
• To establish whether VIP modulates pituitary hormone release in vitro, and in
particular LH secretion.
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Chapter 2: MATERIALS AND METHODS
2.1 General materials
2.1.1 Standard reagents
All reagents were obtained from Fisons (Loughborough, Leicestershire, U.K.),
BDH (Poole, Dorset, U.K.) or Sigma (Poole, Dorset, U.K.), unless indicated.
The water was purified by pre-filtration and reverse osmosis purification by Milli-
RO and Milli-Q systems (Millipore Waters, Watford, U.K.).
Peptides were obtained from the following sources: chicken vasoactive intestinal
polypeptide (cVIP) (Penninsula Laboratories pic.), ovine pituitary adenylate
cyclase activating polypeptide (oPACAP) (Penninsula Laboratories pic.), chicken
pituitary adenylate cyclase activating polypeptide (cPACAP) (A gift from Prof. A.
Arimura, Tulane University Herbert Centre, Los Angeles, U.S.A.), and chicken
gonadotrophin releasing hormone 1 (cGnRH-1) (Penninsula Laboratories pic.).
2.1.2 Standard solutions
Blocking buffer: 2 x SSC, 0.05% Triton X-100.
Buffer l(xlO): 1M Tris NaCl (pH 8.0).
Denhardts solution: 0.02% Ficoll, 0.02% polyvinylpyrolidone, 0.02% BSA.
Equilibrated phenol: Re-distilled phenol was repeatedly equilibrated with equal
volumes of 0.5M Tris until the pH was greater than 7.0. This was then stored with
an equal volume of TE and 1.0% hydroxyquinoline at -20°C.
Gel loading dye: 50% glycerol, 50% 2 x TAE, 2.5 mg bromophenol blue, 2.5 mg
xylene cyanol.
Phosphate buffer (PB): 0.1 M Na H2 PO4, 0.1M Na2 HPO4 (pH 7.4).
PBS: 0.1 M PB, mM NaCl (pH 7.4).
RNase buffer: 0.01 M Tris (pH 8.0), 0.5 M NaCl, 1 mM EDTA
SSC: 15mM Sodium citrate, 150 mM NaCl.
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TE Tris EDTA: lOmM Tris-HCL (pH 8.0), 1 mM EDTA.
TAE Tris acetate electrophoresis buffer: 40 mM Tris-acetate, 1 mM EDTA.
TAE acetate : lOOmM TAE ammonium acetate pH 2.5.
TAE formate : lOOmM TAE formic acid pH 3.5.
TBE Tris borate electrophoresis buffer: 89mM Tris-borate, 2.5 mM EDTA.
2.1.3 Animals
The animals used in these experiments were adult female bantam hens obtained
from the Roslin Institute flock (Roslin, Midlothian, U.K.). They were individually
caged, fed layers pellets ad libitum, and water was freely available through
drinking nipples. The lighting schedule was 16-hours light and 8-hours dark
(lights on at 00-00 GMT). Broodiness was induced by transferring groups of five
birds to floor pens (4m x 2m) containing 5 nest boxes, and maintaining the same
light pattern. The birds were inspected daily for 3-5 weeks for evidence of
broodiness, which was recognised by persistent nesting, and characteristic
clucking. Furthermore ovarian regression in incubating hens, was confirmed by
surgical examination at autopsy.
2.1.4 Blood samples
Blood samples were taken from the brachial wing vein with heparinised (Pump-
hep, Leo Laboratories, Princes Risborough, UK) syringes, and plasma obtained
by centrifugation at 250 x g for 15 min. Samples were then stored at -20°C before
radioimmunoassay for hormones (see Section 2.9 ).
2.2 Immunocytochemistry
2.2.1. Reagents
All the solutions and the washes used were made with 0.1M PBS pH 7.4, and all
incubations were carried out in a humid incubation chamber at 4°C, unless
otherwise indicated. The following antibodies used in this study will be described
in Chapters 3, 5 & 6: anti-chicken vasoactive intestinal polypeptide (anti-cVIP)
(code/6DL/31/4); anti-chicken prolactin (anti cPRL) (code/31/1); anti-turkey
luteinising hormone B-subunit (anti-LH; 783) anti-chicken growth hormone (anti
cGH); anti- S-100 and anti-glial fibrillary acidic protein (anti-GFAP) were
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purchased from DAKO (High Wycombe. Bucks., U.K.). The antibodies to type-I
and type II VIP-Receptor were kindly donated by Dr. E.J. Goetzl (Dept. of
Medicine and Microbiology-Immunology, University of California, San
Francisco, CA, U.S.A.), mammalian pituitary adenylate cyclase activating
polypeptide (anti-mPACAP) was donated by Prof. A. Arimura (Tulane University
Medical Centre, U.S..-Japan Biomedical Research Laboratories, Los Angeles,
U.S.A.) and the anti-chicken adrenocorticotrophin hormone (anti-ACTH; code/5.
81) was supplied by Prof. P. Lowry (University of Reading). All sera (NDS,
NSS, NRS, DARS) were obtained from the Scottish Antibody Production Unit
(SAPU, Law Hospital, Carluke, U.K.).
2.2.2 Tissue collection
The anterior pituitary glands were obtained from laying and broody bantam hens.
The hens were killed by cervical dislocation (Scientific Procedures Act, 1986) and
decapitated. The lower mandible was removed from the head and trimmed by
removing the tissue and bone rostral to the orbital recess and overlying the base of
the brain. The anterior pituitary was detached from the median eminence and then
separated from the neural lobe. The basal hypothalamus was then dissected with a
scalpel by making vertical cuts posterior and anterior to the optic chiasma. The
tissue fragments were then placed in fixative or liquid nitrogen according to the
experimental protocol.
2.2.3 Perfusion
The hens were deeply anaesthetised with sodium pentobarbitone (60mg/kg)
(Sagatal, Rhone Merieux), injected into the brachial wing vein. Then the brain
was perfused via the carotid artery with a cannulae (Portex Ltd, Kent, U.K.)
directed towards the head, with physiological saline 250-300ml (0.9% NaCl w/v)
containing heparin (lOU/ml), After severing the jugular vein, the brain was
perfused with 400-500 ml of Zamboni's fixative (4% paraformaldehyde, 15%
aqueous saturated picric acid, 0.1 M PBS, pH 7.4)
2.2.4 Microwave Fixation
The tissue was fixed in Bouin's ( 0.1M copper acetate; 0.015% aqueous saturated
picric acid; 4% formaldehyde) for 2-3 hours and processed further by microwave
irradiation (H2500 Microwave processor, Bio-Rad, Hemel Hempstead). The
tissue was irradiated in a series of steps: 4 min at 55°C in fixative; 60 min at 67°C
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in 100% ethanol; 45 min at 74% in isopropanol and for 15 min in xylene with a
250 ml water load (Boon and Kok, 1988). The tissue was embedded in
polystyrene (100,000 Mr) (lOOg polystyrene, 400ml xylene, 25ml benzyl alcohol,
5ml dibutyl phthalate) (Fragioni and Borgioli, 1979), in a tissue embedding mould
(Peel-A-Way, Polysciences Inc., Warrington, PA, U.S.A.) and baked in an oven
for 24-36 hours at 60°C (Fragioni and Borgioli, 1979). When the polystyrene had
hardened the plastic mould was removed and the block trimmed (5x5x5 mm)
and attached to a perspex chuck (Roslin Institute, Dept. of Engineering Services)
with adhesive. The embedded tissue was then stored at room temperature or
sectioned immediately on a microtome.
2.2.5 Microtome sectioning
A motorised microtome (Microtome, LKB Instruments, Surrey, U.K.) equipped
with a glass blade, was used to section the polystyrene embedded tissue at a
thickness of 2-5(im. Two hundred to three hundred microlitres of paraldehyde
solution (10%v/v), was dispensed onto a subbed-slide, and the sections were
removed from the glass blade with a pair of forceps and placed onto the fluid. The
slide was then transferred to a hot plate (80°C) for 3-5 seconds, until the solution
became milky and the sections flattened. The slide was then removed, allowed to
cool at room temperature for 1 min; the excess paraldehyde solution aspirated off
the slide, and dried on a warm plate (40°C) to ensure tissue adhesion to the slide.
The sections were then stored (1 month) in a suitable container or used
immediately for immunocytochemistry.
2.2.6 Vibratome sectioning
A Vibratome (shaking microtome) (Bio-Rad, Hemel Hempstead, U.K.) was used
because the morphological preservation of the sectioned material is better than that
of frozen sections and is capable of sectioning larger blocks of material (Priestley,
1987). Therefore this was the method of choice when sectioning large areas of the
brain (Chapters 3 and 5). The perfused tissue was attached to a horizontally
orientated chuck with adhesive and then embedded in 2% agar to provide structural
support. The chuck was placed in a small tank on the shaking microtome with
buffer (PBS). The vibrating razor blade was then advanced horizontally through
the tissue, and the sections (70p,m) floated off into the buffer for collection, and
transfered to suitable receptacles for immunocytochemical staining.
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2.2.7 Immunostaining on mounted slides
All the washes were carried out in 0.1M PBS, pH 7.4 unless otherwise indicated.
The immunocytochemical procedure described below was used for all the
experiments, but variations were made, and described in later chapters. The slides
were cleared with xylene and rehydrated (5 min) with a graded series of alcohols;
100%; 95%; 90%; 70%; 50% and then washed 3 times in PBS.
The most commonly used enzyme label was horseradish peroxidase, and sections
stained by this method were incubated in methanol containing 0.3% H202 (30 min)
to block endogenous peroxidase activity in the tissue. All sections were washed in:
PBS for 5 min; Triton X-100 (0.4%) for 5 min and PBS for 5 min. The area
around the tissue sections was dried with a strip of fibre-free blotting paper (Agar,
UK), and encircled with a layer of synthetic wax (DAKO-PEN, DAKO, High
Wycombe. Bucks., U.K.). A suitable blocking (5%; NDS or NGS) solution was
then applied to each tissue section (50pl) and stored in a horizontal slide holder and
incubated for 30 min. The antibody was prepared to the desired concentration (1:
100-20 000 see Table 2.1), in 0.1% blocking solution, and 50|ll applied to each
section, after the excess block solution had been removed, and incubated
overnight.
Table 2.1 Antibodies used for immunocytochemical studies and the dilution used
in the pituitary and hypothalamus. Abbreviations: A.P. anterior pituitary; Bov
bovine; Gp guinea pig; Hu human; Hyp. hypothalamus; Rb rabbit; Sh sheep; and
Tur turkey. The antibodies were described in Section 2.2.1.
Antibody Specificity Working Dilution
(code) A.P. Hyp.
ACTH (5.81) Rb anti-Ch. 1:500 /
GH Rb anti-Ch 1:500 /
LH (783) Rb anti-Tur. 1:1000 /
LH a subunit Sh anti-Ch. 1:1000 /
PRL (31/1) Rb anti-Ch 1:20 000 /
PRL Gp anti-Ch. 1:1000 /
S-100 (Dako) Rb anti-Bov. 1:500 1:500
Vasotocin Rb anti-Ch / 1:10 000
VIP (6DL/34/1) Sh anti-Ch 1:2000 1:10 000
VIP-RI (A, B) Rb anti-Hu. 1:100 1:100
VIP-RII Rb anti-Hu. 1:100 1:100
(4, 5, 6, 22 &23)
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The method used to identify a specific primary antibody is described in more detail















Figure 2.1 A schematic representation of the two immunocytochemical staining
methods used in this study. The (a, b) primary antibody recognises a specific
antigenic site and binds to it. A second antibody is then used to bind to the primary
antibody. The secondary antibody may be (a) conjugated directly to a marker, such
as FITC or rhodamine, or (b) be biotinylated (open circle). The biotinylated second
antibody acts as a bridge linking the avidin-peroxidase enzyme complex to the
primary antibody. The avidin-biotin complex (ABC) is visualised when DAB is
added (filled circle), and is oxidised by peroxidase (+) to a brown product
(Adapted from Sternberger, 1979).
The sections stained with the fluorochromes fluorescein isothiocyanate (FITC;
SAPU) or Lissamine rhodamine isothiocyanate (LSRC; Jackson Laboratories,
Stratech Scientific, Beds., UK), were mounted in an aqueous mounting medium
(90% v/v glycerol/PBS), containing the anti-fading agent diazo-bicyclo-2,2,2,-
octane (DABCO). The addition of dihydrochloride, 4', 6-diamidino-2-phenyl-
indole (DAPI), facilitated the visualisation of nuclei. The sections were then
examined on a fluorescent microscope (Nikon Optiphot) or a scanning laser
confocal microscope (Bio-Rad MRC-, Herts., U.K.).
The sections stained with a peroxidase conjugate were incubated with the
chromagen 3,3'-diaminobenzidine (DAB) in 50 mM Tris pH 7.4, 0.3% hydrogen
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peroxide, until the desired staining was obtained. DAB acts as an electron donor
for peroxidase, and when oxidised, forms an insoluble precipitate at the reaction
site. The sections were washed in PBS and several times (x3) in distilled H20, and
dried in an oven for 2-3 hours at 37°C. The slides were then washed twice in
KEMSOL-30 (Kem Serv, Ltd, U.K.) for 10 min and mounted in DPX mountant
(Agar Scientific, Stansted, U.K.) and viewed by light microscopy (Olympus,
Loughborough, Leics., U.K.).
2.2.8 Immunostaining on free floating sections
The method used to stain free floating sections is principally the same used to stain
sections on mounted slides (Section 2.2.7). The sections were stored in a
receptacle (2-3 sections) which allowed the sections to be transferred to different
solutions, without handling or damaging the sections. The immunostaining was
performed by transferring the receptacle holding the sections to the required
development solution, such as DAB for the desired amount of time (1-5 min).
2.3 RNA Isolation
2.3.1 Reagents
All materials and reagents used for RNA isolation were purchased free of
ribonuclease (RNAse) activity, and any solutions which were not, were treated
with diethlypyrocarbonate (DEPC) 0.1 % v/v for 24 hours and then autoclaved.
2.3.2 Tissue collection
The anterior pituitary glands were obtained from laying and broody bantam hens in
the same manner as described in 2.2.1. The tissue was placed in sterile tubes,
weighed, snap frozen in liquid nitrogen and stored frozen at -70°C.
2.3.3 Isolation of total RNA
Total RNA was extracted from tissue using a modified version of the acidified
phenol-chloroform method of Chomczynshi and Sacchi (1987). Approximately
five to ten anterior pituitary glands or hypothalamic tissue (50-100mg) was
homogenised in 0.9 mis of RNAzol B solution (Witney, Oxon, U.K.) and left in
ice for 5 minutes. A further 0.9 mis of RNAzol B solution was added to each tube
and vortexed thoroughly, and placed on ice for another 5 minutes. Chloroform
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(0.2 mis) was added to each tube which was vortexed and placed on ice for 15
minutes, before spinning at 12 000 rpm for 15min at 4°C.
The clear aqueous phase, containing the total RNA, was carefully removed and
precipitated with an equal volume of pre-chilled (-20°C) isopropanol and stored at -
20°C for 1 hour. The RNA was precipitated into a pellet by centrifugation at 12
000 rpm for 30 minutes at 4°C. The pellet was washed with 75% ethanol and then
70% ethanol, before being vacuum dried. The pellet was re-dissolved in water,
and the yield and purity of the total RNA was estimated by measuring the optical
density of an aliquot (2pl) by UV spectrophotometry at 260nm and 280nm. The
sample was then diluted with water to a pre-determined RNA concentration and
stored frozen at -70°C.
2.4 Polymerase chain reaction
Genomic DNA can be amplified using the polymerase chain reaction (PCR) (Saiki
et al. 1990), which comprises three steps, which when combined, make 1 PCR
cycle. Firstly, the double stranded DNA is heat-denatured, and then the single
stranded DNA is cooled to allow two oligonucleotide primers to anneal to
complementary regions on the target DNA. Finally the thermo-stable DNA
polymerase Taq amplifies the oligonucleotide targeted DNA.
2.4.1 Reverse transcription-PCR
The PCR does not amplify RNA because the Taq enzyme used in the reaction is
DNA dependent, therefore the RNA is reverse transcribed (RT) to generate
complementary DNA (cDNA). Reverse transcription polymerase chain reaction
(RT-PCR) uses similar principals and protocols as standard PCR, but the template
or target is derived from reverse transcribed RNA or complementary DNA (cDNA)
(Frogman et al. 1988).
The total RNA was prepared by the method described in Section 2.3.3 and the
optical density measured to determine the concentration required for the RT
reaction. RNA was reverse transcribed to cDNA using a first strand synthesis kit
(Pharmacia Ltd.) containing the following reaction components: 5|Ltg RNA in 8pl
DEPC-H20: 2fil of mix (3.5|il DDT, 3.5pl Oligo. DT primer); 5pl first strand
synthesis kit. The RT reaction was allowed to proceed at 37°C for 1 hour and
stopped by increasing the temperature to 95°C for lOmins.
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The PCR was also set up using reagents supplied as a kit (Promega). The reaction
mixture consists of (Table 2.2): RT cDNA; oligo primer mix; reaction buffer;
NTPs (Promega); DEPC-H20; Taq enzyme (Boehringer) and mineral oil. The
volumes of reagents are shown in Table 2.2. The samples were dispensed into
microcentrifuge tubes and placed in the hot block of a PCR machine (Hybaid,
Teddington, Middlesex, U.K.).
Table 2.2 Reagents used in the polymerase chain reaction, and the format used
for PCR.
Sample h2o MIX cDNA/RNA
h2o 25(il 25pl /
Tissue cDNA 15jil 25pl 10pl
Tissue rna 15pi 25pl lOjLLl
Cycle 1: 94°C for 4 min; 65°C for 45 sec and 74°C for 45 sec.
Cycle 2: 94°C for 45 sec; 65°C for 45 sec and 74°C for 45 sec.
The cDNA templates were amplified by oligonucleotide primers, which were
selected from the chicken VIP cDNA sequence (Fig. 2.2). The primers were
designated 215L and 275Z (Oswell DNA Service, Edinburgh, UK) (Table 2.3).
Table 2.3 The oligonucleotide primers derived from the chicken VIP cDNA
sequence used for PCR. The base numbers relate to the position of primers in the
VIP 19 cDNA.
215L Bases 259-279 (5' exon 3) 5'-GATGCAGCCAGTGAATCTGAC-3'
275Z Bases 514-534 (3' exon 6) 5'-GGTCGGTTTGAAGCTCCACTT-3'
The PCR machine was pre-programmed with the number and duration of cycles, in
addition to the desired melting, annealing and extending temperatures. When the
reaction had completed,the PCR products were visualised on a 3% GTG-NuSieve
agarose gel (Section 2.5.1).
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760 780 800 820
taaaagttgatatttacattgtaaatactattctagagttctctactgaaagc.tgtacatatggatgccag
840 860 880 900
ttaaacaaatgagaagtctgtaagtccatatgctgtaaatcctttacttcaataaattcatttgaaaatgaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
Figure 2.2 The sequence of chicken VIP cDNA (VIP19) and the corresponding
predicted amino acid sequence as described by Talbot et al., 1995. The amino acid
sequence of mature VIP is in bold. The underlined sequences are those of
oligonucleotide primers used for PCR, 5' (215L, *) and 3' (275Z, **).
2.4.2 Restriction enzymes
The restriction enzymes were purchased from Boehringer Manneheim (BCL,
Lewes, Sussex, U.K.) or Pharmacia (Milton Keynes, Buckinghamshire, U.K.).
The use of restriction enzymes was according to manufacturers recommended
instmctions.
2.5 Agarose gel electrophoresis
2.5.1. Double stranded DNA
The PCR products were analysed by agarose gel electrophoresis using a submarine
electrophoresis tank (BRL, Paisley, U.K.) and 1 x Tris acetate electrophoresis
buffer (TAE; 40mM Tris acetate, ImM EDTA). The most frequently used agarose
was 3 or 4% NuSieve gels (Flowgen Inst., Ltd.), because it was designed to
improve the separation of small DNA fragments and has a low melting point. The
agarose was added to TAE buffer and dissolved by gently heating the mixture in a
microwave. The mixture was allowed to cool until 'hand hot' and l-2|xl ethidium
bromide (5mg/ml) was added. The gel was cast into a plastic mould with a casting
comb. When the gel had set the casting comb was removed and the gel placed in
the electrophoresis tank and covered with TAE buffer. The PCR product samples
were mixed with (1:1) 2-3|LLl of blue gel marker (bromophenol blue 0.25%w/v,
xylene cyanol 0.25% w/v & glycerol 30%w/v in DEPC-H20). The samples and
DNA size markers (Boehringer Mannheim, Lewes, U.K.) were dispensed into
appropriate wells, and the gel run for 2-3 hours at 70mV. After electrophoresis the
gel was removed and observed with an UV transilluminator and photographed.
The ethidium bromide has an affinity for nucleic acids and was used for the
visualisation ofDNA by UV transillumination (UV products).
2.5.2 RNA
The analysis of RNA was performed on 3% NuSieve agarose (3:1) containing
2.2M formaldehyde and 1 x gel running buffer (MOPS) (1M
morpholinopropanesulphonic acid, pH 7.0, 50mM sodium acetate, 5mM EDTA
pH 8.0). The agarose was dissolved in the H2O, 25 x gel running buffer and
12.3M formaldehyde. The samples 1-2(0.1 (10-20p,g) were treated with 2|il 12.3M
formaldehyde and 0.7|Ltl formamide and heated at 56°C for 15 minutes. The
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samples were then mixed with gel loading dye and run with a RNA size ladder
(Gibco) submerged in 1 x gel running buffer for 2-3 hours at 55mV.
2.5.3 Northern analysis
The formaldehyde agarose gel was washed 4 times in H20 for 5 min and then
soaked for 45 min in 50 mM NaOH and 10 mM NaCl. The gel was neutralised in
0.1M Tris HCL pH 7.5 for 45 min, and 20 x SSC for 1 hour. The gel was placed
on a glass plate and a piece of Hybond-N (Amersham International) was placed on
top of the gel, followed by 2-3 cm of blotting paper and paper towels. A weight
(0.5kg) was then applied and the blot left overnight. After transfer the blot was
washed briefly in 2 X SSC, and then exposed to UV radiation in a UV Cross
linker (Stratagene).
2.6 In situ Hybridization
In situ hybridization allows the localisation of mRNA to be visualised at the
cellular level. This method involves the hybridization of a specific nucleotide probe
with a specific target nucleic acid within a tissue section. The use of cloning
techniques has increased the development of in situ hybridization techniques,
which has allowed the production of probes for the detection of specific mRNA
sequences.
2.6.1 Probe Production
RNA probes for in situ hybridization were produced as described by Cox et al.
(1984). The single-stranded RNA probe (riboprobe) was generated by a RNA
polymerase (T7 or T3) transcribing a cDNA sequence cloned downstream of the
appropriate polymerase initiation site. The probe sequences used were cloned into
the pBluescript sk (+) plasmid and flanked by two RNA polymerase promoter
sites. The linearization of the plasmid by different restriction enzymes enabled the
generation of specific sense or antisense probe sequences (Fig. 2.3).
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Figure 2.3 A schematic representation of method used to generate RNA probes
from a nucleotide sequence, which has been cloned into the multiple cloning site of
a plasmid (VF 48). The plasmid was linearised by a restriction enzyme, and
labelled probes are generated by incorporating labelled nucleotides (DIG-UTP) in
the RNA transcription reaction.
The RNA probe was transcribed from the linearised template, by an DNA-
polymerase RNA polymerase enzyme (T3 or T7), which recognises the promoter
sequence and generates 'run off transcripts. The labelled probe was generated by
incorporating labelled nucleotides, such as digoxigenin labelled uridine
triphosphate (DIG-UTP) with unmodified nucleotides in the reaction mix.
Approximately l|lg of DNA template generates 1 Opg of full length DIG-labelled
RNA transcript, of which every 20-25th nucleotide incorporated was DIG-UTP
(Fig. 2.4).
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Table 2.4 The components of the RNA probe transcription reaction mix
l|ig-2pg Linearised DNA template
2pl DIG-labelling kit (xlO, Boehringer Mannheim)
lp,l RNase block
4pl Transcription buffer (x5, Boehringer Mannheim)
40U T7 or T3 RNA polymerase (Stratagene)
Incubation volume 20pl
The transcription mix was incubated for 1-2 hours at 37°C, and the template was
removed by incubating 2pl RNAse-free DNase for a further 15mins at 37°C.
Precipitation of the probe was achieved by adding 2pl 2.0M EDTA, 1,25|i l 8M
LiCl, 75|ll pre-chilled ethanol and incubating for 2 hours or overnight at -20°C.
The pellet was obtained by centrifugation and washed with 70% ethanol, prior to
vacuum drying. The probe was then resuspended in 98pi DEPC-H20, ljj.1 RNase
block, IjllI tRNA (lOmg/ml), incubated for 30 min at 37°C, and stored at -20°C.
The probe was analysed to ensure that the transcription reaction had produced long
transcripts of the correct size. A lpl sample of probe was subjected to Northern
transfer (see Section 2.5.3) and the Hybond-N washed in Buffer 1 (100 mM Tris
HCL pH 7.5, 150 mM NaCl) for 5 min. Then washed in buffer 2 (buffer 1,1%
marvel) for 30 min. The probe was stained with a suitable primary antibody
(Boehringer) conjugated to either alkaline phosphatase or peroxidase and
developed according to the manufacturers instructions.
2.(5.2 Tissue collection
The brain was rapidly removed and lowered into a beaker (100ml) containing
isopentane, which was pre-chilled (-25-30°C) by immersing the base of the beaker
in liquid nitrogen for about 1 minute. An alternative procedure was to freeze the
brain by placing it on a layer of aluminium foil placed on dry ice. This method was
considered to be a less abrasive method for freezing the brain, and was less likely
to produce large cracks or fractures in the tissue. The brain was then stored at -
80°C prior to hybridisation. Frozen sections 10-15(im were cut on a cryostat
(Shandon) and thaw mounted on gelatin coated slides (Supafrost/Plus, CellPath).
The sections were dried out on the slides at room temperature for 1 minute to allow
attachment, and then the slides were stored at -80°C until required (2-3 weeks).
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2.6.3. Tissue processing
Several steps were performed prior to hybridization to enhance tissue preservation
and the probability of hybrid formation. A number of precautions were also taken
to prevent RNAse contamination: gloves worn at all times, all glassware was heat
baked (180°C); all materials were RNAse-free and solutions made with DEPC-
treated H2O. The slides were removed from cold storage (-80°C) and dried quickly
with a hair dryer to remove condensation and moisture from the sections, and
placed into the chosen fixative. The Table (2.5) below lists the processing steps
used to prepare the tissue sections for hybridization with the RNA probe.
Table 2.5 An in situ hybridization protocol used to process the tissue sections up
to the hybridization stage. The slides were placed in a slide rack and passed
through the following RNase-free solutions.
2.6.4 Hybridization
The protocol for the localization of VIP mRNA by in situ hybridization developed
in this study, is discussed in the results chapters. Briefly, the previous steps were
designed to provide the optimum conditions for the hybridization reaction. There
were several variables which can enhance the hybridization signal including, probe
length, probe concentration, stringency of hybridization conditions and
preservation of tissue morphology. The hybridization buffer used routinely in this
study is shown in the Table (2.6) below.
Treatment
0.1M PBS pH 7.4, 4% Paraformaldehyde
0.1M PBS pH 7.4
DEPC-H20
TEA
TEA, Acetic anhydride (1% v/v)
2 x SSC
Ethanol: 70%; 95% & 100%
Chloroform
Time
5 min x 1.
5 min x 2.
5 seconds.
5 seconds.
10 min x 1.
3 min x 1.
3 min each
5 min x 1.
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Tris 1M, pH 8.0
EDTA 0.5M










The final hybridization buffer also included probe and tRNA in the following
composition: 75% hybridization buffer; 20% TE containing probe and 5% tRNA.
For hybridization, the tissue sections were covered with 70- lOOpl of hybridization
buffer, then covered with a parafilm coverslip (Sigma) ensuring no air bubbles
were trapped, and sealed with rubber cement (Sanford Corporation, Newell UK.).
The slides were then placed in a humid incubation chamber and incubated
overnight in an oven set to the desired temperature.
2.6.5 Post-hybridization washes
The reason for post-hybridization washes was to reduce the non specific binding
(background) of the RNA probe to tissue, and non-homologous RNA sequences.
The most effective method of reducing the background was RNase treatment (John
et al., 1969; Lynn et al., 1983). In addition, a series of washes of increasing
stringency was used to reduce background without compromising the level of
specific hybridization signal. This was achieved by varying the salt concentration
(2 x SSC- 0.1 SSC) and temperature (37°C-55°C) of the post-hybridization
washes.
2.6.6 Immunolabelling
After the hybridization and post-hybridization steps the tissue sections were
immunostained in a similar manner to mounted sections described previously
(Section 2.2.7). Briefly, the slides were placed in a blocking buffer (Section
2.1.2) containing 2% normal sheep serum, for 1 hour at room temperature, then
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washed twice in Buffer 1 (0.01M Tris pH 8.0, 0.05% Triton X-100) for 10 min.
Then 100|J.l of anti-digoxigenin antibody (anti-DIG<POD>; 1: 100) solution
(Buffer (1), containing 0.3% Triton X-100 (Boehringer Mannheim) was applied to
each slide, covered with a parafilm coverslip and sealed with rubber cement. The
slides were placed in a humid incubation chamber and incubated overnight at 4°C.
2.6.7 Visualisation
The slides were re-racked in buffer (1), and washed twice in buffer (1) for 15min.
Then 400-500|il of DAB solution (see Section 2.2.7) was applied to each slide.
The slides were placed in a humid incubation chamber, which was wrapped in foil
to protect the slides from the light. In addition 2-3 slides were placed in a petri dish
wrapped in foil, these were checked periodically for staining development. The
DAB solution was reapplied if the staining period was prolonged. The length of
staining was approximately 1-3 hours and varied according to the type of tissue.
The reaction was stopped by placing the slides in a PBS wash for 10 min (x2).
A cresyl violet stain was used to identify the nuclei of neuronal cell bodies and
pituitary cells, and confirm that specific staining by the DIG-labelled antisense
probes. Sections were dehydrated through a series of graded ethanol washes: 50%
3 min ; 70% 3 min; 95% 3 min and 100% 3 min (x2). The slides were then placed
in xylene for 5 min (x2) and mounted in DPX (Agar Scientific, Stansted, U.K.).
The staining was visualised by light microscopy.
2.7 Solution hybridisation and RNase protection assay
The most sensitive and accurate technique used to show specific mRNA
expression in a tissue is the solution hybridisation/RNase protection assay
(Jakubowski and Roberts, 1991). A high-specific-activity radiolabeled RNA
probe is used to hybridise to a complementary target mRNA sequence in a liquid
phase. The resulting RNA-RNA hybrid is protected from RNase digestion, which
digests all the remaining single stranded mRNA and unhybridized RNA probe in
the liquid phase.
2.7.1 Probe Production
The antisense RNA probe was transcribed with an RNA transcription kit
(Stratagene) from pVP39G2 (Talbot et al., 1995) digested with Xbal. The sense
strand targets complementary to the radiolabelled probe, were transcribed from
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either VIP 19 or pVP39G2 digested with Xba I or Eco RI respectively. The
nucleotide rCTP was replaced by [32P]CTP (Amersham International pic) in the
reaction mix. Table (2.7) below shows the components of the RNA transcription
reaction used to generate the probe.
Table 2.7 A list of components required for RNA transcription reaction, used to
generate a radiolabelled [32P] RNA probe.
Component Volume






RNA guard (10U) 0.5|il
DNA template (VIP 19 or pVP39G2) 0.2jll1
[32P]CTP 2|lx1
Enzyme (T7 or T3) (Promega) lpl
DEPC H20 1.8)0.1
The reaction mixture was incubated for 30 min at 37°C, and then 1 pi DNase was
added to each tube and incubated for a further 15 min at 37°C. The probe was
diluted with 90p) of DEPC-H20, and lfll was placed onto two pieces of DE-81
paper discs (Whatman, Maidstone, Kent, U.K.) to measure the incorporation of
radioactivity in the probe. When the drops of probe mix had dried onto the paper
discs, one disc was placed into a scintillation tube and filled with scintillant (2ml)
(Pharmacia), and the remaining disc was washed three times (5 min) in 0.5M
sodium di-hydrogen orthophosphate (NaH2 PO4). This disc was also placed into
another scintillation tube and filled with scintillant (2 ml), and both tubes were
placed on a 6-counter (Pharmacia, Wallac 1410, Liquid scintillator Counter).
Purification of the RNA probe was achieved using G-50 microcentrifuge spin




The total RNA used for the solution hybridisation reaction was isolated using the
RNAzol B method described in Section 2.3.3. The concentration of RNA was
determined by optical density measurement and the required amount of RNA was
incubated with radiolabeled probe in 20pl 4M guanidine isothiocyanate (GuSCN)
at 32°C (see Table 2.8).
Table 2.8 The components used to incubate with sample RNA for solution
hybridization.
RNA Label 4M
Radiolabeled probe 0.5pl 0
tRNA 2pl 23pl
Sense target 2pl 23pl
Sample RNA 5pl 25pl
2.7.3 RNase protection
A stock RNase solution was made containing 400|ll 1M Tris pH 7.5, 300|il 4M
NaCl; 16pl RNase A and 8pl RNase T (Boehringer Mannheim) 300pl was added
to each tube except the 'probe only tube', and incubated for 1 hour at 32°C. Then
20pl SDS (0.1% w/v) and 5pi Proteinase K (lOpg/ml) was added to each tube,
heated for 2 min at 68°C, and finally at 48°C for 30min. The RNA-RNA hybrids
protected from RNase digestion were then separated and purified by phenol-
chloroform extraction described in Section 2.3.3, and precipitated with 100%
ethanol for 1 hour at -20°C. The sample was dried down in a vacuum desiccator
and re-dissolved in stop solution before separation on a polyacrylamide gel
(PAGE). The Figure (2.4) below summarises the steps used in the solution
hybridization RNase protection assay.
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Figure 2.4. A simplified version of the solution hybridization RNase protection
assay.
2.7.4 Polyacrylamide gel electrophoresis
All the gels were 14 x 14 x 1.5 mm and run in a vertical slab gel unit model SE400
(The Sturdier, Hoefer Scientific Instr., California, U.S.A.). The gel mix
comprised, 6% 19:1 acrylamide:bisacrylamide, 6M urea, 1 x TBE, and
polymerisation was initiated with 0.03% ammonium persulphate and 1.28 |il/ml of
TEMED. The gels were typically run at 400V in 0.5 x TBE for approximately 1.5
hours or until the xylene blue dye had run off the bottom of the gel. After
electrophoresis was complete the gel was transferred to 3M filter paper (Whatman,
Maidstone, Kent, U.K.), and the gel surface covered in Saran wrap (Dow,
Genetic Research instr., Essex, U.K.) and dried on a gel drier (Zabona AG Basel,
Switzerland). A phosphor imager (Molecular Dynamics, U.K.) was then used to
quantify the amount of radioactivity in each protected band.
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2.8 Tissue concentration of VIP
2.8.1 Acetic acid extraction
The tissue was obtained as described in Section 2.2.2, weighed, placed in
microcentrifuge tubes, snap frozen in liquid nitrogen and stored at -80°C until
required. The cVIP was extracted by boiling the tissue in 1ml of 2M acetic acid for
10 min. The tissue was sonicated (Heat Systems-Ultrasonics Inc.) and centrifuged
at 13 000 rpm for 15 min at 4°C. The supernatant was removed, stored on ice, and
the pellet resuspended in 1M acetic acid sonicated and boiled for a further 5 min.
The centrifugation step was repeated and the second supernatant fraction removed
and stored in a second tube. All the supernatant fractions were then dried down
with a vacuum concentrator (Hetovac) and stored at -70°C.
2.8.2 RP-HPLC purification
Reverse-phase HPLC (RP-HPLC) incorporates a hydrocarbon-bonded (octadecyl,
CI8) stationary support, with an aqueous eluent containing a proportion of organic
solvent (methanol or acetonitrile) (Knox, 1978). The more polar solutes have
greater affinity for the eluent and so elute in reversed order of polarity i.e. most
polar first. The advantages of chemically bonded phases is that polar and ionic
molecules such as cVIP can be chromatographed more efficiently, and an elution
gradient can be used without stripping the stationary phase. The addition of
trifluoroacetic acid (TFA) can improve the retention of packing material, by (ion
suppression) reducing the pH of the mobile phase and suppressing the secondary
ionisation of the phosphate groups.
2.8.3 Column characterisation
This investigation was designed to characterise the elution profile of synthetic
vasoactive intestinal polypeptide (Penninsula), and compare with the elution profile
of peptides, including VIP, extracted from brain tissues. The preliminary studies
used a C-18 Apex ODS column (Jones Chromatography, Mid Glamorgan, UK).
The samples were pumped onto the column by a HPLC pump with a flow rate
1.5ml/min, (Millipore Waters, Watford, UK) and the column eluents were
monitored for absorbance at 280nm (Millipore Waters, Watford, UK). Four
successive step-wise elutions were performed with acetonitrile (ACN) 0.1 % TFA,
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lOOmM TEA phosphate pH 2.5, TEA acetate pH 2.5, TEA formate pH 3.5 with a
linear gradient for 40 min.
However, the characteristics of the Apex ODS column were not suitable for the
elution of cVIP, regardless of the solvent system used. Therefore, a Vydac column
(218TP5415) was used, which produced the desired elution profile for synthetic
cVIP. This type of column was also used for the purification of cVIP from brain
tissue extracts and iodinated VIP ([125I]-VIP). The samples were subjected to RP-
HPLC using a linear gradient (Table 2.9) from (A) to (B) for 40 min, with an
ACN buffer system (H20: ACN: 10%TFA), where (A)=90%:10:1 and
(B)=10:90:l. The results are described in Chapter 3 (Section 3.4.1).
Table 2.9 The linear gradient used to elute synthetic VIP from a RP-HPLC
column.
Time Flow rate % Concentration
(min) (ml/min) A B
0 1.5 100 0
20 1.5 65 35
25 1.5 50 50
30 1.5 100 0
2.9 Hormone measurements
The pituitary hormones LH, PRL, GH, ACTH and VIP were measured by the
appropriate assay, and are described in the following sections.
2.9.1 Luteinising hormone radioimmunoassay
The chicken LH radioimmunoassay used in these studies was a modification of the
double antibody method developed by Sharp et al. (1987), and an LH assay
diluent : 160 ml 0.5M sodium phosphate buffer; 17.5g NaCl; 5.84g EDTA, 2g
sodium azide and 40 ml horse serum (Gibco).
2.9.1.1 Iodination of LH traces
All reagents used were made in 50 mM Na phosphate (NaP) buffer, pH 7.4,
unless indicated elsewhere. A 1.25|J.g aliquot of chicken LH (PRC-AEl-s-1) was
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mixed with 25p.l of NaP in a 1.5 ml microcentrifuge tube, by a magnetic stirrer. A
37 MBq unit (10pl) of [l25I]-Na (IMS-30, Amersham International pic) was added
to the tube, and the iodination reaction started with lOpl of 3.55 mM chloromine
T, which proceeded for 1 min at room temperature. The reaction mix was stopped
by adding lOpl of 5.26 mM sodium metabisulphite, and diluted with lOOpJ of
0.6M KI.
2.9.1.2 Purification of iodinated LH
APD-10 Sephadex column (LKB-Pharmacia was pre-equilibrated, with column
buffer (NaP containing 0.2% gelatine). The reaction mix was added to the PD-10
column and column buffer (200pl) was used to rinse the microcentrifuge tube, and
added to the column. Column buffer was added to the column when required, and
25 fractions of 10 drops were collected into LP4 plastic tubes (Denley-Luckham
Ltd.). The iodinated LH was typically eluted in fractions 4-7, and was diluted with
RIA diluent (Section 2.9.1) to a concentration of approximately 500 000 counts
per minute (cpm) per 10pl and stored at 4°C for up to 4 weeks.
2.9.1.3 Preparation of standards
A chicken LH standard (RI-LH-1) was stored lyophilised at -20°C containing
192p,g. This standard was reconstituted with 1 ml of NaP, and split into aliquots
of 26jllL The dilution of this aliquot with 974p,l of LH diluent produced a working
standard of 5|lg/ml. A series of 16 dilutions produced a series of 14 standards
designated (Stdl4-Stdl) 5.0, 4.0, 2.5, 2.0, 1.0; 0.5, .0.25, 0.125, 0.0625,
0.0313, 0.0156, 0.007, 0.003 and 0.002 ng/ml, which were used in the LH
assay.
2.9.1.4 LH assay procedure
The LH assay procedure was also used as a standard assay protocol for the PRL
and VIP radioimmunoassay, and any divergence from this method is discussed in
the appropriate section. Briefly, the samples and standards (200|ll of each) were
dispensed into plastic LP2 (Denley-Luckham) tubes with an automated dispenser
(Hamilton MicroLab-M, Howe & Co. Ltd); and mixed with the anti-chicken LH
primary antiserum (LH 3/3), used at a final dilution of 1: 19 000, and stored at 4°C
for 24 hours (See Table 2.10). Radiolabeled [125I]-LH was added to all tubes (12
000 cpm per 50jll1) and incubated for another 24 hours. On day 3 of the LH assay,
50|il of normal rabbit serum (NRS) diluted to 1: 200, and 50)0.1 of donkey anti-
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rabbit serum (DARS) diluted to 1: 20, were added to each tube and incubated for
24 hours. All the tubes, except the TC were then centrifuged (Sorvall RC-3B) at
1500 x g for 30 min at 4°C. Then 50pl of a 6% starch solution was added to each
tube to maintain the integrity of the pellet and centrifuged for another 15 min. The
supernatant fraction was then aspirated to waste and the pellets and TC were
counted for 60 seconds on a gamma counter (1277 GammaMaster, LKB-
Pharmacia), and the data analysed with AssayZap™ (AssayZap Universal Assay
calculator, Biosoft).
Table 2.10 The protocol for the radioimmunoassay of chicken LH.
Abbreviations'. TC Total counts; NSB Non specific binding; TB Total binding;
STD LH standards; SAM Samples; NRS Normal sheep serum; DARS Donkey
anti-rabbit serum; Nil. No addition made; Dil LH diluent.
Solution TC NSB TB STD SAM
DAY 1
Dil. Nil. 250|ol 200pl Nil Nil.
SAMPLE Nil. Nil. Nil. 200pl 200p,l
ANTIBODY Nil. Nil. 50pl 50|Ol 50pl
DAY 2
LH LABEL 50|ol 50|Ol 50|il 50jll1 50pl
DAY 3
NRS (1: 200) Nil. 50fxl 50pl 50|ol 50pl
DARS (1: 20) Nil. 50|il 50pl 50|ol 50pl
DAY 4
CENTRIFUGATION AT 1500 x g at 4oC for 30 min.
STARCH Nil. 50|ol 50pl 50jll1 50|ol
CENTRIFUGATION AT 1500 x g at 4oC for 15 min.
2.9.2 Prolactin radioimmunoassay
The PRL radioimmunoassay used in this study was a modification of the method
developed by Talbot and Sharp (1994).
2.9.2.1 Preparation of PRL standards
A 5p,g aliquot of prolactin stored in microcentrifuge tubes, was diluted to a
working concentration of 500ng/ml. The top standard was produced by diluting
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the stock 1: 5 with diluent. (StdlO-Stdl, 125, 62.5, 31.25. 15.63, 7.81, 3.91,
1.95, 0.98, 0.49 and 0.24ng/ml).
2.9.2.2 Iodination of PRL traces
The reaction mixture was composed of 8(il prolactin (5jLLg), 22p,l NaP buffer, lOpil
1251 (lMCi) (Amersham International, Amersham UK) and 10pl 3.55mM
chloromine T, and incubated for lmin. The reaction was stopped with 200p,l
20mM Tris/HCL, pH 7.5, containing 0.1% Tween 20. The reaction mixture was
added to a PD10 column and topped up with 0.1M Tris. The eluent was collected
(12 drops) in 18 tubes, and the peak identified by counting the tubes with a
monitor. The peak of bound activity was further chromatographed, on a Sephacryl
HR100 column, equilibrated with 0.1M Tris/HCL, pH 8.5, containing 0.1%
Tween 20, and eluted with a flow rate of lml/min. The four fractions with the
highest activity were pooled and diluted 1:2 with assay diluent and stored at -70°C
until used in the assay.
2.9.2.3 PRL assay procedure
The PRL assay procedure was essentially the same as that of the LH-RIA
described in Section (2.9.1.4), except that all sample and standard volumes were
lOOfll, and the NSB and TB were 150|al and 100|ll respectively.
2.9.3 VIP radioimmunoassay
Chicken VIP was labelled using a modification of the method described by Sharp
et al. (1989). The 125-I labelled VIP was separated from the reaction mixture by
the reverse-phase HPLC method described in Section 2.8. .
2.9.3.1 Preparation of VIP standards
The chicken VIP standard (5|ig) (Peninsula Laboratories pic.) was diluted with
assay diluent (LH diluent) to a volume of 1.2 ml of diluent (4pg/ml). A series of
17 dilutions produced a series of 13 standards designated Std 13-Std 1: 4000, 2000,
1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.81, 3.9, 1.9, 0.98 and 0.49 pg/ml.
64
2.9.3.2 VIP assay procedure
The VIP assay protocol was the same format as that of the LH radioimmunoassay
(Section 2.9.1.4), but 125-I VIP (15 000 cpm/ tube in 50(ll1) was added to each
tube on day 3. The bound cVIP was precipitated on day 4 with anti-sheep
precipitating serum (DASS) and non-immune sheep serum (NSS) at final
concentrations of 1:20 and 1:200 respectively.
2.9.3.3 Validation of VIP antibodies for VIP radioimmunoassay
Three sheep anti-chicken VIP antibodies 33/8, 33/4 and 31/4, were analysed for
their suitability in a radioimmunoassay. Dilution curves were used to establish the
binding characteristics of each antibody over a range of dilutions 1:100-1:128 000.
Standard curves were set up for each antibody, with a predetermined antibody
dilution which was extrapolated from the dilution curves, to give a specific binding
of 25%. The cVIP standard displaced [125I]-VIP from the antibody 33/4 more
effectively than the other two antibodies, and was used as the standard VIP
antibody in the VIP radioimmunoassays .
2.9.4 Growth hormone
GH was measured by an enzyme linked immunoabsorbant assay (ELISA)
modified by Houston et al. (1991).
2.9.4.1 Preparation of the pre-coated plates
The antibody code 6F5 was diluted with 50 mM NaHCC>3 pH 9.6, to give a
working concentration of l(tg/ml 6F5 / 1 OOpl; which was added to each well
(lOOjn.1) of a number of 96 well plates and incubated for 24 hours at 4°C. The
plates were washed 3 times (Wash buffer, PBS containing 0.25%(v/v) Tween 20)
with a plate washer and then incubated (200|ll per well) with a block solution of
2% RIA grade BSA, for 1 hour at 37°C. The plates were washed another 3 times
(wash buffer) and then each well was incubated with 200jlx1 of a 30% sucrose
solution, for 2 hours at room temperature. The sucrose solution was aspirated to
waste and the plates allowed to dry at room temperature, and stored at 4°C until
required.
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2.9.4.2 Preparation of biotinylated antibody
The purified GH (B4E4) antibody (1.5-2.0 mg) was dialysed overnight at 4°C in 4
litres 0.1 M NaHC03 pH 8.0, and the protein concentration measured by
absorbance at 280 nm. Five mg of biotin succinimide ester was dissolved in 2 ml
of DMSO and then added to the antibody at a concentration of 50|itl per ml
antibody, and incubated at room temperature for 2 hours. The anti- chicken GH
biotinylated antibody was dialysed for 24 hours at 4°C in PBS pH 7.4, and the
concentration measured by absorbance at 280 nm.
The samples and GH standards (800, 400, 200, 100, 50, 25, 12.5, 6.25pg/100|ll)
were made in PBS pH 7.4 containing 2% BSA, and 100|ll were dispensed to each
well and incubated for 2 hours at room temperature. The wells were washed 6
times (wash buffer) and then incubated with (lOOfil per well) biotinylated B4E4 at
a concentration of 0.5(lg/100(tl, for 1 hour at room temperature. The plates were
washed 6 times again, and a streptavidin-horseradish peroxidase solution (1:1000
in blocking buffer), was (100(ll) added to each well. The plates were washed (6
times) for a final time, and then 100pi of the developing solution (26 mM
NaHP04, pH 5, 24 mM citric acid, 0.5mg/ml phenylenediamine) was added to
each well and incubated for 3 min, followed by 50(il of stop solution (2M
H2SO4). The optical density of each sample was read at 490nm in a MR700 plate
reader (Dynatec Laboratories, Burgess Hill, UK), against a blank (PBS only).
2.9.5 Adrenocorticotrophic hormone
The measurement of ACTH in tissue culture media was kindly performed by Dr.
F. Antoni using a double antibody precipitation ACTH-RIA described by Werner
et al. (1989). The antibody no. 6 (G.B. Mahara, Budapest, Hungary), and the
assay standard human ACTHl-39 (CIBA Geigt, Basel, Switzerland), were diluted
with an assay buffer (0.5mM NaP buffer, pH 7.4), containing 6% polyethylene
glycol (PEG, MW 6000), 1% BSA, 0.1% Tritron X-100, 2.5mM EDTA, 100
kallikrein U/ml of aprotinin. A 50|il sample was incubated with 50pl antiserum,
and 10(11 tracer (10 000 cpm/10|il) for 24hrs. Then precipitating serum, anti-rabbit
IgG and non-immune rabbit serum were added and incubated for 3hrs at room
temperature. Finally, 1ml of 3% PEG was added to each tube, spun for 30min, the




DNA replication in a cell is principally confined to the S phase of the cell cycle,
and it has been shown that cells in the S phase can incorporate modified DNA
precursors. The use of radiolabeled DNA precursors such as 3H or 14C isotopes
of thymidine, have been used to identify dividing cells in vivo or in vitro. The
introduction of a pyrimidine analogue of thymidine, 5-bromo-2-deoxyuridine
(BrdU), in conjunction with the development of monoclonal antibodies to BrdU




Figure 2.5 Structural comparisons of 5-bromo-2-deoxyuridine and thymidine.
The usual method for BrdU administration has been intramuscular or intravenous
injection, however this technique is not very practical over a long period of time. A
BrdU pellet had been designed (Innovative Research of America, Ohio, U.S.A.) to
deliver a pre-determined dose of BrdU over a specified time period, which has
been used in several species (Weghorst, 1991).
A Matrix-driven delivery (MDD) system controls the release of BrdU over a 21
day period. The calculated hourly release rates for the pellets were determined to be
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approximately 20, 50, 100, 200 and 200|ig per hour for the 5 doses of lOmg,
25mg, 50mg, lOOmg and 200mg BrdU respectively (Fig. 2.7). The BrdU pellets
were implanted into 5 groups of laying bantam hens, which were transferred to
floor pens to induce broodiness.
Figure 2.6 A photograph of the bromodeoxyuridine (BrdU) pellets which were
implanted into the neck. The pellets are aligned in descending size and dosage;
200mg, lOOmg, 50mg, 25mg and lOmg BrdU.
2.10.2 Pellet implantation
After an injection of local anaesthetic (lignocaine), the skin on the back of the birds
neck was pulled and a small incision was made the size of the pellet, with a
scalpel. A pocket was made horizontally with a pair of forceps, about 2 cm beyond
the incision site. The pellet was placed in the pocket with a forceps. A stitch (cat
gut) was used to close the pocket and an antibiotic (Aureomycin, Cynamid,
Gosport, U.K.) was applied to the wound as a precaution. The bird was then
monitored on a daily basis for any adverse affects, resulting from the pellet
implantation procedure.
2.10.3 Experimental procedure
Thirty laying bantam hens were chosen at random, and allocated to a group (n=5),
and administered a predetermined dose of BrdU, in the form of a 21 day release
pellet (see Section 2.10.1). A small incision was made in the neck of control
animals to mimic the implantation procedure. After pellet implantation, each group
was transferred to a floor pen with 5 nest boxes to induce broodiness, and were
monitored on a daily basis for any characteristic signs of broody behaviour. In
addition, the birds were weighed and a blood sample taken on days 1,7, 14 and
21 days of the study, and these samples were analysed by PRL radioimmunoassay
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(see Section 2.9.3). The number of laying birds transferred to floor pens at any
one time was staggered, to reduce the workload at the end of the experiment. Ten
birds were placed into their respective floor pens on day 1, and then two further
groups of 10 birds were transferred on subsequent days. The birds were terminally
anaesthetised and perfused with heparin/saline (see Section 2.2.3), on day 21. The
anterior pituitary glands were removed for microwave fixation and processing (see
Section 2.2.4).
2.10.4 Blood smear
Blood samples were taken from the brachial wing vein with heparinised syringes,
and a drop of blood was applied to a slide with a plastic Pasteur pipette. A blood
smear was formed by pushing the drop of blood down the slide, and allowed to air
dry. The slides were then stored in a dry box, until required for
immunocytochemical staining.
2.10.5 Tissue collection
The experimental birds were perfused (Section 2.2.3) with 250-300ml (0.9%
NaCl w/v) containing 750IU heparin, for 10-15 min to remove the blood from the
brain and then the anterior pituitary gland was dissected using the method
described in Section 2.2.2.
2.10.6 Immunocytochemical detection ofBrdU labelling in tissue sections
The anterior pituitary glands were subjected to microwave fixation and microtome
sectioning as described in Section 2.2.5. The anterior pituitary tissue sections were
processed for peroxidase staining (mouse, Vector ABC kit) (Section 2.2.7), except
for the inclusion of a DNA denaturation step. Briefly, the sections were incubated
successively in methanol (0.3% H202) PBS washes, 2M HC1 for 1 hour at 37°C,
and borate buffer (neutralisation) (0.1M, pH 8.5) for 10 mins. The acid treatment
was required to relax the DNA and aid antibody accessibility (Dinjens et al.,
1992). A mouse monoclonal anti-BrdU (1:1 000) antibody was used to detect the
incorporated BrdU in anterior pituitary sections. The peroxidase was visualised by
immersing the sections in 0.025% DAB containing 0.03% H2O2 in 0.05M Tris,
pH 7.5. The sections were dried, cover slipped in DPX mountant and viewed by
light microscopy (Olympus).
69
2.10.7 Immunocytochemical detection ofBrdU labelling in blood smears
The blood smears were fixed in methanol (6 mins) and air dried. The blood smears
were subjected to the same acid hydrolysis and neutralisation treatments, described
previously in Section 2.10.6. Then the sections were incubated overnight with a
mouse monoclonal anti-BrdU (1:1 000) antibody. The primary antibody was
visualised by incubating the sections with an anti-mouse FITC conjugate (1:50)
second antibody (Sigma), mounted in aqueous mounting media and coverslipped
for examination by blue epi-illumination (Nikon Optiphot) (see Section 2.2.7).
2.11 Tissue Culture
2.11.1 Reagents
All procedures were performed in a laminar air cabinet (Flow Labs) using aseptic
conditions, and sterile solutions and equipment. The medium used for cell culture
was medium 199 (Ml99), supplied as a sterile powder which was redissolved in
sterile H2O, bicarbonate buffered (26.2M, NaHCOs) and pH adjusted with HC1 to
7.4. The medium was supplemented with lOOU/ml penicillin, 100(a,g/ml
streptomycin, 4 mM L-glutamine and 2% (v/v) steroid stripped newborn calf
serum (NBCS), and filtered with a 0.22|J.m bottle top filter (Costar Ltd, High
Wycombe, U.K.). The steroids were stripped from NBCS by mixing with 1%
(w/v) charcoal and 0.1% (w/v) dextran T-70 overnight at 4°C, followed by
centrifugation (Beckman J2-21M/E, JA-20 rotor) at 20,000 x g for 30 mins. at
4°C, and sterilised by filtration.
2.11.2 Tissue collection and processing
The anterior pituitary glands were removed from the hen and placed in a sterile
30ml plastic Universal vial containing 10ml of medium Ml99 at room temperature.
The vial was then transferred to the flow cabinet and the tissue placed onto a new
recepticle containing supplemented medium Ml99 and the pituitary glands were
washed 3-4 times in medium. The pituitary glands were then placed in a sterile
glass petri dish and cut along the midline with a razor blade, to produce Hemi-
pituitary glands. These were washed twice, in the manner described previously.
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2.11.3 Culture method
The Hemi-pituitary glands from laying or broody bantam hens were randomly
selected from each group and placed into a well containing 500|ll medium, in a
multi-well culture plate (24-well plate) (Costar Ltd, High Wycombe, U.K.) and
cultured at 37°C in a humidified atmosphere of 5% CO2: 95% air.
2.11.4 Pituitary tissue stimulation protocol
The Hemi-pituitary glands were incubated for 3 hours, which was considered a
wash period. The 500|ll medium was removed and replaced with 500)0.1 of fresh
medium in the presence or absence of treatment. After the incubation time had
elapsed the medium was removed and frozen at -20°C for LH and/or PRL
radioimmunoassay. The wet pituitary weight was then measured.
2.12 Data presentation and analysis
The data were processed by Apple Macintosh. The determination of statistical
significance, of data obtained from radioimmunoassay was by ANOVA, followed
by post hoc comparisons when appropriate, using the Dunnett's test. A Students t-
test (StatWorks) was also used for the analysis of VIP extracted from the
hypothalamic tissue, of laying and broody hens. The data was expressed as the
mean ± standard error of the mean for each experimental group (SEM) (Cricket
Software), where P<0.05 was considered significant.
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Chapter 3: THE IMMUNOCYTOCHEMICAL
LOCALISATION OF VIP IN THE ANTERIOR
PITUITARY GLAND
3.1 Introduction
Vasoactive intestinal polypeptide (VIP) has been reported to be synthesised within
the anterior pituitary gland of the rat (Arnaout et al., 1986; Hagen et al., 1986). A
cell which expresses VIP immunoreactivity (VIP-ir) has been observed but the
specific cell type remains uncertain. In the rat the lactotroph may synthesize intra-
pituitary VIP (Morel et al., 1982; Steel et al., 1989), and regulate prolactin secretion
in an autocrine manner (Nagy et al., 1988). However this observation is not
supported by similar immunocytochemical studies, where the VIP-cell type has
been found to be distinct from that of lactotrophs and thyrotrophs (Lam et al., 1989;
Segerson et al., 1989; Carrillo and Phelps, 1992). The aim of this investigation was
to develop an immunocytochemical method, to localise VIP in the anterior pituitary
of the bantam hen and to determine the cell types in which VIP occurs.
3.2 The immunocytochemical localisation of VIP in the anterior
pituitary gland
3.2.1 Validation of immunocytochemical procedure
The immunocytochemical procedure was developed to allow the use of thin
sections, which retained their morphology and resolution when viewed at a high
magnification. Initial trials used a method devised by Fragioni and Borgioli (1986),
and the fixative Kryofix (Merck) which was used for microwave fixation (Boon
and Kok, 1987). The method was suitable for the immunolocalisation of VIP-ir and
PRL-immunoreactivity (PRL-ir), but was not compatible with any anti-LH
antibody. Therefore, the fixation was modified and a Bouin Hollande fixative was
substituted for the Kryofix and was established as the standard
immunocytochemical fixative throughout the studies. The VIP-ir was localised in
the anterior pituitary gland of laying (n=6) and broody («=6) bantam hens and was
visualised using a donkey anti-sheep FITC (SAPU) conjugated antibody and
viewed by fluorescent microscopy (Section 2.2.7)
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The immunolabelling of VIP cells in the anterior pituitary was abolished (Fig. 3.1)
by pre-absorbing the VIP antiserum with 20(ig VIP/ml antiserum diluted 1:2000,
No staining was observed when the sections were incubated with VIP primary
antiserum only, or when the primary anti serum was replaced with normal donkey
serum. Finally, sections of the mediobasal hypothalamus and median eminence
region were used as a positive control tissue (Fig. 3.1), to confirm that pre-
absorption of the VIP antiserum with VIP, abolished all specific immunostaining
(Fig. 3.1). The characteristic labelling of gonadotrophs and lactotrophs using
antibodies against luteinising hormone (LH) and prolactin (PRL) respectively, was
achieved with a donkey anti-rabbit Lissamine conjugate (Jackson).
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Figure 3.1 Photomicrographs illustrating the (a) distribution of VIP-
immunoreactivity type in the anterior pituitary (pt) gland and the (Mag. x200) (b)
VIP-immunoreactive terminal fibres in the median eminence (ME) (Mag. xlOO).
The immunostaining was abolished in the (c) median eminence (Mag. xlOO) and the
(d) anterior pituitary using the VIP antiserum diluted 1:2000 pre-absorbed with
20pg VIP/ml (Mag. x400).
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3.2.2 Distribution of VIP, LH and PRL in the anterior pituitary
The VIP-ir was found in both the cephalic and caudal lobes of the anterior pituitary.
An attempt was made to count VIP-ir cells in the pituitary gland using an image
analysis programme, but was unsuccessful. The VIP-ir in the anterior pituitary of
the laying bantam hen (Fig. 3.2) appeared to be more intense compared to that of
the broody bantam (Fig. 3.2). The intensity of VIP-ir staining in the cephalic lobe
in the pituitary of the broody bantam was less, than in the caudal lobe (Fig. 3.3).
LH-immunoreactive (LH-ir) cells were distributed throughout the cephalic and
caudal lobes in the anterior pituitary of both the laying (n=5) and broody («=5)
bantam hen, and was similar to the distribution of the VIP-ir cells (Fig. 3.2). The
LH-ir appeared to be more intense in the pituitary of the laying hen compared to the
broody hen; and the immunoreactive labelling in the cephalic lobe appeared to be
less intense compared to that of the caudal lobe in the broody bantam (Fig. 3.2).
The PRL immunoreactive (PRL-ir) cells were confined to the cephalic lobe in the
anterior pituitary of the laying (n=5) and broody (n=5) bantam hen (Fig. 3.2).
However, the PRL immunoreactive labelling in the cephalic lobe of the broody
bantam hen was more extensive than in the cephalic lobe of the laying hen. (Fig.
3.2 ).
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Figure 3.2 Composite photomicrographs showing the distribution of (a, b) VIP-ir
cells, (c, d) LH-ir cells and (e, f) PRL-ir cells in the anterior pituitary gland of the
(a, c, e, left page) laying bantam and (b, d, f, right page) broody bantam hen. (ce)
Cephalic lobe, (ca) Caudal lobe.
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3.2.3 The VIP-cell type
The VIP-immunoreactivity was confined to the cytoplasm. There were two VIP-cell
types which were arranged singly or in clusters of 2-6 cells. One cell type stellate in
shape, with an irregular shaped nucleus, and long cytoplasmic projections which
extended between neighbouring pituitary hormone secreting cells (Fig. 3.4).It was
weakly immunolabelled and distinctive from that of the normal pituitary hormone
secreting cell types (Fig. 3.4). The second VIP-cell was often larger than LH and
PRL cells, with a large nucleus, polygonal shape and greater immunoreactive
labelling (Fig. 3.4). In contrast, the LH- and PRL-cells were more rounded or oval
in shape compared to that of the VIP-cell.
a b
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Figure 3.4 Photomicrographs illustrating the two types of VIP-immunoreactive
cell types, visualised by an immunocytochemical procedure using antibodies raised
against chicken vasoactive intestinal polypeptide, (a) One VIP-cell type (S) was
more stellate in shape with long cytoplasmic projections, and the second VEP-cell
(V) was larger but more polygonal in shape. The (b) nuclei were labelled with
DAPI (Magnification x 1000).
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Figure 3.3 The distribution of VIP-immunoreactivity (VIP-ir) and PRL-
immunoreactivity (PRL-ir) in the anterior pituitary gland of a broody bantam hen.
The (a) VIP-ir appears greater in the caudal lobe compared to that of the cephalic
lobe. The (b) PRL-ir is confined to the cephalic lobe (Mag. xlOO).
3.2.4 Relationship between gonadotrophs, lactotrophs and the VIP-cell
The VIP-ir cells were closely associated with both LH and PRL cells. The VIP-cells
were often positioned centrally in groups of LH cells in the pituitary of a laying
bantam (Fig. 3.5a), or closely surrounded adjacent LH cells in the pituitary of a
broody bantam (Fig. 3.5b). There was no evidence for the colocalisation of VIP-ir
in LH-ir cells. There was also a close relationship between VIP-cells and PRL cells
in the cephalic lobe of a laying (Fig. 3.5c) and broody bantam (Fig 3.5d), but there
was no evidence of VIP-ir and PRL colocalisation.
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3.2.5 The localisation ofS-100 and GFAP immunoreactivity in the hypothalamus
The aim of this study was to establish the distribution of S-100 and GFAP in the
hypothalamus, to confirm the specificity of the immunolabelling observed in the
anterior pituitary gland (n=3). Both proteins are reported to occur in the
hypothalamus of several species, avian brain (Goto et al., 1988; Cameron-Curry et
al., 1991), and are specific markers for glial and folliculo-stellate cells..
S-100 and GFAP-immunoreactivity occurred in the basal hypothalamic region. S-
100(+)-ir occurred in glial-like cells, which were irregular in shape with numerous
fibre structures in the paraventricular area of the hypothalamus (Fig 3.6), but little
or no immunoreactivity was observed along the third ventricle (Fig 3.6). The
GFAP immunoreactive (GFAP(+)) cells were the same as those of the S-100(+)
cells. They had an irregular shaped cell body with several projections, and occurred
in the paraventricular hypothalamus (not shown).
Little or no S-100(+) or GFAP(+) immunoreactivity occurred elsewhere in the
hypothalamus and appeared to be absent along the third ventricle (Fig 3.6). A DAPI
stain was also used to identify the nuclei on the specimen, and confirm the S-100
and GFAP immunoreactivity was associated with specific cell structures. The S-
100 and GFAP antibodies immunolabelled cells within the hypothalamus, which
appeared to be glial like as described previously (Goto et al., 1988; Cameron-Curry
et al., 1991).
3.2.6 The localisation ofGFAP and S-100 protein in the anterior pituitary
The localisation of folliculo-stellate cells (FS-cells) in the chicken anterior pituitary
gland was visualised using antibodies raised against S-100 protein, and glial
fibrillary acidic protein (GFAP), which are specific markers for astroglia and FS-
cells. The antibodies have been characterised, and used to demonstrate the
distribution of S-100 immunoreactivity in the chick brain (Atoji et al., 1990) and
GFAP-immunoreactivity in the quail central nervous system (Cameron-Curry et al.,
1991).
In the present study, S-100-like immunoreactive (S-100(-t-)) cells were distributed
throughout the anterior pituitary gland in both lobes of the laying and broody
bantam hen. GFAP-immunoreactivity was not seen in the chicken anterior pituitary
gland. The majority of S-100(+) cells were intensely immunoreactive and ,formed a
dispersed network of stellate cells, linked by fine cytoplasmic processes, which
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encircled numerous pituitary hormone secreting cells|(Fig 3.7c). Less intensely
stained S-100(+) immunoreactive cells were also observed. These were less stellate
and had a large nuclear: cytoplasm ratio, and occurred in clusters (Fig. 3.7a). The
morphological features of the heavily labelled S-100(+) cells were characteristic of
folliculo-stellate cells (FS-cells) (see Section 1.9.1).
a
Figure 3.6 Photomicrographs showing the lack of (a, c) S-100 immunoreactivity
(Mag. xlOO). The (e) S-100(+) immunoreactivity occurred in glial-like cells
contained in the paraventricular region of the hypothalamus (Mag. x 1000). The
nuclei (b, d, f) were immunolabelled with DAPI.
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Figure 3.7 A photomicrograph of (a) the weaker S-100(+) stained cells (Mag.
xlOOO) in the cephalic lobe of the anterior pituitary and (b) the nucleus visualised
with aDAPI stain (Mag. xlOOO). The dispersed network of FS-cells is distributed
(c) throughout the anterior pituitary gland, visualised by an immunocytochemical
procedure using an antibody raised against S-100 protein (Mag. xlOO).
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3.2.7 Co-localisation of VIP and S-100 in the pituitary
The morphology and distribution of VIP-cells and FS-cells was similar, and both
occurred in the cephalic and caudal lobe of the anterior pituitary gland. VIP was co-
localised with S-100 in many FS-cells (Fig. 3.8). However, not all VIP-
immunoreactive cell types contained S-100 immunoreactivity, and these VIP-ir cells
were larger and more intensely stained (Fig. 3.8).
Figure 3.8 Co-localization of (a) VIP- and (b) S-100-positive cells in the anterior
pituitary gland. After double labelling using FITC (green) to visualise VIP and
Lissamine rhodamine (red) to visualise S-100 in FS-cells, (a) VIP-ir was seen in
(b) FS-cells. The presence of (c) nuclei in VIP- and FS-cells was achieved by
staining the section with DAPI (blue) (Magnification x 1000).
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3.3 Distribution of PACAP-like immunoreactivity in the basal
hypothalamus and anterior pituitary.
In the previous section (3.2.1) VIP-ir was demonstrated in the anterior pituitary
gland and basal hypothalamus, however it was not confirmed whether or not the
chicken VIP antibody cross reacted with the recently discovered neuropeptide,
pituitary adenylate cyclase activating polypeptide (PACAP). The aim of this study
was to confirm that the immunoreactivity observed in the anterior pituitary was due
to the presence of VIP, and not due to a cross reaction with PACAP. PACAP-
immunoreactivity is reported to occur throughout the hypothalamus and median
eminence of several mammalian species (Koves et al., 1990b; 1991; Vigh et al.,
1991). Sections of hypothalamus tissue from a laying bantam (n=3) were used as a
positive control, in conjunction with the anterior pituitary gland (n=3). The
localisation of PACAP-ir was determined using a specific mammalian anti-
PACAP27 (mPACAP) antibody (a gift from A. Arimura). The specificity of the
cVIP (code/6DL/31/4) and mPACAP antibodies, was determined by pre-incubating
the primary antibodies with cVIP, cPACAP38 or ovine PACAP38.
3.3.1 The localisation of VIP and PACAP immunoreactivity in the hypothalamus and
anteriorpituitary gland
The optimal dilution of the mPACAP antibody used on free-floating hypothalamic
sections was 1: 4000, when visualised by DAB staining (Section 2.2.8), and 1:
2000 when visualised by Lissamine rhodamine fluorescent labelling method
(Section 2.2.7). The mPACAP antibody was used on thin (2p,m) sections of the
anterior pituitary gland (Section 2.2.5), with a range of dilutions (1: 100-2000),
and also visualised with a Lissamine rhodamine fluorescent labelling method
(Section 2.2.7). The antibody has been fully characterised, and shows no cross
reaction with a number of related peptides, including mammalian VIP, and the
density and distribution of PACAP-like immunoreactivity in the hypothalamus was
similar regardless of treatment (Koves et al., 1990b).
VIP-immunoreactivity was seen throughout the anterior pituitary gland, but
PACAP-ir was absent (Fig. 3.9). The PACAP antiserum stained a discrete network
of cell bodies and fibres in the medio-basal hypothalamus and median eminence, of
the laying bantam hen. The PACAP-ir cell bodies and fibres were confined to the
tuberal region, lining an area adjacent the wall of the 3rd ventricle (VIII) and
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extending as far as the infundibular nuclei (Fig. 3.10a, b). In the median eminence
a dense network of fibres were also present in the external zone (ME) but
significantly less staining was present in the internal zone of the median eminence
(Fig. 3.10c).
Figure 3.9 Photomicrographs showing the lack of (a) PACAP-immunoreactive
labelling in the chicken anterior pituitary gland. The (b) VIP-ir labelling was not
abolished by pre-absorption of the cVIP antiserum with cPACAP (Mag. x400).
3.3.2 Colocalisation ofPACAP and VIP immunoreactivity in the hypothalamus
Double staining of the neurons in the basal hypothalamus («=3) using the PACAP
(1: 2000) and VIP (31/4; 1: 10 000) antibodies showed that both peptides were
present in the same group of neurons (Fig. 3.11). The hypothalamic sections were
also incubated with PACAP antiserum pre-absorbed with an excess amount (10[!g
per ml diluted antiserum) of chicken PACAP38, ovine PACAP38 (oPACAP38) or
chicken VIP. The VIP antiserum was also tested for cross-reactivity by pre-
absorbing the antibody with the same peptides, prior to incubation with adjacent
sections of the basal hypothalamus. No cross-reactivity was demonstrated between
the VIP antiserum and cPACAP or oPACAP peptides (not shown), but specific
labelling was abolished by pre-absorption with cVIP (Fig. 3.11). The PACAP
immunoreactive labelling was abolished by pre-absorption of the PACAP antiserum
with both PACAPs and cVIP, and demonstrated the mammalian PACAP antiserum
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3.4 The analysis of anterior pituitary extracts by HPLC and
radioimmunoassay
The aim of this study was to confirm that VIP immunoreactivity extracted from the
anterior pituitary gland of laying and broody hens, has the same HPLC elution
profile as synthetic chicken VIP. A positive control was also incorporated into the
study, by including VIP immunoreactivity extracted from the medial basal
hypothalamus of both laying and bantam hens, which contains VIP cell bodies and
VIP mRNA (Sharp et al., 1989; Talbot et al., 1995).
3.4.1 Column characterisation
A reverse-phase (RP) column (Vydac 218TP5415) was set up using conditions
which were described previously (Section 2.8.3). In brief, the samples were
subjected to reverse-phase high performance liquid chromatography (RP-HPLC) on
a Vydac 218TP5415 column using a linear gradient of acetonitrile (ACN) with
0.1% TFA at a flow rate of 1.5 ml/min for 40 min. The elution profile of synthetic
chicken VIP (cVIP) was characterised as a single peak (see Section 3.3.2), with a
retention time of 14-15 min (Fig. 3.12a).
3.4.2 Production and purification of iodinated VIP [,25I]-VIP.
The same conditions were applied to separate cVIP from that of iodinated cVIP
([125I]-VIP) after the iodination reaction (Fig. 3.12b, c). Initial studies established
the concentration of chloramine T necessary to iodinate 5|lg of cVIP, was 1 mg/ml;
by replacing Na125I with Nal during the reaction. The major peak of cVIP was
eluted after 14-15 min and the cold iodinated VIP ([I]-VIP) was eluted after 16-17
min. The separation of [I]-VIP from cVIP, by HPLC is shown in Figure 3.12.
These conditions were then used for the separation and purification of [125I]-VIP,
which was collected and used in the VIP radioimmunoassay (Fig. 3.13).
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Figure 3.12 The elution profile of (a) synthetic VIP (cVIP) as recorded by U.V.
absorbance at 280 nm (Waters). cVEP had a retention time of 14-15 min, Iodinated-
VIP (I-VIP) was eluted when cVIP was incubated with (b) 0.2 mg chloramine T
and (c) 1 mg chloramine T for 1 min in the iodination reaction. The column flow
rate was 1.5 ml / min. Solvent system: linear gradient elution from (A) to (B) for 40
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Figure 3.13 The HPLC purification of iodinated VIP ([125I]-VIP), which was
loaded onto a HPLC column (Vydac 218TP5415), eluted in 0.75 ml fractions, and
collected in fractions number 41-43. The column flow rate was 1.5 ml / min.
Solvent system: linear gradient elution from (A) to (B) for 40 min. H2O: CH3CN:
10%TFA, (A) 90:10:1, (B) 10:90:1.
3.4.3 Radioimmunoassay ofcVIP
The anti-VIP antibodies show no cross reaction with a wide range of VIP-like
neuropeptides (Sharp et al., 1989), but have not been tested with the recently
discovered polypeptide chicken PACAP (cPACAP). The specificity of both VIP
antibodies 6DL/33/4 (RIA) and 6DL/31/4 (ICC), was confirmed and did not show
any cross reaction with cPACAP either (Fig. 3.14). The cVIP displaced the binding
of [125I]-VIP, from both VIP antibodies, but cPACAP did not cross react with
either antibody and therefore did not inhibit the binding with the antibody. This
result confirmed the observation that the VIP-immunoreactive product localised in
the anterior pituitary gland (Section 3.2.8) and detected by VIP radioimmunoassay,
was chicken VIP and not cPACAP.
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Figure 3.14 A radioimmunoassay for chicken VIP (cVIP) using two antibodies
(codes/6DL/31/4 & 33/4) showing the displacement of [125I]-VIP by the cVIP
standard (filled symbol) and cPACAP (empty symbol). The cVIP displaced the
binding of [125I]-VIP from both VIP antibodies, but cPACAP was ineffective.
3.4.4 Measurement ofVIP extractedfrom pituitary tissue
Vasoactive intestinal polypeptide immunoreactivity was extracted (Section 2.8.1)
from the basal hypothalami and anterior pituitary glands from laying (n=10) and
broody (n=10) bantam hens and subjected to RP-HPLC, and analysis by chicken
VIP radioimmunoassay (VIP-RIA). The VIP-RIA detected VIP immunoreactive
material from the hypothalamus, pituitary and synthetic VIP (standard 5|ig), eluted
in fraction number 29-30 which corresponds to a retention time of 14-15 minutes
(Fig. 3.15). The immunoreactive material extracted from hypothalamic and anterior
pituitary tissues was cVIP, because it shared the same elution profile and retention
time as that of synthetic cVIP.
Figure 3.15 The reverse-phase HPLC of (a) synthetic cVIP chicken (b, d)
anterior pituitary and (c, e) hypothalamic extracts from (b, c) broody and (d, e)
laying bantam hens. The VIP immunoreactivity was observed in fraction number
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The VIP content of the hypothalamus and anterior pituitary gland, from both laying
and broody bantam hens was determined by VIP radioimmunoassay (Table 3.1).
There was a small but Unsignificant. difference between the VIP content of medio-
basal hypothalamus from a laying (n=5) and broody (n=5) bantam hen. Any
discrepancy may have been due to an inaccurate dissection procedure, as the birds
selected for this broody group exhibited all the characteristic features of an
incubating bantam hen for at least 1-2 weeks. The VIP tissue content of the laying
anterior pituitary glands (n=10) was greater than that of the VIP tissue content of
broody hen anterior pituitary glands (n=10) (Table 3.1). However, because these
values were determined from two pooled tissue samples, it was not possible to
determine the statistical significance of this latter difference.
Table 3.1 A comparison between incubating and laying bantam hens of the
amount of chicken vasoactive intestinal polypeptide (VIP) in the medio-basal
hypothalamus and anterior pituitary. The hypothalamic values are means ± SEM
(n=5) (Student's Mest), and the anterior pituitary gland values were determined
from a pooled laying or broody sample (n=10).
Brain region
VIP Content [ng/ml/mg tissue]









This study demonstrated the presence of VIP-immunoreactivity in the anterior
pituitary gland of laying and broody bantam hens. The RP-HPLC separation and
VIP-radioimmunoassay analysis of pituitary extracts confirmed that the major
immunoreactive product identified was VIP. The VIP antibodies used for
immunocytochemistry (6DL/31/4) studies and RIA analysis (6DL/33/4) are highly
specific and showed no cross reaction, with a wide range of VIP related peptides
(Talbot et al., 1989), including cPACAP which shares approximately 60%
homology with chicken VIP. In addition, VIP-immunoreactive labelling in the
anterior pituitary and hypothalamus was not affected by pre-incubation of the VIP
antibody (6DL/33/4) with cPACAP, and therefore confirmed the specificity of VIP-
immunoreactive labelling in both tissues, with this antibody.
Vasoactive intestinal polypeptide immunoreactive (VIP-ir) cells occurred in the
cephalic and caudal lobes of the anterior pituitary gland of both laying and broody
hens. A number of authors have reported that only a few VIP-ir cells occur in the
anterior pituitaries of intact male rats (Koves et al., 1990a), and a few or no VIP-ir
cells occur in the pituitaries of intact female rats (Lam et al., 1989; Koves et al.,
1990a; Steel et al., 1990). These authors reported that VIP-ir was colocalised in a
small population of lactotrophs (Morel et al., 1982), after long term oestrogen
treatment (Koves et al., 1990a; Steel et al., 1990) and may regulate prolactin
secretion in an autocrine manner (Nagy et al., 1988). In contrast, this study showed
that no VIP-ir was localised in lactotrophs or gonadotrophs, in the chicken anterior
pituitary gland. This observation is consistent with the reports of some authors, that
VIP-ir in the anterior pituitary of the rat occurs in cells other than the lactotroph or
thyrotroph (Lam et al., 1989; Steel et al., 1990; Carrillo and Phelps, 1992).
The discrepancies between our results and others, may be due to different
experimental protocols or VIP antibody specificity and variability. This study used
a Bouin's fixative, but other studies using a paraformaldehyde (4%) fixation
method (Lam et al., 1989; Koves et al., 1990a) were not as successful, and
detected limited numbers of VIP-ir cells. Immunoreactive VIP is susceptible to
damage from fixation and processing, and in particular the C-terminal and mid-
portions of VIP are affected during paraffin processing (Larsson, 1982). Therefore,
the microwave processing used in this study, combined with a Bouins fixation may
94
enhance the conditions required to visualise VIP-immunoreactivity in the anterior
pituitary. The attempt to count the number of VIP-ir cells was not successful,
because the intensity of immunostaining often faded after prolonged illumination,
and the image analysis system (Magiscan 2, Joyce Lobel Ltd., Gateshead, Tyne
and Wear, U.K.) used to quantify the cell number, was unable to discriminate
weakly stained stellate VIP-ir cells from the background.
One VIP-ir cell type was stellate in appearance, with an irregular shaped nucleus
and cytoplasmic projections between unstained pituitary secretory cells. A stellate
VIP-ir cell has been reported by several groups, which differs from classical
pituitary hormone cell types (Lam et al., 1989; Segerson et al., 1989; Carrillo and
Phelps, 1992). The morphological features of the VIP-ir cells were similar to those
of the folliculo-stellate cells (FS-cell) (Harrison et al., 1982). The FS-cells were
identified throughout the anterior pituitary of the chicken, with an antibody raised
against S-100 protein, which is a molecular marker for FS-cells of the anterior
pituitary of mammals and birds (Cocchian and Miani, 1980; Atoji et al., 1990). The
S-100 protein occurs in the anterior pituitary gland of most mammalian species. The
glial cell marker GFAP (glial fibrillary acidic protein) is also used to identify FS-
cells in the human anterior pituitary gland (Velasco et al., 1982; Trojanowski et al.,
1984), but is not detected in the anterior pituitary glands of the bull, goat or sheep
(Shimada, 1992). This study also failed to demonstrate GFAP immunoreactivity in
the chicken anterior pituitary gland, which supports the findings of the latter study
(Shimada, 1992).
A number of FS-cells contained both S-100- and VIP-immunoreactivity, but the
larger VIP-ir cells which were more polygonal in shape did not appear to contain S-
100 immunolabelling. A number of S-100(+) cells in the pituitary were weakly
immunolabelled and were also polygonal in shape. There are reports of round or
oval S-100 immunoreactive cells in the quail anterior pituitary gland (Van Nassauw
et al., 1987; Atoji et al., 1990). This suggests that the VIP-ir cells which do not
contain S-100 protein, may be a differentiated FS-cell, or possibly a separate
category of pituitary cell (Segerson et al., 1989).
The VIP-ir visualised immunocytochemically in the anterior pituitary gland of an
incubating hen, seemed less than the VIP-ir occurring in the laying hen, which was
processed at the same time. Although, there was no significant difference between
the VIP content measured by HPLC-RIA, in the anterior pituitaries of the laying
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and incubating hens. VIP-ir was found in the caudal and cephalic lobes, but the
lactotrophs only occurred in the cephalic lobe. The topographical relationship
between VIP-ir cells and lactotrophs in the cephalic lobe and lack of association
between these cell types in the caudal lobe, suggests that intra-pituitary VIP may not
be an important regulator of PRL secretion in the chicken. It may be the case, that in
the chicken, hypothalamic VIP is the main factor which regulates PRL secretion
associated with incubation behaviour, and that the role of intra-pituitary VIP in the
chicken is mediated by the action of oestrogen.
This view is supported by the observation that increased plasma PRL in the rat
suppresses intra-pituitary VIP concentrations, but is overridden by oestrogen
treatment (Prysor-Jones et al., 1987). In the ovariectomised rat oestrogen treatment
increases pituitary VIP cell number (Steel et al., 1989) and VIP mRNA (Reichlin,
1988; Lam, 1991). In the broody hen ovarian steroids are depressed (Cogger et al.,
1979; Sharp et al., 1979) and hypothalamic VIP levels are increased (Sharp et al.,
1989), which may explain the apparent reduction of VIP-immunolabelling in the
anterior pituitary.
The distribution of cells containing VIP-ir and LH immunoreactivity was essentially
the same, and there was also a close association between the two cell types. The
intensity of VIP immunostaining appeared greater in the anterior pituitary of the
laying hen than of the incubating hen, and there was a close relationship between
VIP and LH cells. Indeed, a number of VIP-cells appeared to envelop neighbouring
gonadotrophs with cytoplasmic projections. VIP may be acting in a paracrine
manner within the chicken pituitary to regulate gonadotroph function. This
hypothesis is supported by the observation that VIP potentiates the LH releasing
activity of LHRH in man (Hammond et al., 1993).
PACAP-immunoreactive (PACAP-ir) cells were localised in the nucleus
infundibularis of the medial basal hypothalamus and PACAP-ir co-expressed with
VIP in the same neurons. However, pre-absorption of the PACAP antisera with
chicken VIP abolished PACAP-immunostaining, but VIP-immunolabelling was not
abolished by the pre-absorption of the cVIP antiserum with cPACAP. Therefore
this study was not able to confirm localisation of PACAP-immunoreactivity in the
hypothalamus or anterior pituitary gland of the chicken. PACAP-immunoreactive
fibres are localised in the ovine hypothalamus, posterior pituitary (Koves et al.,
1990b) and is reported to occur in the chicken brain (Yasuhara et al., 1993).
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PACAP mRNA was also detected in the anterior pituitary of the rat (Wuttke et al.,
1994), but independent studies failed to detect PACAP-immunoreactivity or
PACAP mRNA in the rat anterior pituitary (Mikkelsen et al., 1995), or human
pituitary adenomas (Vertongen et al., 1995b). This study cannot discount the
possibility that PACAP is produced and expressed by the anterior pituitary of the
chicken, but has confirmed that the VIP-immunolabelling in the anterior pituitary
was not due to PACAP.
Further studies are needed to establish whether PACAP is expressed in the
hypothalamus, ME or the anterior pituitary gland of the chicken using antibodies
which are more specific for chicken PACAP. The distribution of PACAP in the
hypothalamus is similar in several mammalian species (Koves et al., 1990b;
Tamada et al., 1994), and is reported to occur in the chicken (Yasuhara et al.,
1992). Therefore, PACAP, like VIP may play an important role as a hypothalamic
factor released in birds and regulate hormone secretion in the anterior pituitary
gland.
In conclusion, VIP-immunoreactivity which cannot be accounted for by cross
reaction with PACAP occurs in the anterior pituitary gland of the chicken. It occurs
in a folliculo-stellate-like cell, and not in lactotrophs or gonadotrophs. The
functional significance of intra-pituitary VIP in relation to PRL secretion remains to
be determined. However, the close relationship between VIP-ir cells and LH cells
in the anterior pituitary gland suggests VIP may be acting as an important paracrine
factor, which modulates LH secretion. The possibility that intra-pituitary VIP may
regulate other pituitary hormone cell types cannot be discounted, and needs further
investigation.
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Chapter 4: THE EXPRESSION OF VIP mRNA IN THE
ANTERIOR PITUITARY GLAND
4.1 Introduction
In the previous chapter it was shown that VIP was detectable in the chicken
anterior pituitary gland using immunocytochemistry and HPLC analysis of
pituitary extracts, but this does not provide evidence that VIP is produced by the
anterior pituitary and not sequested by cells. The mRNA encoding VIP occurs in
the anterior pituitary gland of the rat (Reichlin, 1988; Lam et al., 1990; 1991) and
human (Byrne et al., 1992). There is evidence to suggest that changes in
expression of VIP in the pituitary are influenced by the alterations in the steroid
environment (see Section 1.6.1). Furthermore, intrapituitary VIP is believed to
play a role of a paracrine/autocrine factor modulating the function of pituitary
hormone secreting cells. The aim of this study was to demonstrate VIP gene
expression in anterior pituitary tissue of the chicken, using RT-PCR and a solution
hybridisation RNase protection assay. An in situ hybridization technique was used
to establish whether the expression of VIP mRNA was specifically localised in the
VIP-cell type, identified in Chapter 3. A positive control was incorporated into the
study by including the VIP cell bodies located in the medial basal hypothalamus
adjacent to the anterior pituitary gland.
4.2 VIP gene expression in pituitary tissue using RT-PCR
RNA was isolated from anterior pituitary (n=10) to confirm the presence of VIP
mRNA in this tissue. The primers 251L and 275Z were based on the sequence of
the VIP cDNA clone VIP19 (Talbot et al., 1995) and span the region homologous
to exon 3 and exon 6 (Section 2.4.1). The RNA was reverse transcribed and the
cDNA amplified by PCR.
A major fragment of 275 bp and a minor fragment of 380 bp was generated from
pituitary cDNA (Fig. 4.1), but no bands were observed in the control samples,
which included a water control, mouse mRNA, cDNA and pituitary mRNA. The
RT-PCR products were digested by a restriction endonuclease (Bst Bl), which
generated two fragments of 185 bp and 93 bp from the 275 bp product and 290 bp
and 93 bp from the 380 bp product. These fragment sizes result from the digestion
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of the 275bp and 380bp fragments which contain a Bst B1 restriction site in the
cDNA sequence and correspond to the fragment size predicted from the VIP cDNA
sequence (Fig. 4.2).
PITUITARY MOUSE PITUITARY MOUSE
DIGESTED BsiBl UNDIGESTED
Figure 4.1 The detection of VIP mRNA by RT-PCR in the anterior pituitary
gland of a laying hen, using reverse transcribed total RNA (cDNA) or RNA from
the chicken anterior pituitary, using primers 215L and 275Z. The 'VIP only' PCR
product was 275bp, and the 'VIP/PHI' (V/phi) PCR product was 380bp. The RT-
PCR products digested by Bst B 1. The size markers were a digest of pBR328 with








VIP only Bst B1 digest
□
Figure 4.2 The relative position of PCR primers 215L and 257Z and the
predicted size of PCR products. The digestion of the PCR products by the
restriction enzyme Bst B1 (arrow), results in the production of 185bp and 93bp
fragments from the 275 bp PCR product and 290 bp and 93 bp fragments from the
380 bp PCR product, which were visualised in Fig. 4.1.
4.3 An in situ Hybridisation (ISH) histochemical investigation
The aim of this study was to establish the cell type which synthesizes VIP in the
chicken anterior pituitary gland. A 45 base oligonucleotide end-labelled with 35S-
dATP by .terminal transferase, was used for in situ hybridisation of VIP mRNA in
the basal hypothalamus, which contains cell bodies synthesising VIP (Sharp et al.,
1989; Talbot et al., 1995). However, this oligonucleotide produced unacceptable
levels of non-specific background product in th'e anterior pituitary which was not
seen in the hypothalamus. Therefore it was decided to abandon this approach and
use a non-radioactive RNA probe which might be more sensitive and produce less
background product.
Initial trials established the conditions for in situ hybridisation using a digoxigenin-
labelled (DIG-labelled) riboprobe (Section 2.6.1) on coronal cryostat sections of
the basal hypothalamus, from the laying bantam hen. Several approaches were
adopted to optimise the in situ hybridization of chicken pituitary VIP mRNA.
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4.3.1 Probe design
The first antisense probe to be used was transcribed from the plasmid VF48
(Section 2.6.1), which was linearised with Nco 1 and was referred to as VF48N.
This probe spanned bases 477-169 of the VIP cDNA sequence (Fig. 4.3), and
included most of exon 5, encoding the VIP peptide. A complementary sense
riboprobe was also generated by transcribing the plasmid VF48 which was
linearised with Eco Rl, and termed VF48E (Fig. 4.3).
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Figure 4.3 A schematic representation of the DNA clones used to generate sense
and antisense probes for in situ hybridization. The restriction enzyme in bold was
used to linearise the plasmid. Abbreviations: A Eco Rl adapter; arrow indicates
direction of transcription by RNA polymerase; T3 and 77 RNA polymerases used
for RNA transcription.
In subsequent studies (Section 4.3.3), an additional non-overlapping antisense
probe was generated and combined in the hybridisation buffer. The second
plasmid VF15 was linearised with Nco 1 and RNA transcription generated an
antisense riboprobe termed VF15N (spanning 474-597) (Fig. 4.3). A third clone
VF11, which contained the same sequence but in the reverse orientation, was used
to produce a sense probe for a control, termed VF11N (Fig. 4.3). The probe
quality was analysed after purification by gel electrophoresis (Section 2.5.2) and
Northern blotting (Section 2.5.3).
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4.3.2 Hybridisation conditionsfor hypothalamic tissue
The antisense and sense probes (VF48N and VF48E) were used at a concentration
of 170ng/slide (1.7ng/(ll) and hybridized at 55°C overnight, using the conditions
described previously (Section 2.6.4) These conditions were used to saturate the
target VIP mRNA. The hybridisation signal was visualised with an anti-DIG
peroxidase detection kit (Boehringer Mannheim), which allowed amplification of
the signal. The sections were incubated in a DAB solution for 0.5 hr to 1.5 hrs
without adversely affecting the signal : noise ratio. The labelling of cells seen using
DIG-labelled VF48N was confined to the basal hypothalamus region known to
express VIP neurons (Sharp et al., 1989). The sense probe VF48E used as a
negative control did not generate any specific labelling on adjacent sections (Fig.
4.4).
The DAB reaction product was concentrated in the cytoplasm of cell bodies and
absent in the nucleus. The labelling of cells identified in the hypothalamus of the
laying hen («=3) was less than that observed in the hypothalamus of the broody
(n=3) bantam (Fig. 4.5a, b).
4.3.3 Hybridisation conditionsfor anterior pituitary tissue
The hybridisation conditions used to localise VIP mRNA in cells of the chicken
anterior pituitary gland (n=4), were the same conditions used to confirm VIP
mRNA in neurons in the basal hypothalamus. The initial studies were
unsuccessful, and no specific signal was visualised in the anterior pituitary after 1
hour in DAB solution. The staining periods were extended for the pituitary
sections, and incubations times of 2-3 hours yielded minimal or no staining.
However, the control sections of the basal hypothalamus, were expressing the




































































































Figure 4.5 The detection of VIP mRNA in neurones of the basal hypothalamus
of the (a) laying and (b) broody hen (Mag. x400). The staining (brown precipitate)
was confined to the (c) cytoplasm (arrow, c) and absent in the nucleus (arrow, n)
(Mag. xlOOO). The cresyl violet counterstain (b) demonstrates the lack of DAB





Figure 4.6 The visualisation of VIP mRNA in the basal hypothalamus (arrow
head) of the (a) laying hen (Mag. x40) and of staining in the (b) anterior pituitary
(400). The riboprobe VF48N was used to localise VIP mRNA. Abbreviations, me
median eminence, pit pituitary and viii 3rd ventricle.
An attempt was made to increase the sensitivity of the ISH method applied to the
anterior pituitary gland by doubling the concentration of VF48N probe in the
hybridization mix. However this was not successful. Trials with the antisense
probe VF15N showed that it was suitable for the in situ localisation of VIP
mRNA in the hypothalamus (Fig. 4.7a) and no labelling was observed using the
corresponding sense probe, VF1 IN (Fig. 4.7b). The two complementary
riboprobes VF48N and VF15N were combined in a further attempt to increase the
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sensitivity of the hybridisation signal in the anterior pituitary. The resulting amount
of label seen in the pituitary was inconsistent and probably non-specific (Fig.
4.7c).
4.3.4 Effect ofproteinase K treatment
In a further attempt to localise pituitary VIP mRNA, the hybridisation protocol was
modified to increase the permeability of the pituitary tissue. Proteinase K (PK)
treatments (1, 5 or 10 |J.g/ml, 15 min at 37°C) were used on the hypothalamic
(n=3) and pituitary (n=3) cryostat sections previously fixed with 4% PFA (see
Section 2.6.3). The PK treatment increased the detection of labelling in the anterior
pituitary, without adversely affecting the specific staining in the basal
hypothalamus. However, a number of artefacts were observed in the pituitary with
the sense probe (Fig. 4.8), and the morphological integrity of the labelled cells






Figure4.7ThelocalisationofVIPmRNAbyinsituhybr d z tionncryostatectionsfthebas lhypothalam sfrlay ge ,w h complementaryriboprobVF15N(Mag.x200).Nspecificlabellingwaseniththpr b( )inant riorpi u tarygland ,x20 ). Nolabellingwass eniththantis n erenseprobVF1I ,it(c)b s lhypot alamudant riorpitui arygl d(M g.x200).
Figure 4.8 Photomicrographs illustrating the labelling visualised in the (a, b)
anterior pituitary of a laying hen using the DIG-labelled VF48N probe, after
proteinase K treatment (5pg/ml for 15 mins), and the artefacts (c, d) observed
using the control probe VF48E. (Mag. x400).
The specificity of the VIP mRNA visualised in the chicken anterior pituitary gland,
by DIG-labelled RNA probes could not be established. Therefore, the ISH study
was abandoned and a solution hybridisation method was used to demonstrate the
expression of mRNA encoding VIP in the anterior pituitary gland.
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4.4 VIP gene expression using Solution hybridization and RNase
protection assay
This technique has a greater degree of sensitivity because it uses a high-specific-
activity probe which is complementary to VIP mRNA, and is not affected by the
problem of penetration, which is common in fixed tissue sections used for in situ
hybridisation
Total RNA was isolated from the gut (n-2), hypothalamus (n=3) and anterior
pituitary gland of a laying hen (n=10). A high specific activity RNA probe was
generated which was complementary to part of exon 4 (102 bp), exon 5 and some
of exon 6 (Section 2.7.1). The RNA probe protected two fragments of 260 bp and
160 bp in total RNA from the gut, hypothalamus and one 160 bp RNA fragment in
the pituitary (Fig. 4.9). The 260 bp fragment corresponded to the predicted size for
an RNA encoding both VIP and PHI. The 160 bp protected RNA fragment in total
RNA from the gut, hypothalamus and pituitary was predicted for a VIP-only
encoding RNA (Fig. 4.9). The VIP/PHI mRNA transcript was not detected in the
anterior pituitary, and no specific bands were found in the tRNA, hepatocyte RNA
or water controls.
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Figure 4. 9 The solution hybridization and RNase protection demonstrates that
the complementary probe has protected VIP mRNA of the predicted size from
RNase digestion. The visualisation of protected bands confirmed that mRNA




The RT-PCR and solution hybridisation studies showed for the first time that
mRNA encoding the chicken VIP gene was found in the anterior pituitary gland of
the laying hen. The solution hybridisation study also showed that this method was
not sensitive enough to detect the larger VIP/PHI transcript, but it was detected by
RT-PCR. The smaller VIP-only transcript was the predominant form in the
pituitary tissue of the laying bantam hen. This observation supports the findings
that the two VIP mRNAs are also present in unequal amounts with the VIP only
transcript dominating in the anterior pituitary, hypothalamus and gut of the chicken
(Talbot et al., 1995) and turkey (You et al., 1995). This observation shows that
VIP is synthesised in the anterior pituitary gland and is not merely sequestered by
the gland from other sources. Furthermore, it is consistent with the indirect (Hagen
et al., 1986; Nagy et al., 1988) and direct evidence (Arnaout et al., 1986; Koves et
al., 1990a; Morel et al., 1982; Lam et al., 1989) that VIP is produced by the
anterior pituitary of the rat. The expression of VIP/PHI mRNA in the anterior
pituitary gland was suggested by the RT-PCR analysis, but at a level significantly
less than that of VIP mRNA, since pituitary VIP/PHI mRNA could not be
demonstrated using solution hybridisation. Prolactin secretion in the turkey is
stimulated by mammalian PHI, although less effectively than VIP (Proudman and
Opel, 1990). PHI may therefore have a role to play in the function of the anterior
pituitary, but the results of this study are not detailed enough to draw any
conclusions.
The in situ hybridisation study was not able to localise VIP mRNA in cells of the
anterior pituitary. However, the specific hybridisation in the basal hypothalamus
was localised to individual neurons, and the distribution was similar to the pattern
described for VIP neurons localised by immunocytochemistry (Sharp et al., 1989)
and by in situ hybridisation using a 35S-labelled (45 base) oligonucleotide probe
(Talbot et al., 1995). The sensitivity of the DIG-labelled RNA probes was not able
to detect the low level of VIP mRNA in the pituitary gland.
There may be several reasons why this approach was unsuccessful. This may have
been a reflection of the quantity of VIP mRNA expressed by both tissues, or the
inability of long riboprobes to penetrate the pituitary tissue to hybridise with the
target mRNA. The concentration of probe may have been too high, and the
saturation of the tissue with probe appeared to result in the formation of artefacts,
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which were not removed by stringent washing or RNAse treatment. The DIG-
labelled probe is likely to lack the sensitivity required for the detection of pituitary
VIP mRNA.
VIP mRNA occurs in stellate cells of the anterior pituitary gland of the hypothyroid
rat, as demonstrated by in situ hybridisation with an 35S-labelled RNA probe, but
it is not present in the normal pituitary (Segerson et al., 1989). The detection of
VIP mRNA in the normal chicken pituitary may not be possible using non¬
radioactive probes. Indeed, the VIP mRNA demonstrated in the pituitary by
solution hybridisation RNAse protection assay was only possible using a high
specific activity 32P-labelled RNA probe. Therefore, endocrine manipulation,
including hypothyroidism, adrenalectomy or oestrogen administration, which
increases VIP gene expression in the rat anterior pituitary (see Section 1.6.1), may
be necessary to increase VIP gene expression in the chicken pituitary in order to
detect it using in situ hybridisation.
An alternative method of hybridisation may have been to use a non-radioactive or
radioactive oligonucleotide (oligos). The oligos have a greater sensitivity than non¬
radioactive probes and are better able to penetrate tissue sections without
pretreatment with proteinase K, which may damage the structural morphology. An
35S-labelled probe was used in trials, but was replaced by a non-radioactive probe
because of high background in pituitary sections, which may be a feature of using
radio labelled probes on this tissue. This is supported by the following
observation. The detection of vasopressin (VP) mRNA in the posterior pituitary of
the rat is hampered by the non-specific signal in the anterior pituitary with the use
of 33P-labelled oligos, but not with hapten-labelled oligos (Trembleau and Bloom,
1995). No VP mRNA occurs in the anterior pituitary (Mohr et al., 1991), and it is
suggested that the background may be an artefactual product of excessive probe
concentration, or cross-hybridisation of the probe with unknown sequences.
Recent research also shows that the use of multiple non-overlapping non¬
radioactive oligonucleotide probes, significantly increase the sensitivity and
resolution of in situ hybridisation detection in which the mRNA is present at low
concentrations (Trembleau and Bloom, 1995). This technique may be a suitable
approach to identify VIP mRNA in the chicken anterior pituitary, and confirm that
the stellate cells identified in Chapter 3, synthesize VIP.
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In conclusion, the RT-PCR and solution hybridisation and RNAse protection
assay confirmed VIP de novo synthesis in the anterior pituitary gland of the
chicken. Further work is needed to identify unequivocally the specific cell type
which produces VIP in the pituitary, but it is likely VIP produced by a folliculo-
stellate cell type, may function as a paracrine regulator of pituitary hormone
function.
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Chapter 5: THE IMMUNOCYTOCHEMICAL
LOCALISATION OF VIP RECEPTORS IN THE
ANTERIOR PITUITARY AND HYPOTHALAMUS
5.1 Introduction
It has been suggested that the VIP receptor is heterogeneous (Laburthe et al.,
1989; Robberecht et al., 1990). High and low affinity VIP binding sites have been
characterised, in mammalian (Laburthe et al., 1989) and avian species (Meunier et
al., 1991; Rozenboim and El Halawani, 1993), and more than one
pharmacologically distinct class of VIP receptor occurs in rat tissues (Robberecht
et al., 1986; Gozes et al., 1991a, b; Blum et al., 1992). Two VIP receptor
subtypes have been cloned from the rat (Ishihara et al., 1992; Lutz et al., 1993)
and human (Sreedharan et al., 1993; Xia et al., 1996), which are referred to as the
subtype-I (VIP-RI, see Section 1.7.4) and subtype-II (VIP-RII, see Section 1.7.5)
VIP-receptor, respectively.
Hypothalamic vasoactive intestinal polypeptide stimulates prolactin secretion and
prolactin gene expression in birds (Talbot et al., 1991; Youngren et al., 1994), and
its mode of action is mediated by a specific VIP binding site (Rozenboim and El
Halawani, 1993; Gonzales et al., 1994b). In the previous chapters it was shown
that VIP is synthesised in the anterior pituitary gland suggesting that it may act as a
paracrine factor to regulate pituitary hormone secretion. The aim of this chapter
was to localise immunocytochemically VIP receptors in the chicken anterior
pituitary cell types using antibodies raised against the predicted amino acid
sequence of the human subtype I (Goetzl et al., 1994) and II VIP receptors (a gift
from E.J. Goetzl). VIP receptor subtypes were also localised in the hypothalamus
to gain evidence for specificity and compare with published information on the
distribution of VIP binding sites in the avian brain (Hof et al., 1994).
5.2 The localisation of the subtype-I VIP receptor
5.2.1 Characterisation ofsubtype-I VIP receptor (VIP-RI) antibodies
The distribution of VIP-R subtype I in the anterior pituitary sections (Section
5.2.6) was visualised using a donkey anti-rabbit conjugated rhodamine antibody
or an ABC peroxidase staining kit. Two primary antibodies were used (Table 5.1)
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the first was raised against a peptide sequence from the first extracellular loop
(Peptide A, 32 amino acids) and the second raised against the carboxyl terminus
(Peptide B, 67 amino acids) (Section 1.7.4). The distribution of immunoreactive
labelling in the anterior pituitary was the same for both anti-peptide antibodies (A
and B) (not shown), but the intensity of labelling was greater when using the
antibody raised against peptide A. Most experiments were therefore carried out
using this VIP-R antibody (1:100).
Table 5.1 Human subtype-I VIP-receptor antibodies used for
immunocytochemistry. Abbreviations +++, excellent staining, ++, acceptable
staining.
Antibody Amino acid no. Epitope location Labelling
from N-terminus Intensity
VIP-RI(A) 191-222 1st extracellular loop +++
VIP-RI(B) 391-457 Carboxyl terminal ++
5.2.2 The localisation of the VIP receptor subtype-I (VIP-RI)
Initial studies showed that VIP-RI immunolabelling was confined to the cephalic
lobe of the anterior pituitary gland of laying (n=4) and broody (n=4) bantams (Fig.
5.1). Immunoreactive labelling visualised using a rhodamine conjugate second
antibody, was in isolated cells and cell clusters throughout the cephalic lobe, in the
cytoplasm but not in nuclei (Fig. 5.1). Immunoreactive labelling in the cephalic
lobe in the broody hen was weaker than that in the laying hen (not shown). The
specificity of antibodies VIP-R(A) and VIP-R(B) was confirmed, by the
observation that immunolabelling in the pituitary was absent when antibodies had
been passed through a column containing Sephadex coupled to the peptide used to
raise the antibodies (Goetzl et al., 1994). (Fig. 5. Id).
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Figure 5.1. The distribution of VIP-RI immunoreactivity in the (a) cephalic lobe
(CE) and (b) lack of staining in the caudal lobe of the anterior pituitary (CA),
demonstrated using a rhodamine conjugated second antibody (Mag. x400). The
VIP-RI immunoreactive cells were found in (c) isolated cells and cell clusters
(Mag. xlOOO). The immunolabelling was (d) abolished by absorbing the VIP-RI
antibody, with the peptide used to produce it (peptide A) (Mag. x400).
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5.2.3 The distribution ofPRL, LH, GH and ACTH cells using the adjacent sections
A series of experiments were carried out to localise the VIP-RI in cells of the
anterior pituitary gland from a laying hen (n=4), using adjacent sections. Thin
(2|im) sections were mounted in groups of three, on consecutive slides, and one
slide was labelled for VIP-RI and the other slide was immunolabelled using an
antibody to either PRL (code/31/1), LH (code/783) ACTH (code/5.81) or GH (see
Section 2.2.7). Immunolabelling was visualised using a biotin-avidin peroxidase
staining kit. The distribution of PRL and LH cells is described previously in
Chapter 3 (Section 3.2.1). The distribution of ACTH immunoreactive cells was
similar to that of PRL and VIP-RI expressing cells, occurring in the cephalic lobe
of the anterior pituitary gland. In contrast, the GH immunoreactive cells were
found only in the caudal lobe.
5.2.4 The localisation of the VIP-RI in pituitary hormone secreting cells using adjacent
sections
Prolactin-producing cells and cells containing VIP-RI were localised in the
cephalic lobe (Fig 5.4), but there was no evidence of colocalisation of PRL and
VIP-RI in the same cell (Fig. 5.4). LH-producing cells did not contain VIP-RI
immunoreactivity in the cephalic lobe (Fig. 5.5), and the GH cells were also not
associated with the cells containing VIP-RI immunoreactivity except along the
cephalic/caudal boundary {not shown). However, the distribution of ACTH cells
and VIP-RI was essentially the same (Fig. 5.6), and the majority of ACTH cells
identified on adjacent sections throughout the cephalic lobe of the anterior pituitary
contained VIP-RI immunolabelling (Fig. 5.6).
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5.3 The localisation of the VIP receptor subtype-II (VIP-RII) in the
anterior pituitary
The distribution of VIP-RII immunoreactivity was visualised on sagittal sections
of the anterior pituitary gland from laying (n=3) and broody (n=3) bantam hens,
using an ABC peroxidase staining kit (see Section 2.2.2). The antibodies used in
this study (Table 5.2), were generated by immunizing rabbits with five different
peptide sequences deduced from the nucleotide sequence of the recently cloned
subtype-II VIP-R (VIP-RII) (Goetzl et al., 1996).
Table 5.2 Human subtype-II VIP-receptor antibodies used for
immunocytochemistry. Abbreviations : +++ good clear staining, ++ acceptable
staining, with high background, + very little or no staining.
Antibody Amino acid no. Epitope location Labelling
from N-terminus Intensity
VIP-RII(4) 54-70 Extracellular amino terminal +
VIP-RII(5) 105-122 Carboxyl terminal +++
VIP-RII(6) 174-195 1st Extracellular loop ++
VIP-RII(22) 19-37 Extracellular amino terminal +
VIP-RII(23) 67-83 Extracellular amino terminal +
5.3.1 The characterisation of the VIP-RII antibodies
Of the five antibodies investigated (Table 5.2) only the VIP-RII(5) and VIP-RII(6)
antibodies were suitable for the localisation of VIP-RII immunoreactivity. The
visualisation of the subtype-II VIP receptor (VIP-RII) was difficult because of a
high non-specific background labelling (Fig. 5.6).
The immunolabelling of cells in the anterior pituitary with the VIP-RII(6)
antibody, was also observed in the cephalic and caudal lobes, but the intensity and
pattern of immunolabelled cells differed from that of the VIP-RII(5) (Section
5.3.2). The VIP-RII(6) immunolabelled cells in the caudal lobe were more
intensely labelled and more distinct than the cells labelled in the cephalic lobe (Fig.
5.6). It was apparent, that although immunolabelled cells occurred in both lobes of
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the pituitary the antibodies were labelling either different cells or the intensity of
immunolabelled cells varied.
Figure 5.6 The immunolabelling of cells in the cephalic and caudal lobes of the
chicken anterior pituitary gland, using the (a, b, c) VIP-RII(6) antibody. (Mag.
x200, c, d; Mag, x400). Note the different labelling of cells in the cephalic and
caudal lobes. Abbreviations, CA caudal lobe, CE cephalic lobe.
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5.3.2 The localisation of the VIP-RII in cells of the anterior pituitary
Several attempts were made to identify the cell types containing VIP-RII
immunoreactivity, but variability of immunolabelling made it difficult to
distinguish between labelled and unlabelled cells. The immunolabelling of cells in
the anterior pituitary («=3) using the VIP-RII(5) antibody was observed in both
cephalic and caudal lobes, and localised in individual cells (Fig. 5.7), and was
similar to that of GH-producing cells. Furthermore, the analysis of adjacent
sections immunolabelled with antibodies raised against VIP-RII(5) or GH,
showed suggested colocalisation (Fig. 5.7), but this could not be established.
5.4. The localisation of the VIP receptors in the hypothalamus
VIP binding sites have been demonstrated in the turkey (Rozenboim and El
Halawani, 1993) and chicken anterior pituitary gland (Gonzales et al., 1994) by
radioligand binding methods. VIP binding sites were mapped in the avian brain
using autoradiography (Hof et al., 1994; Kuenzel et al., 1996). The aim of this
experiment was to localise VIP receptors in the chicken hypothalamus and
compare it with the studies of ligand binding sites.
5.4.1 The localisation of the VIP-RI in the hypothalamus
The distribution of VIP-RI immunoreactivity was localised using free-floating
coronal sections through the hypothalamus of laying hens (n=3), in the plane of
the Kuenzel and Masson (1988) stereotaxic atlas, and staining was visualised
using an avidin-biotin peroxidase staining kit (see Section 2.2.7). VIP-RI
immunoreactivity was found in the internal zone of the median eminence (Fig.
5.8), and the nucleus periventricularis (PHN) (Fig. 5.9), but was not seen in the
nucleus paraventricularis magnocellularis (PVN) (Fig. 5.9) or the nucleus
supraopticus (SO) {not shown). VIP-RI immunoreactivity was localised in the
cytoplasm of fusiform and multipolar cell bodies.
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Figure 5.8 The immunocytochemical localisation of VIP-receptor subtype-I
(VIP-RI) in the (a) internal zone of the median eminence (Mag. x40) and (b) high
power image (Mag. xlOOO). A VIP-RI immunoreactive cell body and fibres are
indicated by arrows. Abbreviations: EZ external zone; 7Z internal zone; ME median









Figure 5.9 The immunocytochemical distribution of VIP-receptor subtype-I
('VIP-RI) in the (a) periventricular nucleus (Mag. xlOO) and (b) an immunoreactive
fusiform cell body (Mag. xlOOO). The VIP-RI immunoreactivity was absent in the
(c) nucleus paraventricularis Mag. xlOO). Abbreviations: PHN nucleus
periventricularis hypothalami, PVN nucleus paraventricularis magnocellularis,
VIII third ventricle.
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5.4.2 The localisation of the VIP-RII in the hypothalamus
The distribution of VIP-RII immunoreactivity was visualised in free-floating
coronal sections through the brain of a laying chicken (n=4), using the method
described previously (Section 5.4.2). The distribution of VIP-RII
immunoreactivity in the hypothalamus was more widespread than of VIP-RI, and
was localised in the preoptic area and middle and posterior hypothalamic areas.
Immunolabelling occurred in the cytoplasm and fibres of cell bodies, but was not
seen in the cell nuclei. VIP-RII labelled cells were seen in the magnocellular
hypothalamic cells of the nucleus paraventricularis and supraopticus. The lateral
nucleus and parvocellular portion of the nucleus periventricularis also contained
VIP-RII immunoreactivity. The VIP-RII labelled cell bodies were observed in the
nucleus habenularis-lateralis, -medialis, and the anterior hypothalamic nucleus.
5.4.3 A comparison of the VIP-RII and vasotocin distributions in the hypothalamus
The distribution of VIP-RII immunoreactive cells was similar to the reported
distribution of vasotocin (VT) neurons in the preoptic-anterior hypothalamus
(Gray and Simon, 1983). A study was carried out to determine whether the
distribution of VIP-RII immunoreactivity corresponded to the distribution of AVP-
immunoreactivity using adjacent coronal free-floating sections.
The vasotocin labelled cells were localised in the nucleus paraventricularis (Fig.
5.11) and periventricularis, supraopticus (SOe, SOv) and preopticus (Fig. 5.10),
which also expressed the VIP-RII immunoreactivity on adjacent sections (Fig.
5.11). No attempt was made to confirm localisation of the VIP-RII
immunoreactivity, in the vasotocin neurons using double labelling but the
distribution of VIP-RII and vasotocin immunolabelling was consistent with co-
localisation.
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Figure 5.11 The distribution of (a) vasotocin and (b) VIP-receptor subtype-II
(VIP-RII) in the nucleus paraventricularis, on an adjacent section. Abbreviations:
PVN nucleus paraventricularis magnocellularis;V7/7 third ventricle.
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5.5 Discussion
This study demonstrated the localisation of vasoactive intestinal polypeptide
receptors in the anterior pituitary gland of the chicken, using antibodies raised
against portions of the deduced amino acid sequence of the human subtype-I
(Goetzl et al., 1994) and subtype-II VIP receptors (a gift from E.J. Goetzl).
The subtype-I VIP-R was localised exclusively in ACTH cells. This is consistent
with the evidence that the VIP-RI mRNA occurs in low levels in the rat anterior
pituitary gland (Usdin et al., 1994; Rawlings et al., 1995), and also occurs in the
corticotroph-like AtT20 cell line (Journot and Rawlings, unpublished results). The
VIP-RI was not seen in PRL, LH and GH cells, but may occur in these cell types
at a concentration too low to be detected using immunocytochemistry.
The mRNA encoding the VIP-RI is reported not to be present in the
lactotroph/somatotroph-like (GH4C1) or the gonadotroph like (aT3-l) cell lines
(Rawlings et al., 1995). However, VIP stimulates cAMP production and a Ca2+
influx response in these cell lines. This observation suggests that the actions of
VIP in these cell lines are mediated by a VIP receptor other than the subtype-I VIP-
R (Rawlings et al., 1995).
This immunocytochemical study was not able to identify the cell type or types in
the chicken anterior pituitary gland which contained the subtype-II VIP receptor,
because of high non-specific background immunolabelling. VIP binding sites
occur in both cephalic and caudal lobes of the chicken, and the specific binding in
the cephalic lobe of an incubating hen is reported to be greater than in a laying hen
(Gonzales et al., 1994a). VIP stimulates PRL secretion and PRL gene expression
in the chicken (Talbot et al., 1991), and VIP receptors are localised on lactotrophs
in the rat anterior pituitary gland (Wanke and Rorstad, 1990). In the rat the
subtype-II VIP receptor is the main VIP neuroendocrine receptor type in the
anterior pituitary gland. This has been demonstrated using in situ hybridization and
RT-PCR (Lutz et al., 1993; Usdin et al., 1994). On the basis of the rat studies it
was anticipated that VIP-RII immunoreactivity would occur in lactotrophs of the
chicken anterior pituitary gland.
The VIP receptors subtype-I and -II are both members of the G-protein-linked
receptor family, which bind to a seven transmembrane spanning receptor and share
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a high degree of homology with each other (Segre and Goldring, 1993). The
human VIP-RI (Sreedharan et al., 1993) shares a 84% homology with the rat VIP-
RI (Ishihara et al., 1992), and the human VIP-RII (Xia et al., 1996), shares a 87%
homology with the rat VIP-RII (Lutz et al., 1993). It is therefore likely that the
chicken VIP-RII is structurally similar to that of the human VIP-RII.
The apparent lack of discrete immunolabelling of individual cells in the chicken
anterior pituitary gland using the VIP-RII antibodies may be due to several factors.
Firstly, the VIP-RII may occur in more than one cell type in the chicken anterior
pituitary gland, which may account for the widespread immunolabelling observed
in the pituitary. This view is supported by the observation that mRNA encoding
the VIP-RIIoccurs in both the gonadotroph-like aT3-l and the PRL secreting
somatotroph-like GH4C1 cell lines (Rawlings et al., 1995). Secondly, this VIP-
RII96) antibody is a polyclonal and may not have the specificity required for use in
different species, which resulted in the lack of discrete immunolabelling in the
chicken anterior pituitary gland.
The failure to obtain immunolabelled cells in the anterior pituitary using VIP-RII
antibodies, contrasted with the clear identification of VIP-RII immunolabelled cells
in specific hypothalamic nuclei. The distribution of VIP-RII immunoreactivity in
the hypothalamus was similar to that reported for distribution of VIP binding sites
in the pigeon hypothalamus (Hof et al., 1991) and VIP-RII mRNA in the rat brain
as determined using in situ hybridisation (Lutz et al., 1993; Usdin et al., 1994).
The VIP-RII antibody used in this study may recognise a VIP-like receptor in the
chicken anterior pituitary and hypothalamus. However, this VIP-receptor may be
different to the specific VIP binding site which has been identified in anterior
pituitary gland of an incubating hen, and is predominantly expressed in the
ceplahlic lobe (Gonzales et al., 1994b,c)
The localisation of VIP-RII immunoreactivity in the nucleus paraventricularis and
supraopticus is consistent with the observation that VIP binding sites are reported
to occur in the nucleus paraventricularis of the pigeon (Hof et al., 1994).
Vasoactive intestinal polypeptide-like immunoreactivity also occurs in the nucleus
magnocellularis preopticus, nucleus supraopticus and periventricularis and
paraventricularis of the chicken (Peczley and Kiss, 1988) and quail (Aste et al.,
1995). This observation suggests that VIP may stimulate the release of
neuropeptides from these nuclei in the chicken hypothalamus. In the rat, VIP
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infused into the cerebral ventricle or PVN, stimulates the release of arginine
vasopressin (AVP), which is an ACTH releasing factor (Alexander and Sander,
1994). It appears that in mammals, VIP indirectly affects the ACTH secretion from
the rat anterior pituitary gland by stimulating the release of oxytocin and or AVP
(Bardum et al., 1987; 1988). It is therefore likely that hypothalamic VIP may act
through VIP receptors in the nucleus paraventricularis or supraopticus (Hof et al.,
1994), and stimulate the release of vasotocin in the chicken.
There was limited or a complete lack of immunolabelling using the VIP-RI
antibody code B (VIP-RI(B)) raised against the carboxyl terminal (CT), and the
VIP-RII antibody codes 4, 22 and 23 (VIP-RII(4), (22), (23)), raised against the
extracellular amino terminal (AT) (See Table 5.2). This suggests that the
accessibility of the CT and AT regions to the VIP-RI or VIP RII antibodies maybe
reduced by fixation, or that these regions are susceptible to enzymatic degradation.
Although, the VIP-RII antibody codes 22 and 23, are raised against epitopes on
the human VIP-RII which are not found in the rat VIP-RII, and do not
immunolabel the VIP-RII in the rat (E.J. Goetzl, personnel communication).
These specific epitopes are probably not highly conserved and are not found on the
chicken VIP-R, and this may account for the lack of immunolabelling, in the
chicken anterior pituitary and hypothalamus.
In contrast, immunolabelling was achieved using the VIP-RI antibody code A and
VIP-RII antibody code 6 (VIP-RII(6)). These antibodies were raised against an
amino acid sequence that occurs on the 1st extracellular loop (ECL-1), of the
human and rat VIP-RI (Goetzl et al., 1994), and the human and rat VIP-RII (E.J.
Goetzl, personnel communication). These epitopes are likely to be found on the
ECL-1 of the chicken VIP-RI and VIP-RII-like receptors, and this is consistent
with the observation that immunolabelling was demonstrated in the chicken
anterior pituitary gland and hypothalamus.
In conclusion, a VIP receptor antibody raised against a specific epitope, which
occurs on the human VIP-RI, allowed the immunocytochemical identification of
specific cells in the pituitary and hypothalamus. The VIP-RI was in ACTH cells of
the chicken anterior pituitary gland, and not localised in PRL, LH or GH cells.
The identity of pituitary hormone cells which contain the VIP-RII was not
established, although widespread labelling occurred throughout the anterior
pituitary. This suggests that lactotrophs are not the only pituitary cell type which
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contain the VIP-RII, since these cells are found predominantly in the cephalic lobe.
Therefore, the human VIP-RII antibodies used in this study may lack the
specificity required to identify the chicken VIP-binding site, which is positively
correlated with the expression of PRL producing cells (Gonzales et al., 1994b,c),
and elevated PR1 secretion during incubation behaviour.
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Chapter 6: VIP AS A PITUITARY MITOGENIC FACTOR
6.1 Introduction
VIP is a neurotrophic factor playing a major role in the development and growth of
the nervous system (Gozes and Brenneman, 1989; Gozes and Brenneman, 1993).
It acts as a mitogenic factor to stimulate DNA synthesis in embryonic neurones
(Pincus et al., 1990), and increases the rate of mitosis in neural and non-neural
tissues in cultured mouse embryos (Gressens et al., 1993). The aim of this
experiment was to determine whether the increase in prolactin secretion in
incubating hens is associated with a proliferation rather than differentiation of cells
producing prolactin. Any such proliferation might be due to increased hypothalamic
release of VIP at the onset of incubation and or to changes in the function of the
VIP-cell type in the anterior pituitary gland.
Cell proliferation both in vivo and in vitro can be measured by the use of a non¬
radioactive thymidine analogue 5-bromo-2-deoxyuridine (BrdU), which is
incorporated into the DNA of replicating cells. A monoclonal antibody (Mab) raised
against BrdU, makes it possible to detect BrdU in mitotic cells
immunocytochemically (see Section 2.10.1). The sensitivity of the BrdU technique
depends on the dose of BrdU administered, and length of time the animal is
exposed to BrdU (Boswald et al., 1990). Typically the animal is exposed to a
single or multiple-pulse BrdU injection, a few hours before being sacrificed, which
only allows a small 'window' of time to demonstrate DNA replication within the
tissue. Since the development of incubation behaviour occurs gradually over a 2-3
week period in the chicken, any changes in mitotic activity within the anterior
pituitary gland may not be detected using a short exposure to BrdU. The
development of slow-release pellets, makes it possible for BrdU to be delivered
continuously for weeks or months, and thereby create a 'window' of exposure, of
sufficient duration to detect an increase in pituitary mitotic activity (Weghorst et al.,
1991).
Slow-release pellets (Section 2.10.1) were used to deliver a pre-determined dose of
BrdU over a 21 day period to laying hens (Section 2.10.3), which were transferred
from individual cages to floor pens, to induce incubation behaviour. The BrdU-
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labelled cells were detected using an immunocytochemical technique (Section
2.10.6).
6.2 The development of incubation behaviour in birds implanted with
BrdU
The birds were not adversely affected by the implantation of the BrdU pellets. The
number of birds that showed incubation behaviour was less than predicted (Table
6.1). This may have been because the birds were young and had not previously
undergone a cycle of incubation and return to egg production. Additionally a drop
in room temperature during the experiment may have inhibited the expression of
incubation behaviour.
Table 6.1 The incidence of incubation behaviour in groups of laying bantam hens
(n=5) transferred from individual cages to floor pens for 21 days, and implanted
with slow release BrdU pellets containing different doses of BrdU. Abreviation, C.
control, Gp group, Inb. incubating,O/R ovarian regression.
Gp 1 Gp 2 Gp 3 Gp 4 Gp 5 Gp 6
Pellet
dose
lOmg 25mg 50mg lOOmg 200mg C.
Inb. 0 1 1 2 2 2
Laying 5 4 4 3 3 3
O/R 0 1 1 2 2 2
The birds in groups 3, 4, 5 and 6 showed a significant decline in body weight,
consistently over the three week period (Fig. 6.1). The body weight of birds in
group 1 also showed a decline in the first week (P<0.005) but was not significant
over weeks 2 (P=0.06) and 3 (P=0.21), and may be due to the fact that no birds in
group 1 became broody. It can therefore be concluded that BrdU treatment has no
adverse effect on body condition.
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Figure 6.1 The effect of inducing incubation behaviour («=5) on the body weight
of laying birds, over a 3 week period. Five groups of five birds were implanted
with a 10, 25, 50, 100 or 200mg BrdU slow release pellet, and transferred to floor
pens containing nest boxes.
6.2.1 Effect ofdifferent BrdU doses on incorporation into blood and anterior pituitary
cells
6.2.1.1 Analysis of blood smears
Blood smears were used to confirm that the marker of cellular replication BrdU,
was incorporated into the nuclei DNA of red blood cells, and to optimise the
conditions for BrdU immunolabelling (Section 2.10.7). The BrdU-positive nuclei
were visualised with an anti-mouse FITC conjugate second antibody. The labelling
of red blood cell nuclei was dose dependent, and increased with dose (Fig. 6.2).
Nuclear labelling was present in the groups which received 50, 100, and 200mg
pellets, and absent in the control group, and in birds that received 10 and 25mg
pellets. The immunolabelling was also abolished when the primary antibody was
omitted, and when the monoclonal BrdU antibody was preabsorbed with BrdU
(10flg/ml).
Immunolabelling was localised around the periphery of the nucleus, in the groups
which received a 50mg pellet (Fig. 6.2). However, the immunolabelling was
distributed more evenly throughout the nucleus in the birds which received the
higher doses of lOOmg and 200mg BrdU pellets (Fig. 6.3).
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Figure 6.2 The immunolabelling of incorporated BrdU into the nuclei of red
blood cells. The birds in each group (n =5) received either a (a) 10, (b) 25, (c) 50,
(d) 100 or (e) 200mg BrdU pellet (Mag. x400).
Figure 6.3 The immunolabelling of BrdU incorporated into the nuclei of red
blood cells, in birds which received (a) 200 and (b) lOOmg BrdU pellet
was localised around the periphery, and dispersed diffusely through out the
nucleus (Mag. xlOOO).
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6.2.1.2 BrdU-labelled nuclei in the chicken anterior pituitary
Bromodeoxyuridine-labelled nuclei were localised in the chicken anterior pituitary
using the monoclonal BrdU antibody (1:1000) and visualised using an avidin-
peroxidase kit (ABC-Vector), because labelling of BrdU-labelled cells with the
FTIC-conjugate (Section 6.2.1) was not sensitive enough to localize BrdU-labelled
cells in the anterior pituitary.
The labelling of mitotic cells in the anterior pituitary was dependent on the amount
of BrdU in the implanted pellet. No BrdU-labelled nuclei were observed in the
anterior pituitary of control birds or those implanted with a 10, 25, or 50mg pellet .
Immunolabelled nuclei were observed in the anterior pituitary of birds which were
implanted with pellets containing the higher doses of BrdU (lOOmg and 200mg),
after prolonged incubation of sections with the DAB substrate (Fig. 6.4). The
immunolabelling was localised in the nucleus, and no specific labelling occurred in
the cytoplasm.
The BrdU-labelled nuclei occurred in cells in the cephalic and caudal lobe of the
anterior pituitary gland (Fig. 6.5), in both incubating and laying hens. There was
no suggestion that BrdU-labelled cells in broody hens were more abundant than in
laying hens. Attempts to co-localise the BrdU-labelled nuclei in the pituitary
hormone secreting cells, using a double immunocytochemical procedure were not
successful, and the identity of the mitotic cells was not established.
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Figure 6.4 The immunolabelling of BrdU cells in the anterior pituitary of a hen
which was implanted with a (a) 100, (b) 200mg slow release BrdU pellet, and (c)
sham operated.
140
Figure 6.5 The distribution of BrdU-labelled cells within the chicken anterior
pituitary gland. The immunolabelled cells were found in the cephalic (a,c) and (b,d)
caudal lobes of both (a,b) laying and (c,d) broody hens.
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6.3 Discussion
This experiment demonstrated that BrdU immunocytochemistry can be used to
detect cell replication within the chicken anterior pituitary gland. The slow release
BrdU pellets were designed to chronically deliver a dose of BrdU over a 21 day
period. This experiment also showed that the dose of BrdU released by the pellets
was critical, and affected the detection of BrdU-labelled cells in the blood and
anterior pituitary. Proliferating cells in the anterior pituitary gland were only
observed when implanted with a 100 or 200mg BrdU pellet.
Immunocytochemical labelling with BrdU in vivo and in vitro, is widely used to
study cell proliferation, including cultured anterior pituitary cells (Carbajo-Peres et
al., 1990; Carbajo et al., 1992). The denaturation of the DNA, and the fixation of
the sample (Dolbeare et al., 1985; Moran et al., 1985; Hayashi et al., 1988) are
important parameters which affect the detection of BrdU incorporated into a tissue
sample. Factors which affect the incorporation of BrdU into the S-phase nuclei are
also important. For example, the concentration and period of exposure to BrdU
influences the detection of cellular proliferation. The amount of BrdU needed for
the detection of BrdU-labelled cells in tissue sections is greater (Carbajo et al.,
1995) than that required to detect BrdU-labelled cells in single cell suspensions by
flow cytometry (FCM) (Dolbeare et al., 1983). Therefore, the detection of BrdU-
labelled cells in the chicken anterior pituitary gland may be an underestimation, and
a consequence of inadequate doses of BrdU administered to the birds.
The dose of BrdU used to detect cell proliferation in vivo, varies greatly in the
literature and ranges from 50 to 200mg/kg body weight (Dolbeare et al., 1983; De
Fazio et al., 1987; Carbajo-Perez and Watanabe, 1990). The use of high
concentrations of BrdU did not appear to cause an adverse reaction, even though it
is reported to be mitogenic (Davidson et al., 1988; Kaufman, 1988) and
carcinogenic in rats (Napalkov et al., 1989), and to inhibit cell differentiation and
DNA synthesis (Chwalinski et al., 1988; Morris et al., 1989).
Since the number of lactotrophs in the pituitary of the incubating hen is much
greater than in the laying hen, it was predicted that there might be a greater number
of proliferating prolactin cells in the anterior pituitary of the incubating hen. This
experiment indicates that there is no obvious difference in the number of mitotic
cells in the anterior pituitary gland of the broody and laying bantam hens. It seems
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therefore likely that another cell type may differentiate into a lactotroph during the
induction of incubation behaviour, which would account for the increase in the
number of PRL producing cells.
Although it is generally accepted that fully differentiated cells rarely undergo mitotic
division, differentiated (granulated) cells in the male rat anterior pituitary gland have
been observed to undergo cell replication (Zambrano and Deis, 1970; Kurosumi,
1971). It is not known which cell type differentiates into the pituitary hormone
secreting cell. It might be mitotic (18%) cells identified in the rat anterior pituitary
which do not contain PRL, LH, ACTH, TSH, GH or FSH immunoreactivity, and
are referred to as immunonegative (agranular) cells (Oishi et al., 1993). It is
suggested that the immunonegative cells may be a folliculo-stellate cell (Oishi et al.,
1993), and the number of proliferating immunonegative cells in the rat decreases
concomitantly with an increase in the percentage of GH and PRL cells (Shirasawa
and Yoshimura, 1982). It is suggested that the FS-cells (Oishi et al., 1993) may
play an important role in the proliferation and differentiation in the rat anterior
pituitary gland. It is therefore possible that FS-cells may differentiate into PRL cells
at the onset of incubation behaviour in the domestic chicken.
Finally, it might be more interesting to establish whether VIP stimulates
proliferation in vitro. A chicken anterior pituitary cell culture system would produce
a controlled environment where VIPs effect on BrdU-incorporation could be
established in the presence of a defined steroid environment. Furthermore, this
steroid environment could be designed to mimick the steroid milieu of the laying or
incubating bantam hen, to determine whether VIP and oestrogen interact to affect
pituitary cell proliferation.
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Chapter 7: VIP AS A PARACRINE REGULATOR OF
ANTERIOR PITUITARY FUNCTION
7.1 Introduction
VIP is the main hypothalamic PRL releasing hormone in birds, (Mauro et al., 1988;
1989; Sharp et al., 1989), but there is little or no evidence showing an effect of VIP
or PACAP on the secretion of other chicken pituitary hormones. However in the rat
there is evidence that VIP (Section 1.4.4) and PACAP (Section 1.8.2) may regulate
the secretion of several pituitary hormones. A specific PACAP receptor occurs in
the mammalian anterior pituitary gland, and its affinity for PACAP is significantly
greater than that for VIP (Gottschall et al., 1990). In addition, VIP and PACAP are
reported to share a similar affinity for the neuroendocrine VIP receptor (VIP-RI/II)
(Christophe, 1994) which occurs in the rat anterior pituitary gland. These
observations support the view that VIP and PACAP may also play an important
role in the regulation of pituitary hormone secretion within the chicken anterior
pituitary gland.
Therefore, the effects of VIP and PACAP on pituitary hormone secretion were
determined in vitro. PACAP's mechanism of action is not fully understood, since it
appears to affect pituitary hormone release when added to a perfusion system, but
is not effective when applied to dispersed anterior pituitary cell cultures (Miyata et
al., 1989). For this reason hemi-pituitaries were used in this study, to maintain the
cellular integrity of the tissue which may be important for the action of VIP or
PACAP. The anterior pituitary glands were collected from laying and broody
bantam hens, and the neural lobe removed. The pituitaries were cut along the
midline to form hemi-pituitaries, randomly selected for each experimental group
and exposed to VIP or PACAP concentrations ranging from 0.001 to lOOOnM.
The incubation medium was replaced after lhr and again after 24hrs for hormone
analysis. These two incubation times were used to distinguish between the
immediate releasing effects of VIP/PACAP on pituitary hormone release, from their
long-term trophic effects on basal production of pituitary hormones.
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7.2 The effect of VIP and PACAP on ACTH secretion
VIP and PACAP had no significant effect on ACTH secretion after 1 or 24 hrs
from hemi-pituitaries of laying hens (Fig. 7.1). The release of ACTH in response
to VIP [InM] was suppressed, but was not significantly different from that of the
control. VIP at high concentrations also had no effect on ACTH secretion after 1 or
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Figure 7.1 The dose response relationship between VIP or PACAP and ACTH
release from the hemi-pituitaries of laying hens. Hemi-pituitary glands from laying
bantam hens were incubated with either VIP or PACAP for (a) 1 hr and (b) 24 hrs.
The bars represent mean ± SEM of 4 replicate wells.
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7.3 Effect of VIP and PACAP on GH secretion
VIP and PACAP did not stimulate GH secretion from the hemi-pituitaries of laying
hens at high concentrations (1-lOOnM) during a lhr incubation (Figure 7.2), and
were also ineffective after 24 hrs (Figure 7.2). VIP had no effect on GH secretion







































Figure 7.2 The dose response relationship between VIP, PACAP and GH release
from the hemi-pituitaries of laying hens. Hemi-pituitary glands from laying bantam
hens were incubated with either VIP or PACAP for (a) 1 hr and (b) 24 hrs. The








0 100 10 0.1 0.01
VIP [nM]
Figure 7.3 The dose response relationship between VIP and GH release from the
hemi-pituitaries of broody hens. Hemi-pituitary glands from broody bantam hens
were incubated in the presence of VIP, for lhr and 24hrs. The bars represent mean
± SEM of 4 replicate wells.
7.4 The effect of VIP and PACAP on LH secretion
VIP and PACAP had no significant effect on LH secretion from the hemi-pituitaries
of laying hens during a lhr or 24 hr incubation period (Fig. 7.4). PACAP and VIP
were also ineffective on LH secretion from the hemi-pituitaries of broody hens after
lhr (Fig. 7.5). Although, VIP did increase LH secretion from the hemi-pituitary
glands of broody hens after a 24hr incubation period, the increase was not
significant (P=0.055, ANOVA) (Fig. 7.5).
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Figure 7.4 The dose response relationship between VIP and PACAP and LH
release from hemi-pituitaries from laying hens. Hemi-pituitary glands from laying
bantam hens were incubated with either VIP or PACAP for (a) 1 hr and (b) 24 hrs.
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Figure 7.5 The dose response relationship between VIP and PACAP and LH
release from hemi-pituitaries from broody hens. Hemi-pituitary glands from laying
bantam hens were incubated with either VIP or PACAP for (a) 1 hr and (b) 24 hrs.
The bars represent mean ± SEM of 5 replicate wells.
7.5 The effect of VIP and PACAP on PRL secretion
PRL secretion, from the hemi-pituitary glands of both laying and bantam hens was
significantly stimulated by both VIP and PACAP. The VIP-stimulated PRL
response from the broody hen pituitary glands was greater than that from laying
hens (Figure. 7.6). The VIP-stimulated PRL response was increased in a dose
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dependent manner, and was 2.7fold greater in broody than in laying hens. PACAP
also stimulated a 1.9 fold increase in PRL release from hemi-pituitaries from
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Figure 7.6 The dose response relationship between VIP and PACAP and PRL
release from hemi-pituitaries from laying and broody hens. Hemi-pituitary glands
from (a) laying and (b) broody bantam hens were incubated with either VIP or
PACAP for 1 hr. The bars represent mean ± SEM of 5 replicate wells, *P<0.05,
** P<0.01.
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7.6 Discussion of studies in vitro
VIP and PACAP stimulated prolactin secretion from hemi-pituitary glands in vitro
from laying and incubating hens. VIP and PACAP did not stimulate GH in vitro
from laying hen pituitaries and LH secretion from laying and incubating hen
pituitaries. These results confirm VIP as the main specific prolactin releasing factor
in the chicken (Macnamee et al., 1986; Sharp et al., 1989; Talbot et al., 1991). In
addition, this experiment suggests that pituitary adenylate cyclase activating
polypeptide may also play a role in the regulation of PRL secretion.
The inability of VIP and PACAP to stimulate GH release in vitro suggests that
these two peptides do not directly regulate the secretion of GH from the anterior
pituitary gland. There is evidence that PACAP stimulates GH secretion and GH
mRNA in a static incubation of rat anterior pituitary culture which contained a high
proportion of GH cells (Velkeniers et al., 1994). However, the reported effects of
PACAP on GH release in a static rat anterior pituitary cell culture appear to be time
dependent. The maximal effect of PACAP on GH release occurs after 15 min, but
prolonged exposure to PACAP desensitises the pituitary (Wei et al., 1993). This
observation may also explain why PACAP has been reported to have no effect on
GH release from the rat anterior pituitary gland after 3hr incubation (Miyata et al.,
1989; Culler and Paschal, 1991). The effects of VIP and PACAP on GH secretion
in the chicken anterior pituitary gland are therefore consistent with the effect on GH
release in the rat.
The absence of a stimulatory effect of VIP and PACAP on ACTH secretion in vitro
after long and short term cultures makes it difficult to explain the functional
significance of the VIP-RI localised on ACTH cells (Chapter 5). VIP is reported to
stimulate ACTH from normal rat anterior pituitary glands, but only at high
concentrations (l-3|lM) (Westendorf et al., 1983). However, the mouse
corticotrophine-like AtT20 cell line and human corticotropinoma cells are
responsive to lower doses of VIP, and the effects of co-incubation with VIP and
corticotrophin releasing factor (Reisine et al., 1982) or arginine vasopressin (White
et al., 1982) are additive to those of CRF or AVP alone. Therefore, VIP and
PACAP may modulate the responsiveness of the chicken ACTH cell to releasing
factors such as AVP.
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This experiment showed that in vitro LH release was stimulated from the anterior
pituitary gland of the broody hen after a long term exposure to VIP [lOOOnm].
However, the increase in LH secretion was not significantly different to that of the
control value when the Dunnett's test was used following a one-way analysis of
variance. This observation if significant may have suggested that VIP released by a
pituitary VIP-cell type may modulate pituitary hormone secretion, and VIP may
have a trophic action on the gonadotroph.
The absence of a stimulatory effect on LH release from the pituitary gland from
laying hens after 24hr incubation with VIP/PACAP suggests that the action of VIP
in the chicken anterior pituitary may be mediated by oestrogen in vivo. The absence
of a stimulatory effect of VIP on LH release from the laying hen pituitary in vitro,
may be because intra-pituitary VIP is already providing the maximum trophic
support to the gonadotroph. Intra-pituitary VIP in the broody hen may be lower
because plasma oestrogen concentrations are lower in the broody hen than in the
laying hen (Cogger et al., 1979). Long term incubation with VIP may replace the
trophic support provided by VIP to the gonadotroph which is normally reduced in
the anterior pituitary of the broody hen. In support of this view, a stimulatory
interaction between VIP and oestrogen has been demonstrated in the rat. The
administration of oestrogen to ovariectomised rats increases the VIP mRNA in the
anterior pituitary gland (Lam et al., 1991; Kasper et al., 1992).
In conclusion, VIP and PACAP stimulate prolactin secretion, which is consistent
with the role of an avian PRL-releasing factor. VIP and PACAP failed to stimulate
ACTH and GH secretion from the hemi-pituitary of a laying hen at very high
concentrations. After a 24 hr not a 1 hr incubation, VIP stimulated LH release, but
not significantly from pituitary gland from the incubating hen in vitro. These
observations support the view that VIP may be released in a paracrine manner from
the VIP cell in the anterior pituitary and provide trophic support for the
neighbouring gonadotroph population.
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CHAPTER 8: GENERAL DISCUSSION
It is established that prolactin but not LH secretion in birds is stimulated by the
hypothalamic releasing factor, vasoactive intestinal polypeptide (VIP) (see Section
1.5). However, active immunization against VIP suppresses both prolactin and
luteinising hormone secretion (Sharp et al., 1993). This observation suggested that
VIP may facilitate the function of LH-producing cells. This Thesis provides
biochemical, molecular and anatomical evidence that VIP produced as a paracrine
secretion by folliculo-stellate-like cells in the anterior pituitary gland, may regulate
the function of gonadotrophs (Fig. 8.1).
The presence of VIP within the chicken anterior pituitary gland was demonstrated
using high performance liquid chromatography (HPLC), radioimmunoassay and
immunocytochemistry. VIP mRNA was also detected in the anterior pituitary, using
RT-PCR and solution hybridization RNase protection assay. A subtype-I VIP
receptor (VIP-RI) was localised immunocytochemically in the anterior pituitary, and
was co-localised in cells containing ACTH but not PRL, LH or GH. The subtype-II
VIP receptor (VIP-RII), identified immunocytochemically, was also distributed
throughout the anterior pituitary but the specific cell type(s) containing VIP-RII
immunoreactivity were not identified. Finally, it was shown in vitro that VIP and a
VIP-like peptide, pituitary adenylate cyclase activating polypeptide (PACAP)
induced a rapid release of prolactin, but not LH, GH or ACTH. After a twenty-four
hour incubation with VIP or PACAP, LH but not ACTH secretion was enhanced in
vitro, from pituitary glands from broody hens.
VIP immunoreactivity was found in a distinct cell type which was distributed
throughout both cephalic and caudal lobes of the anterior pituitary gland. One VIP-
cell type was stellate, with cytoplasmic projections which extended between
neighbouring pituitary hormone cells. The morphological features of this VIP-cell
were similar to those of the folliculo-stellate cell (FS-cell), and most contained the
Ca2+ binding protein S-100, a specific marker for FS-cells. A second larger VIP-
cell type was more intensely labelled, polygonal in shape, and did not appear to
contain S-100 protein.
Ultrastructural and histochemical evidence suggests that FS-cells are agranular and
do not secrete hormones, but some small granules have been observed in FS-cells
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(Vila-Porcile and Olivier, 1984). It is possible that the larger polygonal VIP-cell
type in the chicken is not of folliculo-stellate cell origin, since it appears to lack S-
100 immunoreactivity. There are a number of likely candidates for the cell type
which contains VIP-immunoreactivity. For example, the corticotroph is described
as stellate shaped (Nakane, 1970; 1975), and like the chicken pituitary VIP-cell has
a characteristic polygonal/stellate shape, and is reported to be found at the centre of
a glandular cell cord and forms cytoplasmic projections between neighbouring cells
(Siperstein and Miller, 1970). Further, thyrotrophs in the rat anterior pituitary gland
are reported to be polygonal in shape, and form clusters at the centre of the gland
with cytoplasmic projections (Nakane, 1970; Baker, 1974). However, in the
chicken it is unlikely that the VIP occurs exclusively in TSH or ACTH cell types,
since these are confined to the cephalic lobes and VIP-immunoreactivity was
distributed throughout both lobes of the anterior pituitary gland.
There is no consensus concerning the identity of the pituitary cell type containing
VIP in mammals (Section 1.6). In the chicken, the VIP-cell type was distinct from
that of lactotrophs and gonadotrophs (Fig. 8.1), which is consistent with the
findings in the rat ( Lam etal., 1989; Steel et al., 1990; Carrillo and Phelps, 1992).
The VIP-cell identified in the chicken was localised in both lobes of the anterior
pituitary, as is the gonadotroph, and was seen to envelop a number of adjacent LH
cells with cytoplasmic projections. This cell-to-cell relationship suggests that the
VIP-cell type may regulate gonadotroph function within the chicken anterior
pituitary gland. A similar situation occurs in the rat, where the FS-cell has been
suggested to have a 'housekeeping role' for the gonadotroph (Section 1.9.5). This
view is supported by the observation that FS-cells closely surround gonadotrophs
and not thyrotrophs after gonadectomy (Shirasawa et al., 1983). Furthermore, the
regulation of gonadotroph function may be modulated by FS-cells which release the
FSH inhibiting peptide, follistatin (Gospodarowicz and Lau, 1989).
The RT-PCR and solution hybridisation RNase protection assay confirmed that the
chicken anterior pituitary gland contains VIP mRNA. These observations
demonstrate that the VIP detected by immunocytochemistry and radioimmunoassay
is synthesised by the pituitary, and is not all sequestered from another source. It
was not possible to confirm that VIP mRNA occurs only in the FS-cell type,
because the in situ hybridisation (ISH) technique was not sensitive enough.
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It might be possible to increase the amount of VIP mRNA in the anterior pituitary
sufficiently for it to be detected by ISH, by endocrine manipulation. For example,
oestrogen treatment following ovariectomy (Carrillo and Phelps, 1992),
thyroidectomy (Lam et al., 1989) or adrenalectomy (Lam et al., 1992) have been
reported to increase the amount of VIP mRNA in the rat anterior pituitary gland.
Oestrogen treatment may also increase VIP gene expression in the chicken anterior
pituitary gland (Fig. 8.1). This view is supported by the observation that the
apparent VIP immunoreactivity in the anterior pituitary of the incubating hen was
less than that in the laying hen, and that plasma oestrogen in the incubating hen is
lower than in the laying hen (Cogger et al., 1979).
The presence of PACAP could not be demonstrated immunocytochemically in the
chicken anterior pituitary gland, using a high titre of an antibody which is specific
for mammalian PACAP. This antibody used at low titre labelled cells in the medio-
basal hypothalamus, although specificity was not confirmed, because the PACAP
antibody cross-reacted with chicken VIP. Although, the chicken brain contains
PACAP (Yasuhara et al., 1992), there are no published reports describing the
distribution of PACAP immunoreactivity in the chicken hypothalamus or anterior
pituitary.
On the basis of these observations, it is likely that PACAP is not present in the
chicken anterior pituitary gland, and that intra-pituitary VIP rather than PACAP is a
paracrine factor which modulates pituitary hormone cell function. This view is
consistent with the observation that PACAP mRNA is not present in the rat anterior
pituitary gland (Mikkelsen et al., 1995) or in human pituitary adenomas cells
(Vertongen et al., 1995b). However, specific high affinity PACAP binding sites
occur in specific cell types in the rat anterior pituitary (Gottschall et al., 1990; Vigh
et al., 1991). This suggests that hypothalamic PACAP in the rat, may play an
important role in the regulation of anterior pituitary cell function. Further
investigation is required to establish the neuroendocrine role of PACAP in birds. A
specific chicken PACAP antibody and a chicken PACAP cDNA is needed to
establish the presence of PACAP in the hypothalamus and the anterior pituitary. A
specific chicken PACAP antiserum would also be valuable for passive
immunization studies to determine the effect of PACAP on the secretion of pituitary
hormones.
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A specific VIP-R occurs in the lactotroph of the rat anterior pituitary gland (Wanke
and Rorstad, 1990a), and it is likely that the stimulatory effect of VIP on PRL
secretion and gene expression in the chicken (Talbot et al., 1991) is also mediated
by a specific VIP receptor (Gonzales et al., 1994b, c) in the lactotroph. This study
used antibodies raised against the subtype-I and subtype-II human VIP, to establish
whether VIP receptors occur in lactotrophs and other anterior pituitary cell types.
The VIP-RI was found only in ACTH cells, and not in PRL-, LH- or GH-cells
(Fig. 8.1). This is consistent with the observation that only small amounts of VIP-
RI mRNA occur in the rat pituitary gland (Usdin et al., 1994; Rawlings et al.,
1995) and that VIP-RI mRNA occurs in the corticotroph-like AtT20 cell line, but
not in the LH-like aT3-l or PRL/GH-like GH4C1 cell lines (Rawlings et al.,
1995).
VIP-RII immunoreactivity was localised throughout both lobes of the chicken
anterior pituitary gland, but the VIP-RII antibody did not clearly identify individual
cells. It is predicted that there should be significant homology between the chicken
high affinity VIP-R and the human VIP-RII for the antibody to recognise a chicken
subtype-II-like VIP receptor. This view was based on the observation that the
amino acid sequences of the human and rat VIP-RII, share approximately 87%
sequence homology (Xia et al., 1996), and it is predicted that a similar homology
should occur between the chicken and mammalian VIP-RII receptors.
The stimulation of PRL secretion by VIP in vitro was expected, since it is
established that VIP is the hypothalamic prolactin releasing factor in birds. The
effect of PACAP on PRL secretion was not unexpected, because of the high degree
of structural homology between cVIP (Nilsson. 1974) and cPACAP (Yasuhara et
al., 1993). It is likely that VIP and PACAP mediate their effects through the same
receptor. The major neuroendocrine VIP receptor localised in the rat anterior
pituitary is the VIP-RII (Lutz et al., 1993; Usdin et al., 1994), which also shares an
equal affinity for VIP and PACAP and occurs principally in lactotrophs (Vertongen
et al., 1995b). The results of this study are consistent with the view that a specific
VIP binding site in the avian anterior pituitary gland (Rozenboim and El Halawani,
1993; Gonzales et al., 1994a), mediates the prolactin-releasing action of VIP and
PACAP.
The release of ACTH was not stimulated by VIP or PACAP. This observation is
consistent with the view that ACTH release from the rat anterior pituitary gland (in
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vitro) is not stimulated by VIP, except at high micromolar concentrations
(Westendorf et al„ 1983). Further, PACAP does not modify ACTH release in the
rat in vitro, (Miyata et al., 1989) in combination with the ACTH releasing factor,
CRF (Culler and Paschall, 1991). Since VIP and PACAP do not appear to affect
ACTH secretion directly the functional significance of the VIP-RI found exclusively
on ACTH cells is uncertain.
Luteinising hormone release was stimulated in vitro from the hemi-pituitary glands
of broody hens, by both VIP and PACAP after long (24hr) but not short term
incubation (lhr). This observation may support the view that the VIP-cells
identified in this study, may release VIP to modulate the function of gonadotrophs
in the chicken anterior pituitary gland. The close association between VIP- and LH-
cells, allows cell-to-cell communication (Fig. 8.1), and suggests a route by which
paracrine factors produced in the VIP-cell, could control the function of the LH cell.
These results are consistent with the hypothesis suggesting that VIP may act as a
paracrine factor, providing trophic support for the gonadotroph.
VIP did not affect LH release in vitro from chicken hemi-pituitary glands, after a 1
or 24hr incubation. LH secretion from the broody hen hemi-pituitary was enhanced
but not significantly, suggesting that the stimulatory effect of VIP on LH secretion
may depend on the physiological state of the bird. In support of this view, in the
ovariectomised rat, VIP mRNA is increased by oestrogen treatment (Lam et al.,
1991; Kasper et al., 1992), and oestrogen may have a similar effect on pituitary
VIP gene expression in the chicken. In the laying hen plasma oestrogen
concentration is higher than in the broody hen (Cogger et al., 1979). Increased
plasma oestrogen may be the factor responsible for the inability of VIP to provide
further trophic support in vitro to LH cells from laying hens. This view is
consistent with the observation that the VIP-immunoreactivity appears greater in the
anterior pituitary of a laying than in broody hens. It is therefore possible that in
laying hens pituitary VIP supplies maximal trophic support to LH cells and
prolonged incubation with VIP in vitro does not further stimulate basal LH
secretion. In contrast, in the broody hen pituitary, VIP gene expression may be
lower as a consequence of lower oestrogen. The long term incubation of hemi-
pituitary gland of broody hens with VIP may have mimicked the paracrine action of
intra-pituitary VIP and resulted in enhanced basal LH release.
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The proposed interaction between oestrogen and VIP in the paracrine control of the
gonadotroph, may explain why active immunization of out-of-lay bantam hens on
short days depressed plasma LH and delayed the onset of egg laying after
photostimulation (Section 1.5.4) (Sharp et al., 1993). While on short days the VIP
antibody may attenuate the paracrine action of VIP produced by folliculo-stellate-
like cells acting on the gonadotroph, and result in a depressive response to GnRH.
After transfer to long days, the initial GnRH induced release of LH might not have
been sustained until oestrogen is produced by the ovary, stimulated sufficient VIP
synthesis in the VIP folliculo-stellate-type cells to attenuate the immunosuppresive
effect of circulating VIP antibody on gonadotroph function.
Intra-pituitary VIP may stimulate LH mRNA synthesis in the gonadotroph, and this
would account for the increase in basal LH release from the pituitary of the broody
hen in vitro. Future studies are necessary to establish whether VIP stimulates LH
a- or (3-subunit mRNA expression in the chicken anterior pituitary gland. It is
reported that PACAP stimulates LH a and (3 mRNA expression in rat anterior
pituitary cells when administered in a pulsitile manner in vitro (Tsujii et al., 1994;
1995), and therefore VIP and PACAP may act in a similar manner to affect LH
synthesis and secretion in the chicken gonadotroph.
In conclusion, this study shows that vasoactive intestinal polypeptide is produced
by the chicken anterior pituitary gland and occurs in a folliculo-stellate cell type.
The VIP-cell type is closely associated with pituitary hormone cells, in particular the
gonadotroph. Vasoactive intestinal polypeptide also enhances basal LH release from
the anterior pituitary gland {in vitro) of broody hens after a prolonged incubation.
These observations are consistent with the view that in the chicken intra-pituitary
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Figure 8.1 A summary diagram showing the proposed interaction between intra-pituitary VIP, and
hormone secreting pituitary cell types. VIP occurs in a folliculo-stellate-like cell, which is closely
associated with gonadotrophs. VIP may be secreted in a paracrine manner to modulate basal LH
secretion.
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